

Contents

Introduction	4
Abbreviations	5
Chapter 1: Why focus on hypertension	6
1.1. Reasons to focus on hypertension	6
1.2. Government of India's initiatives on hypertension control	
1.3. Essential components of scalable treatment of hypertension	9
Chapter 2: Hypertension diagnosis & treatment using practical treatment procotols	11
2.1. Measurement of blood pressure	11
2.1.1. Whose blood pressure should be measured	11
2.1.2. How to measure blood pressure	11
2.2. Diagnosis of hypertension	16
2.3. Treatment of hypertension	16
2.3.1. Who should receive hypertension treatment?	16
2.3.2. The goal of hypertension treatment	16
2.3.3. Available medications for treating hypertension	16
2.3.4. Use a standardized protocol	18
2.3.5. Patient education	22
2.3.6. Treatment inertia	23
2.3.7. Frequently asked questions (FAQs) on hypertension treatment	23
Chapter 3: Drugs & Technology	27
3.1. Regular and uninterrupted availability of medication	27
3.1.1. Drug supply chain:	27
3.1.2 Key considerations to ensure uninterrupted drug supply under IHCI	29
A. State level: State Programme Managers & drug procurement corporation officials	29
B. District level: District Programme Managers & Warehouse Pharmacists	30
C. Facility level: Medical Officers/ Pharmacists	31
D. Monitoring by programme supervisors	32
3.2. BP Measuring devices	35
3.2.1. Types of devices	35
3.2.2. Maintenance and calibration	36
3.2.3. Validation of blood pressure measuring devices	36
3.2.4. How reliable are automated, digital blood pressure measurement devices?	36

Chapter 4: Task sharing and patient-centred care	44
4.1 Task sharing	44
4.1.1 Advantages of task sharing	44
4.1.2 Requirements to initiate and establish task sharing in a facility	45
4.1.3 Steps for implementing task sharing	45
4.1.4 Responsibilities which can be shifted to non-physicians	46
4.2 Opportunistic screening and patient flow	47
4.3 Patient-centred services	48
4.3.1 What are the ways to improve patient-centred services?	48
4.3.2 Strategies to establish patient-centred services	49
4.4 Decentralisation to sub-centres/health and wellness centres (HWC)	49
4.4.1 Strategies for decentralisation	50
4.4.2 Patient flow under decentralisation	51
4.4.3 Format for line list register at the sub-centre	51
4.5 Health and Wellness Centre (HWC)	52
4.5.1 Implementing IHCI in HWCs	52
4.5.2 Services to be provided in HWCs under IHCI	53
4.5.3 Roles of various field staff under the program	53
4.6 Lost to follow up – prevention, identification, and retrieval	54
4.6.1 Prevention of Loss to follow up	55
4.6.2 Identifying 'missed visits'	58
4.6.3 Retrieval of patients who missed follow up visits	60
Chapter 5: Information systems - monitoring indicators and reporting tools	63
5.1 Core indicators	63
5.1.1 Quarterly indicator – 3 to 6 monthly hypertension control rates	63
5.1.2 Annual Indicator	66
5.1.3 Hypertension Registration Rate	71
5.2 Paper-based reporting tools	72
5.2.1 Patient BP Passport	72
5.2.3 Hypertension treatment card	74
5.3 Digital systems	110
5.4 Facility reports	113
5.4.1 Facility quarterly report	116
5.4.2 Facility annual report	116
5.5 Monitoring cycle	117
Answer key for Monitoring Indicators and Reporting tools	118

Chapter 6: Supportive supervision	125
6.1 Purpose of supervision	125
6.2 Approaches to supervision	125
6.3 Steps of supervision	127
6.3.1 Step 1: Planning supervisory visits	127
6.3.2 Step 2: Conducting supportive supervision visits	131
6.3.3 Step 3: Follow-up activities	139

Introduction

India is facing the rising burden of non-communicable diseases (NCDs) in general and hypertension in specific. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular diseases and Stroke (NPCDCS) has given due recognition to this and has set a goal of 25% reduction in mortality due to non-communicable diseases by 2025. NPCDCS has initiated a population-based screening program (PBS) for hypertension, diabetes, and cancers of the breast, cervix and oral cavity. India Hypertension Control Initiative (IHCI), a multi-partner initiative, complements this screening program by strengthening the management of hypertension in primary health care settings. It aims to accelerate progress towards the Government of India's NCD target by supplementing and intensifying evidence-based strategies towards strengthening the building blocks of hypertension management and control. IHCI partners include the Ministry of Health & Family Welfare, Government of India, State Governments, Indian Council of Medical Research (ICMR) and World Health Organization (WHO) India. Resolve to Save Lives, an initiative of Vital Strategies, is a technical partner.

IHCI was launched in November 2017 and is currently operational across 26 districts in Punjab, Kerala, Madhya Pradesh, Telangana, and Maharashtra. The phase-2 of the project was launched in July 2019 and will cover a total of 100 districts across all Indian States.

The major aim of this module is to build competencies of health professionals at the primary health care level to treat hypertension as per the standard state-specific treatment protocol using a patient-centric approach. This module also aims to build capacity for strengthening drug logistic systems at the district and health facility levels. Additionally, this module provides strategies and guiding principles for information systems, monitoring and supervision of the hypertension control program.

This module has strived to avoid duplication of the existing modules of various cadres of health workers. It should be considered a supplement to the existing training materials for different cadres of health care providers under the NPCDCS.

States can use these modules for team-based training at the primary health care level such that all members are aware of the entire team's roles to ensure the best outcomes for the patient as well as for control of hypertension in their areas.

This module has been jointly prepared by all partners of the India Hypertension Control Initiative.

Abbreviations

ASHA Accredited Social Health Activist

AIDS Acquired Immunodeficiency Syndrome
ACEI angiotensin-converting enzyme inhibitor

ARB angiotensin receptor blocker

App application

ANM auxiliary nurse midwife

BP blood pressure

CCB calcium channel blocker

CHEP Canada Hypertension Education Project

CCU cardiac care unit

CVDs cardiovascular diseases
CKD chronic kidney disease
CHC community health centre
DBP diastolic blood pressure

DH district hospital

DLHS District Level Health Survey DDC drug dispensing counter

EDL Essential Drug List

ELM Essential List of Medicine
FDC fixed dose combination
FAQ frequently asked questions

Gol Government of India

HWC Health and Wellness Centre

HTN Hypertension

ID identification details

IHCI India Hypertension Control Initiative

LFU loss to follow up

LMIC Low- and Middle-income countries

MLHP mid-level health provider

MoHFW Ministry of Health and Family Welfare
NLEM National Essential List of Medicine
NFHS National Family Health Survey

NHM National Health Mission

NPCDCS National Programme for Prevention and Control of

Cancer, Diabetes, Cardiovascular diseases and Stroke

NCDs non-communicable diseases
OPD outpatient department
PHC primary health centre

Q Quarter

RAS Renin-Angiotensin System

RKS Rogi Kalyan Samithi SMS short messaging system

SC sub-centre

SBP systolic blood pressure

TB Tuberculosis

Chapter 1: Why focus on hypertension

Expected competency on completion of session: Ability to convey to patients, health care workers, and leaders the importance of treatment and control of hypertension.

Audience: Health care providers and facility managers.

In this session, you will learn about:

- Burden of cardiovascular disease and hypertension- global and Indian scenario
- Reasons to focus on hypertension
- Essential components of a scalable hypertension program

1.1. Reasons to focus on hypertension

a. Hypertension is the number one cause of mortality and morbidity: Cardiovascular diseases (CVDs), which include heart attacks and stroke, are the most common cause of mortality and morbidity across the world and are responsible for one-third of total deaths in India. While the deaths due to CVDs are decreasing in rich countries, they are increasing in lowand middle-income countries (LMICs).

Uncontrolled blood pressure is one of the main risk factors for CVD and is estimated to be responsible for more than 10 million deaths per year, which is more than all infectious diseases combined (*figure 1*). Hypertension contributes to an estimated 1.6 million deaths annually in India, due to ischemic heart disease and stroke.¹




Figure 1: High blood pressure is the world's leading killer 2

b. Large burden of hypertension - both globally and in India: An estimated 1.4 billion people worldwide have high blood pressure, but just 1 in 7 people have it under control. With one in four adults detected with high blood pressure (DLHS 4 ≥18 years), it is estimated that there are more than 20 crore adults with hypertension in India. However,

less than half of them are aware of their hypertension status and less than one-tenth of all people with hypertension have their blood pressure under control (NFHS 4, 15-49 years).³

Repeated cross-sectional surveys have shown that the prevalence of hypertension has almost doubled in the past 20 years, with narrowing of the rural and urban gap. While the number of people with hypertension has increased over the years, the rates of blood pressure control have remained low.⁴

- **c. Hypertension control can save most lives:** Hypertension is the number one cause of death. Improving blood pressure treatment will:
 - Save maximum lives by preventing fatal heart attacks and strokes;
 - Reduce disability, by preventing non-fatal heart attacks and strokes, and preventing dialysis;
 - Reduce medical costs spent on caring for patients who are having heart attacks and strokes, and for the rehabilitation and nursing care needed in the aftermath of a stroke or heart attack;
 - Improve productivity by reducing the number of people who are disabled by CVDs and are unable to work and who may require long-term nursing care.

Treatment of hypertension among adults in primary care can save more lives than any other primary care program. Deaths due to hypertension are largely preventable. In comparison to other evidence-based interventions for non-communicable diseases, control of hypertension has the largest potential to save lives (figure 2).⁵

It is estimated that increasing coverage of antihypertensive medications to 70% of people with raised blood pressure alone can delay 39.4 million deaths globally over 25 years.⁶




Figure 2: Hypertension control is key to reducing CVD deaths

d. Hypertension control is simple, affordable and essential

- <u>Easy to diagnose</u>: Hypertension is easy to diagnose and requires only a well-functioning BP measuring device.
- <u>Simple:</u> Treatment of hypertension need not be complicated. Practical, precise, and simplified protocols such as those adopted by the India Hypertension Control Initiative (IHCI) are based on evidence generated from thousands of clinical trials over several decades. The protocol medications are safe and effective in lowering blood pressure and preventing CVDs.

- Affordable: The medicines to treat hypertension are inexpensive and available in generic form. Patients in all countries have access to the same medications, which are safe and effective. Further, the bulk purchase of medications for a single standard protocol-based treatment will reduce the cost further.
- <u>Essential</u>: Just as we give vaccines to children to prevent the development of illnesses against which we are vaccinating, we treat people with hypertension because there is, at present, no way to predict which patients will have a heart attack or stroke or other complications. And although many heart attacks and strokes occur among older people, death or disability from CVDs at a younger age is particularly tragic and preventable.
- e. Hypertension control program can be easily integrated in primary health systems: More than 90% of hypertension cases can be managed by a primary care physician. The use of practical protocols and effective generic medications further simplify hypertension management. Further, most tasks related to hypertension management can be carried out by non-physicians nurse, pharmacist, auxiliary nurse midwife (ANM). These tasks include and are not limited to blood pressure measurement, refilling medication for patients with controlled blood pressure, sending reminders to patients for follow up and recording and reporting.

A well-functioning hypertension control program can impart discipline in management of non-communicable diseases (NCDs) in the primary health care system, thus increasing the system's confidence in managing NCDs.

f. International experiences suggest high hypertension control rates are achievable: In the early 1990s, hypertension control rates in Canada were low. The Canada Hypertension Education Project (CHEP) identified the gaps in awareness, treatment, and control of hypertension and focused on linking every individual to a primary health care system for screening, treatment and follow up of high blood pressure. As a result, the population-level control of hypertension improved from 13% in 1985-92 to 68% in 2012-13.7 CHEP also demonstrated a reduction in rates of stroke, myocardial infarction, and cardiac failure.

Thailand used a team-based approach to the management of hypertension in primary health care. Subsequent surveys showed significant improvements in hypertension control rates. From 2004 to 2014, the hypertension control rates increased by more three-folds (8.6% to 29.7%).^{8,9}

1.2. Government of India's initiatives on hypertension control

The Government of India (GOI) has adopted a National Action Plan for the prevention and control of non-communicable diseases with specific targets to be achieved by 2025. These targets include:

- 25% relative reduction in overall mortality from cardiovascular diseases,
- 30% relative reduction in mean population intake of salt/sodium, and
- 25% relative reduction in the prevalence of raised blood pressure.

In order to achieve a 25% relative reduction in the prevalence of raised blood pressure by 2025, approximately 4.5 crore additional people with hypertension will need to have their blood pressure effectively treated.

The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) was launched in 2010 to address the rising burden of non-

communicable diseases in India. Under NPCDCS, a population-based screening program (PBS) has been initiated - for hypertension, diabetes, and cancers of breast, cervix and oral cavity. The India Hypertension Control Initiative (IHCI), a multi-partner initiative, complements this screening program by strengthening the management of hypertension in primary health care settings. IHCI provides a continuum of care to those diagnosed with hypertension during screening, by ensuring treatment, control, and documentation.

1.3. Essential components of scalable treatment of hypertension

Most patients with hypertension can be successfully managed by ensuring provision of five key components of care:



There are five steps needed to effectively control blood pressure



1 Implement practical treatment protocols

which are drug- and dose-specific and which establish steps to take if blood pressure is not controlled.

Use of standardized, evidence-based protocols reduces clinical variability, and results in more efficient and costeffective selection of medications and treatment approaches.



2 Regular and uninterrupted supply of medications and equipment

to ensure that the right medications and equipment get to the right place at the right time, and reach the patients who need them.



3 Team-based care and task sharing

to involve nurses, health workers, and ASHAs for counseling and follow up of the patients and to improve adherence to treatment



Patient-centered services

reduce barriers to care by increasing the convenience of medical visits and refills at Health & Wellness Centres and other primary health care facilities, and improving access to BP monitoring.



5 Information systems that allow continuous, real-time monitoring

to improve follow-up of patients whose blood pressure is not under control, measure program quality and coverage, and allow analysis of program data to improve patient care and system performance.

These 5 components are based on the Global Hearts Initiative and complement the NPCDCS.

The Global Hearts Initiative comprises five technical packages that provide a set of evidence-based interventions that, when used together, can potentially have a major impact on improving global heart health: (1) HEARTS for the treatment of hypertension in primary care services, (2) MPOWER for the reduction in tobacco use, (3) SHAKE for reduction in population salt consumption, (4) REPLACE action package to eliminate industrially-produced trans fats from the global food supply, and (5) Active technical package for increasing physical activity.

Key Messages

- More than 20 crore Indians have hypertension
- Less than half of those with raised blood pressure in India are aware of their status
- Less than one-tenth people with hypertension in India have their blood pressure under control.

Exercise 1: Estimate the number of persons with hypertension in your state/district



To do this exercise, we need information on (1) adult population of the state/district and (2) hypertension prevalence rate

- (1) Adult Population of the state/district:
- Use the most recent census data for your state or district. Age disaggregated data for a
 district from 2011 census are available at http://www.censusindia.gov.in/2011census/C-series/C-13.html
- Get the total adults aged ≥ 30 years in the state/district
- (2) Prevalence of hypertension: Use the most recent, comprehensive, population-level estimate of hypertension of the state/district.
- District Level Household Survey 4 (DLHS-4) conducting during 2012-13 provides hypertension prevalence estimates for states and most districts and can be accessed at http://rchiips.org/DLHS-4.html
- If your district prevalence is missing, assume the average rate of the state and if the state value is missing, use the national average (25%)
- If there is a more recent and reliable regional data available, please use that information

Calculate the total number of adults with hypertension:

Multiply the adult population (aged ≥30 years) & hypertension prevalence

References

- 1. Gupta R, Indian Heart J. 2018;70(4):565–572. doi: 10.1016/j.ihj.2018.02.003
- 2. GBD 2016, Lancet. 2017; 390:1345-1422
- 3. Prenissl J, PLoS Med. 2019 May 3;16(5):e1002801.
- 4. Roy et al. BMJ Open. 2017; 7(7): e015639.
- 5. Institute for Health Metrics and Evaluation, 2015 data.
- 6. Kontis Circulation. 2019; 140:00-00. DOI: 0.1161/CIRCULATIONAHA.118.038160
- 7. Canadian Heart Health Surveys (CHHS) -1985-92 & Canadian Health Measures Survey (CHMS) -2012-13
- 8. Wichai A Journal of Hypertension.2012; 80(9):1734–1742
- 9. Thailand National Health Examination Survey 2014.

Chapter 2: Hypertension diagnosis & treatment using practical treatment procotols

Expected competency on completion of session:

- Ability to correctly measure blood pressure and diagnose hypertension.
- Ability to treat hypertension patients using a standardized protocol, follow up for adherence to treatment and manage associated co-morbidities to achieve target blood pressure control.

Audience: Healthcare providers, facility managers, supervisors

In this session you will learn about:

- Whose blood pressure should be measured?
- How to measure blood pressure?
- Diagnosis of hypertension
- Who should receive treatment?
- Medications used for treating hypertension (class, dose, side effects)
- Treatment goal for hypertension
- Standardized protocol adopted by the state
- Ensuring adherence to medication
- Lifestyle advices

2.1. Measurement of blood pressure

2.1.1. Whose blood pressure should be measured

Population-based screening: Under the population-based screening (PBS) program of NPCDCS, all adults in the population ≥30 years are to be screened for hypertension at least once every year.

Opportunistic screening at health facilities: High blood pressure can occur in young adults. About 12% of adults between 18-30 years have hypertension. Therefore, it is recommended that all the adults aged \geq 18 years visiting a health facility should undergo blood pressure measurement.

Most people with raised blood pressure have no symptoms and measurement of blood pressure is the only way to identify persons with high blood pressure. Therefore, it is important to measure the blood pressure of all adults attending out-patient clinics irrespective of their symptoms. Accurate measurement and recording of BP are essential for diagnosis and management of hypertension. Strategies to improve opportunistic screening at public health facilities are detailed in *chapter 4*.

Measure blood pressure of all adults ≥ 18 years visiting the outpatient clinic.

2.1.2. How to measure blood pressure

Preparation of the patient

- The patient should avoid tea/coffee, exercise, and tobacco use for at least 30 min before measurement.
- The patient should have rested for at least 5 minutes before measurement.
- Ensure s/he has emptied his/her bladder.

 When taking blood pressure, the patient should be seated, with back supported and both feet resting on the ground.

Arm

(cm) 22-26

27-34

35-44

circumference

• The patient should not speak while blood pressure is being measured.

Choosing the cuff: The ideal cuff bladder length and width are ≥80 percent and ≥40 percent of the patient's arm circumference, respectively.

Applying the cuff

- Explain the procedure to the patient.
- If the patient is wearing a thick-sleeved garment, ask the patient to uncover the arm by either removing the top garment or rolling up the sleeve. If the cuff is tied over the clothing, ensure that it is tied snugly and evenly.
- The patient's arm should be supported on the table and relaxed.
- Make sure the arm cuff is properly deflated (air is out) before placing it around the patient's upper arm.
- Wrap the cuff comfortably or snugly above the elbow, about 2 cm (or 2 finger breadths) from the elbow and secure the Velcro tape.
- Keep the cuff at the heart level during measurement.



Recommended cuff

size

(width x length in cm)

12x22 (small)

16x36 (large)

16x30 (medium)

Taking a blood pressure measurement


a. Using a digital blood pressure device

- Turn the monitor on from the on/off button.
- Ask the individual to stay still, breathing normally, without talking or laughing.
- Press the START/STOP button to begin the measurement.
- The BP cuff will automatically start to inflate. This might be uncomfortable for some. Reassure the patient that the discomfort is temporary.
- The cuff will slowly deflate to take the measurement.
- When the reading is complete, the systolic (SBP) and diastolic blood pressure (DBP) readings and pulse rate will appear on the screen.
- Note the BP readings exactly as seen in the device in the patient record. Please do not round off.
- If the monitor/machine does not record the reading, re-position the cuff and try again after 1-2 minutes and repeat the above-mentioned steps.
- Turn the machine off and remove the cuff.



b. Using a manual instrument

- The cuff has a bulb at one end of the tube that you will squeeze to inflate the cuff.
- Apply the cuff on the individual's arm and place your stethoscope where you will be able to hear the sounds of blood flowing. The place is where you can feel the pulse. You can find the place by placing your index and middle fingers of one hand in the crease of a relaxed elbow.
- Put your stethoscope on and hold the head of the stethoscope in place.
- Screw the valve tight and inflate the cuff to 200 mmHg.
 Keep holding the stethoscope at the right spot.
- Slowly let the air out of the cuff while listening for the sounds of blood flowing. Keep a rate of deflation 2–3 mmHg per second (equals one line on the dial every second).
- When you start letting the air out, you should not hear any distinct sounds at first. You will
 then hear a thump, which will be followed by several other similar thumping sounds. The
 number on the dial when you heard the first thump is the patient's systolic blood pressure.
 The thumping sounds will eventually stop. The number on the dial when you heard the last
 sound is the patient's diastolic pressure.



Although many guidelines recommend measuring multiple blood pressures at each visit, this may not be practical in a primary care setting.² These guidelines also frequently recommend discarding certain results and averaging others, a complex computational task that may be difficult, if not impossible, to do consistently and accurately in busy clinics and primary care health delivery systems.

A practical approach:

- 1. If the first blood pressure (BP) is <140/90 mmHg, then no other blood pressure measurement is needed during that encounter.
- There is a 95% chance that second BP will be lower than the first, so if the first BP is <140/90 mmHg, the mean blood pressure would be <140/90 mmHg.³
- 2. If the first BP is >140/90 mmHg, perform a second BP and use the second reading as the recorded BP for the encounter.
- Averaging the two measurements to determine mean BP in a busy primary care setting is a time-consuming exercise and is potentially prone to errors.
- The second BP is likely closer to the actual average than the first because the first BP measurement in a series is usually the highest. Subsequent repeated measurements have a tendency to be closer to the actual BP.
- 3. If there is a large difference between the first and second reading (>5 mmHg), it is reasonable to do a third measurement and use the third BP as the recorded BP.
- A third BP is often much closer to the second BP than to the first BP, moving the mean closer to the second and third BP measurements.




Table 1: Common errors during BP measurement and their impact on measured BP ^{4,5,6}

Error in Measurement	Variation in BP (mmHg)		
Unsupported back/feet	6		
Unsupported arm	10		
Wrapping the cuff over clothing	5-50		
Incorrect cuff size	2-10		
Sitting with crossed legs	2-8		
Talking	10		
Full bladder	10		

BP Measurement Checklist

Measure blood pressure of all adults ≥ 30 years



2.2. Diagnosis of hypertension

- Hypertension diagnosis is established if the systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, on two different days.
- However, if the blood pressure is ≥160 mmHg or ≥100 mmHg at the first reading, second reading should be taken on the same day to establish the diagnosis.
- If the patient has other symptoms requiring immediate treatment in addition to high blood pressure, the diagnosis and treatment of hypertension are at the discretion of the medical officer.
- If the patient had the blood pressure measurement done during the screening program at the community level, then the BP reading during clinic visit can be considered as the second reading.
- If only the systolic, or only the diastolic blood pressure is raised, manage according to the higher number.

Key Messages

- Measure blood pressure of all adults visiting the out-patient clinic.
- Diagnosis of hypertension is made if the systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, on two visits on different days.



Exercise 2: Practice measuring blood pressure

2.3. Treatment of hypertension

2.3.1. Who should receive hypertension treatment?

Hypertension treatment is indicated for all adults diagnosed with hypertension as defined in the previous section (SBP \geq 140 mmHg and/or DBP \geq 90 mmHg, on two different days). Patients with SBP \geq 160 mmHg or DBP \geq 100 mmHg may be indicated for immediate treatment.

2.3.2. The goal of hypertension treatment

The goal of hypertension treatment is to keep blood pressure under control. BP is considered under control when the systolic blood pressure is <140 mmHg **AND** diastolic blood pressure is <90 mmHg.

2.3.3. Available medications for treating hypertension

Three main classes of medications are recommended for the first-line treatment of hypertension - calcium channel blockers, renin-angiotensin system (RAS) inhibitors (Angiotensin receptor blockers and Angiotensin-converting enzyme inhibitors), and thiazide/thiazide-like diuretics. Amlodipine, telmisartan, and chlorthalidone are the medications of choice in the standardized treatment protocols being followed in most States.

Other medications can be added as substitutes and in special cases. The various medications used for the treatment of hypertension are mentioned below:

 Table 2: Common medications used in the management of hypertension

Class	Medication	Starting	Intensification	Important notes
Cluss	Medication	dose	dose	important notes
Calcium channel blocker	Amlodipine	5 mg	10 mg	 Doesn't require any metabolic monitoring. Therefore, a good first choice for primary health centers Can be given to women in childbearing age who may become pregnant Ankle oedema ~10% cases (particularly at 10 mg dose and absence of ACEI/ARB)
Angiotensin receptor blocker (ARB)	Telmisartan	40 mg	80 mg	 Should not be given to women who are or may become pregnant Benefits some patients with kidney disease, prior heart attack, and low ejection fraction Addition of ARB to CCB reduces the incidence of ankle oedema
	Losartan	50 mg	100 mg	 ARB and ACE-I should not be combined together Risk of hyperkalemia especially if the patient has CKD – consider checking serum creatinine and potassium before initiating treatment and thereafter at least once a year.
Angiotensin converting enzyme (ACE) inhibitor	Enalapril	5 mg	10 mg	 Should not be given to women who are or may become pregnant Benefits some patients with kidney disease, prior heart attack, and low ejection fraction Addition of ACE inhibitors to CCB reduces the incidence of ankle oedema Can cause persistent cough ~ 10% cases ARB and ACE-I should not be combined together Risk of hyperkalemia especially if patient has CKD – consider checking serum creatinine and potassium before initiating treatment and thereafter at least once a year
Thiazide or thiazide-like diuretics	Hydrochlorothiazide Chlorthalidone	25 mg	50 mg	 Should not be given to women who are or may become pregnant Risk of hypokalemia – consider checking serum creatinine and potassium before
		12.3 mg	23 mg	initiating treatment and thereafter at least once a year. Using along with ACE Inhibitor/ARB will reduce the risk of hypokalemia
Beta-Blocker	Atenolol	50 mg	100 mg	 Not the first choice of drug for the treatment of hypertension Recommended to be added to initial treatment of patients with a history of a heart attack within the last 3 years or atrial fibrillation or heart failure Should not be stopped abruptly as withdrawal may worsen symptoms of angina. Should be tapered over 5-10 days.

In addition to above anti-hypertensive medications, below medicines can be used in specific cases:

- Low dose aspirin: 75 mg aspirin once a day is recommended to be given to patients with a history of heart attack or stroke.
- **Statins:** Atorvastatin 10 mg is recommended in patients with a history of heart attack or stroke. Should not be given to women who are or may become pregnant.

Fixed-dose combinations

A high proportion of people with hypertension require two or more drugs to achieve BP control. Fixed-dose combinations (FDC) medication includes two or more classes of anti-hypertensives in a single pill. FDC initial treatment compared to initial single drug treatment provides:

- Reduced number of pills resulting in less burden on the patient
- Improved adherence to therapy
- Greater and more rapid blood pressure reduction
- Reduced CVD in observational data
- Drug combinations with single drugs in clinical practice are often suboptimal

Potential disadvantages of FDCs include a lesser ability to individualize drug titration and to identify adverse drug effects. In addition, there must be no contraindication for both drug components.

In July 2019, the World Health Organization included four FDCs for hypertension management in its Essential medical list (EML)⁷.

Table 3: Fixed-dose combinations of antihypertensive drugs in WHO's essential medicines list ⁷

Classes	Combination drugs	Doses	
ACEI+ CCB	lisinopril +	10 mg + 5 mg; 20 mg + 5 mg;	
	amlodipine	20 mg + 10 mg	
ACE+ thiazide	lisinopril +	10 mg + 12.5 mg;	
diuretic	hydrochlorothiazide	20 mg + 12.5 mg; 20 mg + 25 mg	
ARB+CCB	telmisartan + amlodipine	40 mg + 5 mg; 80 mg + 5 mg;	
		80 mg + 10 mg	
ARB+ thiazide	telmisartan + 40 mg + 12.5 mg; 80 mg + 12		
diuretic	hydrochlorothiazide	80 mg + 25 mg	

2.3.4. Use a standardized protocol

The ability to rigorously follow a standardized hypertension protocol is an important step to achieve a target BP control. The standardized protocol defines short specific steps to achieve treatment goals and is different from clinical guidelines provided by professional bodies. Table 4 provides the differences between a standardized protocol and clinical guidelines.

Table 4: Differences between protocol and guidelines

	Protocol	Guidelines
Scope	Specific for a local setting (district/state/hospital)	Summary of evidence-based practices issued by professional bodies
Complexity	Low	High
Length	One page	50-500 page
Specificity	High- specific information such as Drug name and dose	Low- Drug classes and many drug options
Dose	Dose titration with specific drug and dose	Overall titration approach
Use in primary care	Easy to understand and implement at primary care level	Better understood by experts
Public health context	Easy to implement at scale	Challenging to implement at scale

Benefits of using standardized, evidence-based protocols:

- Reduces unwarranted clinical variability and inappropriate therapeutic inertia
- Enables the health care team to advance patients safely and efficiently along the treatment pathway
- Sends a strong signal to clinical staff that hypertension control is a priority
- Results in a more efficient and cost-effective selection of medications and treatment approaches
- Facilitates logistics, training, supervision, evaluation, and overall program implementation and increases the impact of treatment programs
- Can potentially be incorporated into electronic health records through clinical decision support tools, registry functions, and measurement to facilitate quality improvement.

Common strategies used for escalation of antihypertensive drugs 13

- Start with one drug, titrate to the maximum dose, and then add a second drug
- Start with one drug and then add a second drug before achieving the maximum dose of the initial drug
- Begin with 2 drugs at the same time, either as 2 separate pills or as a single pill combination

This module provides two commonly used protocols in India (see page no 20 & 21) and the protocol of your state may be slightly different. However, the goals and principles of the standardized protocol remain the same.

Please note that:

- Medical Officers should follow the state-specific standardized protocols.
- It is important to be familiar with the side effects of the different protocol medications in order to make an informed decision and be able to recognize them on follow up.
- In any protocol, the health care provider must consider the treatment targets and be familiar with the medications.

The goal of the hypertension treatment is to reach systolic BP <140 **AND** diastolic BP <90 mmHg.

India Hypertension Control Initiative

Hypertension Protocol

Measure blood pressure of **all adults** over 30 years

High BP: SBP ≥ 140 or DBP ≥ 90 mmHg

Check for compliance at each visit before titration of dose or addition of drugs.

If BP is high:*

Prescribe Amlodipine 5mg

After 30 days measure BP again. If still high:

Increase to Amlodipine 10mg

After 30 days measure BP again. If still high:

Add Telmisartan 40mg

After 30 days measure BP again. If still high:

Increase to Telmisartan 80mg



After 30 days measure BP again. If still high:

Add Chlorthalidone 12.5mg**



After 30 days# measure BP again. If still high:

Increase to Chlorthalidone 25mg**



After 30 days measure BP again. If still high:

Check if the patient has been taking medications regularly and correctly. If yes, refer to a specialist.

If SBP \geq 180 or DBP \geq 110, refer patient to a specialist after starting

If SBP 160-179 or DBP 100-109, start treatment on the same day. If SBP 140-159 or DBP 90-99, check on a different day and if still elevated, start treatment.

Hydrochlorothiazide can be used if Chlorthalidone is not available (25 mg starting dose, 50 mg intensification dose).

Pregnant women and women who may become pregnant

- ▲ DO NOT give Telmisartan or Chlorthalidone.
- Statins, ACE inhibitors, angiotensin receptor blockers (ARBs), and thiazide/thiazide-like diuretics should not be given to pregnant women or to women of childbearing age not on effective contraception.
- Calcium channel blocker (CCB) can be used. If not controlled with intensification dose, refer to a specialist.

Diabetic patients

- Treat diabetes according to protocol.
- Aim for a BP target of < 140/90 mmHg.

Heart attack in last 3 years

Add beta blocker to Amlodipine with initial treatment

Heart attack or stroke, ever

- Begin low-dose aspirin (75mg) and statin.

People with high CVD risk

Consider aspirin and statin.

Chronic kidney disease

ACEI or ARB preferred if close clinical and biochemical monitoring is possible.

Lifestyle advice for all patients









Avoid tobacco and alcohol

Exercise

Reduce salt. 2.5 hr/week under 1 tsp/day

Eat less

Eat 5 servings of fruits and vegetables per day.

Avoid papads, chips, chutneys, dips, and pickles.

Use healthy oils: E.g. sunflower, mustard, or

groundnut.

Limit consumption of foods containing high amounts of saturated fats.

Reduce weight if overweight.

Reduce fat intake by changing how you cook:

- Remove the fatty part of meat
- Use vegetable oil
- Boil, steam, or bake instead of fry
- Limit reuse of oil for frying

Avoid processed foods containing trans fats.

Avoid added sugar.

India Hypertension Control Initiative

Hypertension Protocol

Measure blood pressure of **all adults** over 30 years

High BP: SBP ≥ 140 or DBP ≥ 90 mmHg

Check for compliance at each visit before titration of dose or addition of drugs.



If BP is high:*

Prescribe Amlodipine 5mg



After 30 days measure BP again. If still high:

Add Telmisartan** 40mg



After 30 days measure BP again. If still high:

Increase to Telmisartan 80mg



After 30 days measure BP again. If still high:

Increase to Amlodipine 10mg



After 30 days measure BP again. If still high:

Add Chlorthalidone 12.5mg**



After 30 days# measure BP again. If still high:

Increase to Chlorthalidone 25mg



After 30 days measure BP again. If still high:

Check if the patient has been taking medications regularly and correctly. If yes, refer to a specialist.

- If SBP ≥ 180 or DBP ≥ 110, refer patient to a specialist after starting treatment.
 - If SBP 160-179 or DBP 100-109, start treatment on the same day. If SBP 140-159 or DBP 90-99, check on a different day and if still elevated, start treatment.
- Hydrochlorothiazide can be used if Chlorthalidone is not available (25 mg starting dose, 50 mg intensification dose).

Pregnant women and women who may become pregnant

- ▲ DO NOT give Telmisartan or Chlorthalidone.
- Statins, ACE inhibitors, angiotensin receptor blockers (ARBs), and thiazide/thiazide-like diuretics should not be given to pregnant women or to women of childbearing age not on effective contraception.
- Calcium channel blocker (CCB) can be used. If not controlled with intensification dose, refer to a specialist.

Diabetic patients

- Treat diabetes according to protocol.
- Aim for a BP target of < 140/90 mmHg.

Heart attack in last 3 years

Add beta blocker to Amlodipine with initial treatment.

Heart attack or stroke, ever

Begin low-dose aspirin (75mg) and statin.

People with high CVD risk

- Consider aspirin and statin.

Chronic kidney disease

ACEI or ARB preferred if close clinical and biochemical monitoring is possible.

Lifestyle advice for all patients









Avoid tobacco and alcohol

Exercise

Reduce salt, 2.5 hr/week under 1 tsp/day

fried foods

Eat 5 servings of fruits and vegetables per day.

Avoid papads, chips, chutneys, dips, and pickles.

Use healthy oils: E.g. sunflower, mustard, or

Limit consumption of foods containing high amounts of saturated fats. Reduce weight if overweight.

Reduce fat intake by changing how you cook:

- Remove the fatty part of meat
- Use vegetable oil
- Boil, steam, or bake instead of fry
- Limit reuse of oil for frying

Avoid processed foods containing trans fats.

Avoid added sugar.

2.3.5. Patient education

Adherence to medication

To promote adherence to medication, the IHCI has adopted the following strategies:

- 1) Standardized protocol
- 2) Uninterrupted drug supply
- 3) Free drugs
- 4) Once a day schedule for drug intake

Additionally, patients should be counselled on the following:

• Education- Explain

- The diagnosis and the need for life-long medication;
- Difference between medicines for long-term control (as in hypertension) and medicines for quick relief (such as for headaches);
- The damage to target organs if blood pressure is uncontrolled (i.e. the possibility of stroke, heart attack, or kidney failure);
- How to take medications at home. Show the patient the appropriate dose;
- Medication should be consumed every day at a fixed time when the patient can remember
- The importance of
 - Keeping enough supply of medications at home till the next visit to the health facility;
 - Taking the medicines regularly as advised, even if there are no symptoms;
- o Potential adverse effects of the medications and what to do

Most importantly check the patient's understanding before the patient leaves the health centre

Reminders:

- Encourage patients to use medication reminders, such as alarms and smartphone applications;
- o Implement patient reminder systems (e.g., e-mail, phone calls, text messages), where possible, to ensure patients adhere to their medication regimen.

A physician can help to increase a patient's compliance with treatment by:

Motivation:

- Good patient-health care provider relationship;
- o Positive feedback: praise adherence through positive feedback and encouragement.

Lifestyle management

Treatment of hypertension must be accompanied by healthy lifestyle choices. This will complement the treatment and address various aspects of healthy choices that aim for overall health improvement. Practical advice is as follows:

- Advise all patients against tobacco use and alcohol intake.
- Suggest ways to increase their physical activity, to improve overall health and weight control.

 Adopt a healthy diet – reduce salt intake (less than 5 g salt per day including salt in processed foods, and salt added while cooking or eating), use healthy oils, increase fruit and vegetable intake, limit red meat, prefer fish and foods rich in omega-3 fatty acids, limit consumption of fried foods, processed foods and foods high in saturated fat, and avoid added sugar.

Table 5: Effect of changes in lifestyle on systolic blood pressure ⁸

Lifestyle	Dose	Approximate Reduction in SBP		
changes		Hypertension	Normotension	
Weight loss	-1 mm Hg for every 1 kg loss	-5 mm Hg	-2/3 mm Hg	
Healthy diet (DASH diet)	Rich in fruits vegetables, whole grains, and low-fat dairy products Reduced saturated and trans fat	-11 mm Hg	-3 mm Hg	
Sodium reduction	<1500 mg/d is optimal goal	-5/6 mm Hg	-2/3 mm Hg	
Increased Potassium	3,500-5000 mg/d, preferably through dietary sources	-4/5 mm Hg	-2 mm Hg	

2.3.6. Treatment inertia

Treatment inertia is defined as a failure to increase the dose of medication or add another medication when a patient's blood pressure is not under control. The potential reasons and solutions are provided below.

- a. The doctor may not notice the high BP recording due to busy crowded clinics
 - A nurse or other staff may highlight the raised BP reading for the doctor (using colour pen/highlighter or symbol)
- b. BP readings are borderline high
 - Discussed in the FAQs (page 26)
- c. The doctor suspects that the patient might have missed medications
 - The nurse should ask detailed history to understand the patient's adherence. How to address missed medications is discussed in FAQs (page 26-27)
- d. A patient might have reported adverse effects
 - Change medications to a different class

It is difficult for a clinician to make a decision with one high BP reading. A well-maintained record (paper/electronic) with multiple BP readings can help the clinician understand the trend of blood pressure and make an informed decision.

2.3.7. Frequently asked questions (FAQs) on hypertension treatment

i. How to manage patients with borderline high blood pressure?

Anti-hypertensive medication should be escalated to the next step in the protocol if blood pressure is equal or slightly higher than systolic 140 mmHg or diastolic 90 mmHg. Evidence suggests that cardiovascular risk increases with every mmHg rise in blood pressures beyond SBP 115 mmHg and DBP 75 mmHg. ⁹

A clinical trial that aimed to compare intensive blood pressure control (SBP <120 mmHg; intensive group) and standard control (SBP<140 mmHg; standard group) showed that the intensive group had 27% lesser cardiovascular events compared to the standard group. ¹⁰ Additionally, treatment adverse effects were similar between both groups. Though some **specific adverse events** (hypotension, electrolyte abnormality, acute kidney injury)¹¹ were higher in the intensive treatment group, most were *mild transient events*; contrast this with mortality or lifetime disability from a major stroke or heart attack.

ii. How should medications be managed when a patient on medications has lower than normal blood pressure?

<u>If the systolic BP is below 110 mmHg:</u> For asymptomatic patients, discontinue one medication (usually the last medication prescribed)

If systolic BP is below 90mmHq & asymptomatic:

- Stop all antihypertensive drugs until blood pressure is re-assessed (ideally within the next seven days).
- Evaluate the causes of low blood pressure side effects from other medications, dehydration, acute inflammatory conditions, or measurement error.
- Request the patient to return for repeat blood pressure measurement <u>If systolic BP is below 90mmHg & symptomatic:</u> Significant symptomatic reductions in blood pressure require immediate individualized assessment and management.

iii. How to treat a patient who is already on non-protocol drugs?

If a patient is on non-protocol drugs

- BP is <140/90:continue to use the same medication(s).
- BP is ≥ 140/90: move to/add on protocol medicines.
- Non-protocol drug is not available at facilities: replace with protocol medicines Most patients who are on treatment in public health facilities in India are likely to be on β blockers, specifically atenolol. β blockers are no longer recommended as the primary treatment of hypertension.

If a patient has controlled blood pressure using β blockers, the same can be continued. However, if the BP is uncontrolled, s/he should be started on protocol drugs and β blockers should be tapered off. Please note that β blockers should not be stopped suddenly. This is because a sudden withdrawal of β blockers may exaggerate symptoms of coronary artery disease. Therefore, it is recommended that the β blocker should be tapered over 5-10 days. For example, for a patient currently taking Atenolol 50 mg 1 tab daily, prescribe Atenolol 50 mg ½ tab daily along with amlodipine 5 mg once daily. After one week, stop Atenolol and continue Amlodipine.

iv. What is the best practice for managing treatment interruption/missed medication doses? "Doctor, I usually take my high blood pressure medicine every day—but not today!" This patient story is familiar to health care workers who manage blood pressure all over the world. The only solution to the missed medication dose scenario is to instruct the patient to take their medications and repeat the blood pressure measurement while on the medication, for example, one week later. Health care workers should not guess what the treated blood pressure would be, as individual patients respond differently to antihypertensive medications.

v. Is it better to take antihypertensive medications in the morning or evening?

The general advice is to take when patient is most likely to remember. Some programs recommend after brushing teeth in the morning. There is insufficient evidence to suggest that taking at any particular time is better – other than at the time when patient is most likely to remember it. It is important to take medication at the same time every day!

vi. How should amlodipine induced ankle oedema be managed?

Treatment of ankle oedema will depend on its severity and other patient factors. Mild oedema which is not troublesome to the patient does not require specific treatment. Whilst ankle oedema associated with amlodipine is rarely clinically serious, it may significantly reduce patient adherence. It is usually refractory to diuretic treatment as it is due to changes in capillary pressure leading to leakage into surrounding tissues, rather than due to water retention. Treatment strategies include:

- <u>Non-pharmacological interventions:</u> Elevation of legs when in a prone position, or graduated compression stockings may help in mild cases
- Reduce dose: For example, if on 10 mg amlodipine, reduce the dose to 5 mg.
- <u>Add ACEI or ARB</u>: Studies have shown that adding an ACEI or ARB to amlodipine reduces the
 incidence of ankle oedema. This may be due to the dilatation of venous vessels, which may
 then lead to a reduction in capillary hypertension and therefore leakage of fluid into the
 surrounding tissues.
- <u>Discontinue & switch to other medications:</u> If the above three options fail, discontinue amlodipine and switch to an antihypertensive from another class of drugs.

vii. If a medication in the protocol is not available, can another medication from the same drug class be substituted? (E.g. substitute Telmisartan by Losartan or Chlorthalidone by Hydrochlorothiazide)

Absolutely. In general, all antihypertensive medications lower blood pressure effectively. Most guideline development groups do not distinguish amongst specific drugs in a particular class based on drug efficacy. ¹² Use the equivalent doses of the alternative drugs as provided in table 2. However, please note that the uninterrupted availability of protocol medications is the key strategy of IHCI. The program expects a seamless supply of protocol medications by improving drug forecasting and supply logistics *(ref chapter 3)*. Therefore, it is expected that the need for substitution is required less frequently.

References

- 1. Zafar KS, International Journal of Research in Medical Sciences, 2017 Vol 5; no. 11
- 2. Whelton PK. AHA Clinical Practice Guidelines. 2018 Jun;71(6):1269-1324.
- **3.** Handler J. The Journal of Clinical Hypertension. 2012;14(11):751-759.
- 4. AHA 2018; https://targetbp.org/tools_downloads/mbp/
- **5.** Pickering. Circulation. 2005;111: 697-716.
- 6. Handler J. The Permanente Journal/Summer 2009/Volume 13 No. 3 51
- **7.** World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
- 8. J Am Coll Cardiol. Sep 2017, 23976; DOI: 10.1016/j.jacc.2017.07.745))
- 9. Prospective Studies Collaboration Lancet 2002; 360:1903-1913.
- **10.** Sprint Research Group N Engl J Med 2015; 373:2103-2116
- 11. Rocco American Journal of Kidney Diseases. 2018; 71:352-361

- **12.** National Institute for Health and Clinical Excellence (NICE). Hypertension in adults: diagnosis and management.2011.
- **13.** JNC 8 guidelines. JAMA. 2014;311(5):507-520.

Chapter 3: Drugs & Technology

Expected competency on completion of session:

- Understand medication supply chain and facility-level drug stock goals.
- Understand various types of BP devices and advantages of digital devices in public health

Audience: Program managers, health care providers, facility pharmacists

In this session, you will learn about:

- · Basics of drug supply chain
- Measures to ensure continued availability medication at the health facility
- · Monitoring drug availability
- · Types of BP monitors
- Advantages of digital BP devices

3.1. Regular and uninterrupted availability of medication

Ensuring access to an uninterrupted supply of medications to people with hypertension is one of the key components of IHCI.

Stockouts inadequacy/shortage of drugs:

- Increases the risk of lack of adherence to treatment & loss to follow up
- Damages the credibility of the health care system/program.

Appropriate forecasting, procurement, stocking, and equitable distribution can ensure uninterrupted availability of medications. In this section, we describe basic principles of drug logistics management and focus on specific activities to be carried out at the level of health facilities to ensure adequate availability of medications.

3.1.1. Drug supply chain: The drug supply chain cycle in the public health care system begins with the selection of drugs and ends with dispensing to patients. A typical supply chain can be outlined as below:



A. **Selection of drugs:** The first step in the drug supply chain is the selection of drugs that need to be procured. Generally, the drugs included in the National List of Essential Medicines (NLEM) or the State Essential Drug List (EDL) would be selected.

ESSENTIAL LIST OF MEDICINES (ELM) is a limited list of carefully selected medicines that satisfy the health care needs of the majority of a population. The concept of ELM was introduced by WHO in 1975 and ELM has been shown to improve the quality and cost-effectiveness of health care delivery when combined with proper procurement policies and good prescribing practices.

The National List of Essential Medicine (NLEM) is revised on a regular basis. Additionally, the States also have their own Essential Drug Lists based on states' disease burden. Typically, the drugs that are in the essential list would be in the State's procurement and supply chain plan.

- B. **Forecasting**: Forecasting is the process of determining the quantity of medication to be required in a set timeframe (typically annually). It is the most important step in ensuring adequate drug availability. Commonly used methods of forecasting are (1) Consumption-based and (2) Morbidity-based.
- **B.1.** The consumption-based method uses data of past consumption of individual medicines or products to project future needs. This method assumes that the previous supply was adequate and uninterrupted. Therefore, the consumption-based method can significantly underestimate the drug requirement if there were drug shortages or stock-outs in the previous year. Further, this method cannot account for changes in disease burden, treatment-seeking behaviours, and treatment protocols. This method cannot be used when a new drug is introduced as there is no data on past consumption. Typically, most states use the consumption method for forecasting annual drug requirements for various disease control programs.
- **B.2.** The morbidity-based method estimates the need for specific medicines or products, based on the frequency of disease (using surveillance and demographic data), expected burden at the health facilities (using service delivery data), and standard treatment guidelines. This method is recommended for an evolving program such as IHCI.

The morbidity-based method is complex, time-consuming and uses several assumptions at the beginning of a program that need to be validated with programmatic data after large scale implementation of the program and revised accordingly.

Table 1: Comparison of consumption & morbidity-based methods of forecasting

Method	Strength	Limitation
Consumption- based method	 Reliable when A drug is been used regularly in the past No major changes expected in demand, such as an increase in the number of cases or changes in the treatment protocol No major shortages or stock-outs in the previous year 	 Is not useful when A new drug is introduced Changes in disease burden, treatment-seeking, and protocols of treatment Major drug shortages or stockouts in the previous year

Morbiditybased method

Used when

- A new drug is introduced
- Anticipated changes in disease burden, treatment-seeking behavior, and protocols of treatment
- Major drug shortages or stockouts in the previous year
- Reliable sources of information on morbidity pattern are available

Is not useful when

- Prevalence/morbidity data is not available or outdated.
- No standard treatment guidelines

May not be needed if the program is stabilized

Procurement: The majority of the public procurements are done through a tender process. The procurement of drugs under the public health system in the state can either be centralised (State level)or decentralised (District level). Additionally, there usually is provision for need-based emergency procurement at the district/health facility level (the proportion varies from state to state). Apart from State/NHM funds, health facilities also have their local funds such as Rogi Kalyan Samiti (RKS) funds using which drugs can be procured as a stop-gap measure in case there is a disruption in supplies.

Storage and Distribution: Drugs procured from suppliers/manufacturers are generally received and stored at regional or district-level warehouses. Supplies to health facilities are made from warehouses at a predefined frequency. The frequency of distribution and mode of last-mile delivery of drugs from the regional/ district stores to health facility stores varies between states.

Some states/districts supply directly to health facilities from the warehouses while in other states/districts, supplies are sent to block health facilities and thereafter distributed to all facilities in the block.

3.1.2 Key considerations to ensure uninterrupted drug supply under IHCI

A. State level: State Programme Managers & drug procurement corporation officials

- a. <u>Essential Drug List:</u> Under IHCI, each state has adopted a specific treatment protocol for the management of hypertension. The treatment protocols generally consist of three classes of drugs: calcium channel blockers (Amlodipine), angiotensin receptor blockers or ACE inhibitors (Telmisartan or Enalapril), and thiazide or thiazide-like diuretics (Chlorthalidone or Hydrochlorothiazide). It is important to ensure that all the recommended treatment protocol drugs are:
 - Included in the essential drug list (EDL) of the state.
 - In the list of medicines to be procured for all levels of healthcare, i.e. primary, secondary & tertiary.

b. Annual forecasting of the drugs at the state: Under IHCI, the recommended hypertension treatment protocol may be different from the previous drug prescription patterns. In addition, with increasing registrations of patients (both through population-based screening and opportunistic screening) and strategies to ensure their return to care, it is expected that there would be a steady increase in the use of the protocol drugs.

Therefore, the *consumption-based method is not suitable* for drug forecasting and *morbidity-based method should be used*. When the program reaches saturation of patient registration and uninterrupted availability of the drugs has been ensured for 2-3 years, then the consumption-based method may be used for future forecasting.

Based on the best available assumptions, tools are available for estimating drug requirements for both AATTCC and ATTACC Protocols. The officials may reach out to the IHCI officers at WHO and/or ICMR to receive the customised tools. Further, IHCI will provide technical support to states in the adoption of the tools to the states.

c. State Procurements:

- Rate contracts (fixed rate with flexibility on quantity to be procured within the duration of
 the contract) should be preferred over quantity contract (fixed quantity procurement
 under a contract) as it allows flexibility of periodic procurement and quantity correction
 based on actual consumption.
- A multi-year rate contract is useful in cutting down tender processes every year, enhancing supplier's confidence in the system and attaining price stability.
- Rate contract with multiple suppliers helps to have an alternate supply source in case of supply failure/noncompliance by a particular supplier.
- Periodic/scheduled procurement (bi-monthly/quarterly procurement based on inventory level) or procurement with scheduled supply should be preferred over one-time procurement.
- It is very important to have rate contracts in continuity. Tenders must be initiated well in advance. A practical suggestion would be at least 4 months prior to the expiry of existing rate contracts (typically it takes about 4 months for the procurement process).

B. District level: District Programme Managers & Warehouse Pharmacists

a. Drug stock goals

- Combined stock available at the facilities plus warehouse should meet at least 6 month's requirements (This includes the buffer/safety stock to cater to supply delays or an unexpected surge in drug uptake).
- If the stock is lower than 6 months requirement, then supply should be sought from the vendor (for decentralized procurement) or Follow up with the state procurement agency. (For centralized procurement)
- At any point in time, health facilities in the district should have 2-3 months stock of medicines

 No health facility should have less than the one-month stock of any protocol drug at any time.

Note:

- The stock levels are expressed as 'months of stock' which indicates how long the drugs will last. For example, 2 months of stock means the stock will last for another two months.
- 6 months requirement is recommended considering a minimum 2-3 month's stock at the field level, typical lead time (time taken between the purchase order placed and goods received) which is about 60 days and quarantine time (time lag for getting quality clearance of the received drugs) of 15-20 days. If orders are not placed in time, then these supplying stores can run out of stock, disrupting the supply chain.
- **b.** <u>Storage and Distribution:</u> Ensuring adequate availability of the drug at each service delivery point is more important than overall availability at the district/state level. To estimate the requirements at each health facility, a ready reckoner (*Annexure C & D*) may be used.
 - Overstocking at some health facilities and stockout/ shortage at others are often seen in public health settings due to disproportionate requisition by a health facility or allocation by warehouses. The distribution of medications usually follows one of the following systems:
- Requisition system (Pull system): Person receiving the supplies calculates the required quantity. (May use ready reckoners in Annexure C & D)
- Allocation system (Push system): Person supplying calculates the required quantity. (May
 use ready reckoners in Annexure C & D)
 - Drug distribution to health facilities should be based on patient load (total patients registered) and stock already available at the health facilities. It can be either through the "Pull" or "Push" system

C. Facility level: Medical Officers/ Pharmacists

a. <u>Drug stock goals at a health care facility:</u> At any point in time, health care facility should have stock in the range of 2-3 months stock

Facilities should avoid having less than the one-month stock of any protocol drug at any time.

Note: The stock levels are expressed as 'months of stock' which indicates how long the drugs will last. For example- 2 months of stock means the stock will last for another two months.

- b. <u>Inventory management at the health facility level:</u> Maintaining optimal levels of drugs at a health facility ensures continuity of treatment of all patients and reduces wastages.
 - A typical health facility that receives a once a month supplyshould maintain 2-3 months stock. (If the facility receives the supply with longer gaps (e.g. 2 to 3 months) then it should use the Min-Max inventory levels (Annexure E).

- At the beginning of the program, ensure a 3-month stock.
- Refilling quantity should be decided considering max-inventory level based on the frequency of the supply. If the stock requirement is dynamic based on patient load, ready reckoner (Annexure C& D) may be used to estimate the stock.
- To calculate indent, subtract the current stock from the 3- month stock requirement (If drug supply is monthly). For other supply which is longer than a month subtract from the maximum requirement as in Min-Max calculation (See Annexure E)
- c. <u>Dispensing of drugs:</u> As per the treatment protocol, patients are called for treatment follow-up after one month. Therefore the drug should be prescribed and dispensed for at least 30 days. Dispensing should be done with a clear message on the importance of regular medication and the consequences of non-adherence.
- d. <u>Maintenance of records:</u> In many states, in addition to supply from states, the health facilities receive drugs from other local resources such as Panchayat funds or untied funds or donations. Health facilities should maintain records of receipt and issue of all drug stocks, irrespective of the source, preferably in a single stock ledger. Health facilities should regularly update the records and report the actual status in the quarterly/monthly reports.

The following records are usually maintained:

- Drug store records
 - Stock Ledger: "Stock ledgers" should reflect both stock in hand and transaction history (receipt & issue).
 - Logistics Management Information System (LMIS): Presently, almost all states are using IT-enabled drug supply chain management systems in all transactions related to the receipt and the issue of stock should be updated.
- Drug dispensing counter records

We suggest including two recording systems at the DDC

- Daily Consumption record at Drug Dispensing Counter (DDC) (See Annexure A)
- Patient wise service uptake at drug distribution counter (Annexure B).

D. Monitoring by programme supervisors

- i. Point of assessment:
 - All the health facilities Main stores and drug distribution counters (DDC)
 - District level/regional level stores

ii. Source of data:

• **Stock ledger:** In general, facility-, district- and regional- stores maintain a "stock ledger" which reflects both stock in hand and transaction history (receipt & issue).

- Physical stock verification: Stock ledgers may not be updated regularly. Therefore, stock verification from ledgers/stock registers should be supplemented by the physical counting of available stock.
- Logistics Management Information System (LMIS): Presently, almost all states are using ITenabled drug supply chain management systems in which information on drug availability at any health facility/store can be obtained from the website. Therefore, is the most convenient source of data. However, LMIS may not be updated regularly, specifically at the health facility level. Therefore, LMIS data may be outdated and not useful.

Table 2: Monitoring of drug information at health facilities

Particulars	Point of assessment	Datapoint	Source document	Tool/ method to be used	Utility
Stock adequacy	Health facility- main store and DDC	Stock on hand	Stock ledger and Physical count	Ready reckoner (Annexure C & D)	Monitoring and maintaining inventory level
The longevity of the available stock	Health facility- main store and DDC	Stock on hand Patients	Stock ledger and Physical count	Described below ^c	Make a decision on procurement, indent or redistribution
Consumption pattern	Health facility level: DDC	registered Opening balance, receipt, closing balance for each drug for a	Stock ledger Consumption record	Correlate drug consumption and patient registration ^d	Monitor program performance and dispensing pattern Supplementary
		specific period Patients registered	Facility register		information on follow up and default

Notes:

- a. Stock data should be collected and documented as a number of tablets (not strips or packs).
- b. The ready reckoner tool (Annexure C & D) can be used by supervisors for assessing stock adequacy at a health facility at any point of time. This can also be used by health facility pharmacist for routine stock level monitoring and as a guiding document for placing monthly indent to the district/regional store from which the health facility gets medicines.
- c. The longevity of available stock: Stock on hand data should be assessed in terms of "how long the stock would last" and not just in numeric quantities. A ready reckoner (Annexure C & D) provides the estimated quantity required for 90 days using AATTCC and ATTACC protocols. A practical tip based on the current assumption to calculate the stock levels in days are calculated as below:

	AATTCC	ATTACC
Amlodipine 5 mg	Stock/(N*1.4)	Stock/(N*1.12)
Telmisartan 40 mg	Stock/(N*0.37)	Stock/(N*0.65)
Chlorthalidone 12.5 mg	Stock/(N*0.06)	Stock/(N*0.06)

^{*}N= number of patients registered

To have a quick and realistic assessment of drug availability status, it should be ensured that all transactions related to drug receipt and issue at all levels should be updated in the software system (if available) or in the physical registers/ledgers.

- d. Consider a health facility with 130 registered patients following the AATTCC treatment protocol. In the month of assessment, 100 patients were followed up in the clinic. We expect that approximately 4200 Amlodipine 5mg tablets would have been dispensed. A significant discrepancy in the number of patients treated and the drug dispensing (in this example let us say <3000 or >6000) may prompt the supervisor to examine the following:
 - Significantly fewer drugs dispensed
 - o Less than 30 days medication dispensed
 - Drug stockout
 - Patients card were wrongly updated
 - Significantly more drugs dispensed.
 - o Treatment cards are not updated
 - Many unregistered patients are being treated



Exercise 1 - Estimation of Min-Max level and quantity of the drug to be issued to a health facility

Problem 1: CHC Rampur has 420 hypertension patients registered. The protocol followed in the CHC is AATTCC. The CHC collects drugs from district drug warehouse each month. The current availability of stocks at CHC is as follows. Please suggest the action to be taken by the health facility pharmacist:

- 1. Amlodipine 5 mg 18,000 tablets
- 2. Telmisartan 40 mg 15,000 tablets
- 3. Chlorthalidone 12.5 mg 12,000 tablets

Problem 2: PHC Madhuban has 170 hypertension patients registered. The protocol followed in the PHC is ATTACC. The PHC collects drugs from the district drug warehouse once in two months. The current availability of stocks at PHC is as follows. Please suggest the action to be taken by the health facility pharmacist:

- 1. Amlodipine 5 mg 80,000 tablets
- 2. Amlodipine 10 mg 5000 tablets
- 3. Telmisartan 40 mg 7000 tablets
- 4. Chlorthalidone 12.5 mg 6000 tablets

3.2. BP Measuring devices

Several barriers to accurate and affordable blood pressure measurement, particularly in lowand middle-income countries include: ¹

- Absence of accurate, easily obtainable, inexpensive devices for BP measurement;
- Frequent marketing of non-validated BP measuring devices;
- The relatively high cost of BP devices given the limited resources available;
- Limited awareness of the problems associated with conventional BP measurement techniques;
- A general lack of trained manpower and limited training of personnel.

To fulfil the requirements related to BP measurement in low resource settings, a BP measuring device should, therefore, be affordable and simple to use, but at the same time be accurate and robust so that it can be easily used for repeated blood pressure measurements.

3.2.1. Types of devices

There are three types of commonly used devices: mercury sphygmomanometers, aneroid manometers, and digital (semiautomatic and fully automatic) devices. In a 2005 policy paper, the WHO noted that "of all the mercury instruments used in health care, the largest amount of mercury is used in mercury sphygmomanometers (80-100 g/unit)."²as a signatory to the Minamata Convention, India is committed to phasing out of mercury devices.

- 1) Mercury sphygmomanometer
 - The gold standard of BP devices- most accurate when used correctly
 - Relies on auscultatory technique
 - Inexpensive and most commonly used instrument in the Indian Public Health System.
 - The government of India is committed to phasing out the use of mercury devices.
 - Prone to observer bias and terminal digit preference
- 2) Aneroid sphygmomanometer
 - Uses a bellow and lever system, which is affected by everyday wear and tear, leading to false BP readings
 - Needs regular calibration (at least every 6 months)
 - Prone to observer bias and terminal digit preference
- 3) Digital device
 - When used correctly, automated, digital blood pressure measurement devices are highly reliable and preferable to manual blood pressure devices.³
 - Specifically, in busy clinics and when the measurement is done by nonphysicians
 - Simplifies the measurement process
 - o Eliminates errors related to hearing deficits, parallax, incorrect initial inflation pressure and rapid deflation
 - o Enables multiple measurements to be taken sequentially
 - Eliminates the subjectivity of measurement by reducing observer errors and terminal digit preference

Table 4: Comparison of commonly used BP measuring devices.

Parameter	Mercury	Aneroid	Digital
Accuracy	Considered the "gold standard"	Mechanical shocks may lead to incorrect readings Needs calibration at least every 6 months	Highly reliable when the validated instrument is used correctly
Observers skills & expertise	High	High	Low
Terminal digit preference	Yes	Yes	No
Observer bias	Yes	Yes	No
Use by field workers	Difficult	Difficult	Simple
Health & environmental effects	Yes	No	No
Availability in the near future	No	Yes	Yes

3.2.2. Maintenance and calibration

All blood pressure measuring equipment should be regularly checked and calibrated in accordance with the manufacturer's instructions. BP cuff and tubing should be regularly inspected and replaced as necessary. Excessive air leakage from damaged cuffs, tubing and tubing connectors may reduce the accuracy of BP readings.

3.2.3. Validation of blood pressure measuring devices

Accuracy is of prime importance when selecting a blood pressure measuring device. Thus, regardless of the type of device used, standardized validation procedures are essential. International protocols for blood pressure measuring device validation have been released by several organizations.⁴

3.2.4. How reliable are automated, digital blood pressure measurement devices?

There is a general mistrust of digital BP devices among health professionals. This is because most BP devices available in the market are not validated and do not meet the prescribed global standards. A study found that of the 500 automatic BP devices available, less than 10% were independently validated. One important accuracy requirement is that the devices produce blood pressure measurements that are within 5±8 mmHg of an auscultatory reference standard (which is meticulously performed, standardized, simultaneous, blinded two-observer auscultation performed using a sphygmomanometer known to be accurate). It is important to use an automated device that has passed at least one of these standards and tested by an independent authority.

Another important factor to be considered in the use of automated devices is durability. Many devices available in the market are for home use and not for office use where BP is measured in larger volume. Therefore, for health facilities, professional models are recommended. Various

levels of professional models are available based on clinic patient volume- low volume, medium volume, and high volume, including arm-in BP instruments.

Annexure- F provides the specification for quality professional BP devices that can be used for tender purposes.

References

- World Health Organization. Affordable Technology: Blood Pressure Measuring Devices for Low Resource settings
- 2. World Health Organization (2005). Mercury in Health Care.
- 3. Padwal R, Campbell NRC, Schutte AE, et al. Optimizing Observer Performance of Clinic Blood Pressure Measurement: A Position Statement from the Lancet Commission on Hypertension Group. J Hypertension In press.
- 4. Stergiou GS, Alpert B, Mike S, et al. A Universal Standard for the Validation of Blood Pressure Measuring Devices. Hypertension. 2018;71(3):368-374. doi:10.1161/hypertensionaha.117.10237.
- 5. World Health Organization. Integrated Management of Cardiovascular Risk. Report of WHO meeting. Geneva 2002.
- 6. http://supplychainhandbook.jsi.com/wpcontent/uploads/2017/02/JSI_Supply_Chain_Manager%27s_H andbook_Final-1.pdf

Annexure A: Daily Consumption record at Drug Dispensing Counter (DDC)

Notes:

	Month:													
SI	Drug name	Opening balance	Receipt during month			Date	wise (consum	nption			Total consumption of the month	Losses / expired (if any)	Closing balance
				1	2	3	4	5	6	 	31			
1	Amlodipine 5 mg	200	2000+3000+2000	270	180	300	10	150	210		240			1200
2	Amlodipine 10 mg													
3	Telmisartan 40 mg													
4	Telmisartan 80 mg													
5	Losartan 25 mg													
6	Losartan 50 mg													
7	Hydrochlorothiazide 25 mg													
8	Chlorthalidone 6.25 mg													
9	Chlorthalidone 12.5mg													

- **Opening balance:** Enter the drug availability, at the drug dispensing counter on the first day of the month. For example, if the DDC has 200 tablets of Amlodipine 5mg on 1st September, enter '200' in the opening balance.
- Receipt during the month: Enter the number of drugs received during the month. For example, in the month of September if DDC received the following amount of amlodipine 5 mg

1st September – 2000

12th September – 3000

25th September – 2000

Enter this as 2000+3000+2000

- In date wise consumption- enter the total quantity of drugs issued by end of each day
- Closing balance- count the stock available on the last day of the month and enter. Note: this would be the opening balance for the next month.

Annexure B: IHCl patient tracking Matrix: drug dispensing counter (DDC)

Name of th	Name of the facility:														
Sl. No.	Redg No.	Apr-19	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar		
	1														
	2														
	3														
	4														
	5														
	6														
	7														
	N														

Notes:

- When a registered patient receives drugs (ALL PRESCRIBED IHCI DRUGS) at a DDC, the pharmacist can put a 'V' against the registered number for the relevant month.
- If one or more prescribed drugs are not available or not dispensed, then put an 'X'
- If a patient did not come to the clinic in a particular month, keep the cell 'blank'
- If an unregistered patient comes to dispensing counter, (s)he can be guided to get registered.

Annexure C: Drug requirement: Ready Reckoner AATTCC protocol

No. of patients	Three	month drug req	uirements	No. of patients	Three	month drug req	uirements
registered (Up-to)	Amlodipine 5 mg	Telmisartan 40 mg	Chlorthalidone 12.5 mg	registered (Up-to)	Amlodipine 5 mg	Telmisartan 40 mg	Chlorthalidone 12.5 mg
20	2520	660	120	520	65520	17160	3120
40	5040	1320	240	540	68040	17820	3240
60	7560	1980	360	560	70560	18480	3360
80	10080	2640	480	580	73080	19140	3480
100	12600	3300	600	600	75600	19800	3600
120	15120	3960	720	620	78120	20460	3720
140	17640	4620	840	640	80640	21120	3840
160	20160	5280	960	660	83160	21780	3960
180	22680	5940	1080	680	85680	22440	4080
200	25200	6600	1200	700	88200	23100	4200
220	27720	7260	1320	720	90720	23760	4320
240	30240	7920	1440	740	93240	24420	4440
260	32760	8580	1560	760	95760	25080	4560
280	35280	9240	1680	780	98280	25740	4680
300	37800	9900	1800	800	100800	26400	4800
320	40320	10560	1920	820	103320	27060	4920
340	42840	11220	2040	840	105840	27720	5040
360	45360	11880	2160	860	108360	28380	5160
380	47880	12540	2280	880	110880	29040	5280
400	50400	13200	2400	900	113400	29700	5400
420	52920	13860	2520	920	115920	30360	5520
440	55440	14520	2640	940	118440	31020	5640
460	57960	15180	2760	960	120960	31680	5760
480	60480	15840	2880	980	123480	32340	5880
500	63000	16500	3000	1000	126000	33000	6000

Example: For a health facility with 210 patients registered, adequate stock for 3 months would be 27720 tablets of Amlodipine 5 mg, 7260 tablets of Telmisartan 40 mg & 1320 tablet of Chlorthalidone 12.5 mg

Note: If there are multiple strengths of the same medication is available, convert to the base strength mentioned in the table.

Annexure D: Drug requirement: Ready Reckoner ATTACC protocol

	Thre	e month drug r	equirements		Three m	onth drug requirer	ments
No. of patient registered (Up-to)	Amlodipine 5 mg	Telmisartan 40 mg	Chlorthalidone 12.5 mg	No. of patient registered (Up-to)	Amlodipine 5 mg	Telmisartan 40 mg	Chlorthalidone 12.5 mg
20	2040	1200	120	520	53040	31200	3120
40	4080	2400	240	540	55080	32400	3240
60	6120	3600	360	560	57120	33600	3360
80	8160	4800	480	580	59160	34800	3480
100	10200	6000	600	600	61200	36000	3600
120	12240	7200	720	620	63240	37200	3720
140	14280	8400	840	640	65280	38400	3840
160	16320	9600	960	660	67320	39600	3960
180	18360	10800	1080	680	69360	40800	4080
200	20400	12000	1200	700	71400	42000	4200
220	22440	13200	1320	720	73440	43200	4320
240	24480	14400	1440	740	75480	44400	4440
260	26520	15600	1560	760	77520	45600	4560
280	28560	16800	1680	780	79560	46800	4680
300	30600	18000	1800	800	81600	48000	4800
320	32640	19200	1920	820	83640	49200	4920
340	34680	20400	2040	840	85680	50400	5040
360	36720	21600	2160	860	87720	51600	5160
380	38760	22800	2280	880	89760	52800	5280
400	40800	24000	2400	900	91800	54000	5400
420	42840	25200	2520	920	93840	55200	5520
440	44880	26400	2640	940	95880	56400	5640
460	46920	27600	2760	960	97920	57600	5760
480	48960	28800	2880	980	99960	58800	5880
500	51000	30000	3000	1000	102000	60000	6000

Example: For a health facility with 210 patients registered, adequate stock for 3 months would be 22440 tablets of Amlodipine 5 mg, 13200 tablets of Telmisartan 40 mg & 1320 tablets of Chlorthalidone 6.25 mg;

Note: In case there are multiple strengths of the same medication is available, convert it to the base strength mentioned in the table.

Annexure E: Min-Max inventory levels

Min-Max inventory levels stand for the minimum and maximum level of the stock to be maintained at a health facility.

- The minimum stock level is the level of stock at which actions to replenish drugs must be ensured.
- Buffer stock is the quantity of stock that should be maintained in case there is a disruption or delay in the regular frequency of supply and is typically kept at one month's stock.

Min stock level = Quantity required for replenishment period + buffer/safety stock

Maximum stock level = 2 X quantity required for replenishment period + buffer stock.

• Under normal circumstances, a facility should not have stock above the maximum stock level.

The decision for minimum and maximum level is dependent upon how frequently the health facility receives the drug stock.

Table: Recommended Min and Max stock based on frequency of supply

Frequency of supply	Buffer stock	Minimum stock	Maximum stock
Monthly	1 month	2 month	3 month
Two monthly	1 month	3 month	5 months
Quarterly	1 month	4 month	7 months

Calculating indent = Max stock quantity level – stock in hand

Annexure F: Specification for quality digital BP instruments

- 1. Designed for professional use in hospital settings (personal homebased use models not to be included).
- 2. Model(s) meets at least 1 of 3 global standards#
 - i. Association for the Advancement of Medical Instrumentation (AAMI)/ American National Standards Institute (ANSI) / International Organization for Standardization (ISO)
 - ii. British Hypertension Society (BHS)
 - iii. European Society of Hypertension International Protocol (ESH-IP)
- 3. Device must have the validation as per international standards and the publication of the device validation should be available.
- 4. Pressure measurement range should be 60 to 290 mm Hg systolic, and 40 to 200mm Hg diastolic
- 5. Pressure display accuracy of +/- 3 to 5 mm Hg
- 6. Measurement method: oscillometric measurement
- 7. Cuff Size: At least two cuff sizes (minimum two cuffs to be supplied for each machine)
- 8. Operable in both battery and electrical outlet (input range 100-240V and output voltage DC 6V) and 150-200 measurements when fully charged
- 9. Availability of replacement cuff/sleeve
- 10. Built-in surge protection to prevent damage to instrument in case of power surge.
- 11. Service centres available within the state
- 12. Devices should include a temperature-stabilizing system, which allows for use in extreme weather conditions.
- 13. Minimum of three years warranty including all spares and re-calibration
- 14. Rate of inflation/deflation to be specified by vendor
- 15. Low Battery indicator and error indicators
- 16. Carrying case/bag to be provided

Chapter 4: Task sharing and patient-centred care

Expected competency on completion of session:

- Understanding how task sharing and Patient centred approaches can be used to provide comprehensive hypertension management in public health systems
- Processes of decentralized care

Audience: Program managers, medical officers, non-physicians (staff nurse, ANMs and others) In this session, you will learn about:

- Implementing team-based care & patient-centred services
- Improving patient flow in clinics
- Decentralization to subcentres and health and wellness centres.

4.1 Task sharing

Strategic redistribution of tasks among various health care workers within the public health clinics can enhance the efficiency of care. Some examples of task sharing in hypertension management are:

- Diagnosis of hypertension by a medical officer
- Blood pressure measurement by a staff nurse instead of a medical officer
- Drug refill by a staff nurse or ANM when BP is under control instead of a medical officer
- Dispensing of NCD drugs by staff nurses at the NCD clinic/corner, instead of a pharmacist
- The entry of patient details in treatment cards by a counsellor *instead of* a staff nurse

Team-based care

- Strategic redistribution of work among members of a practice team
- All the members play an integral role in providing patient care
- Deliver better services and care

Task shifting

- Reassignment of clinical and non-clinical tasks
 from one level or type of health worker to
 another while maintaining quality
- Health services can be provided more efficiently
- Increases the accessibility of services to the patients and increases adherence

Task Sharing

4.1.1 Advantages of task sharing

- Expanded access to care
- Provision of better support to patients

- Improved patient awareness
- Improved adherence to medications
- Improved follow up visits and BP control
- Time-saving and cost-efficient
- Enhanced patient and health staff satisfaction

4.1.2 Requirements to initiate and establish task sharing in a facility

- Identification of potential staff by Medical officer
- Training of health staff on tasks such as BP measurement and dispensing of medications
- Enable existing health staff cadres such as supervisors, entry operators to enter patient details in treatment cards or Simple app
- Clearly define roles and responsibilities for each cadre of health staff
- Ability to monitor the process regularly and take feedback for further improvement

4.1.3 Steps for implementing task sharing

- 1. **Engage the team:** At the health facility, bring together a team of health staff of various cadres such as regular and/or NCD staff nurses, supervisors, pharmacists, counsellors, lab technicians, and non-clinical staff such as attenders. The team should be guided and managed by a physician/medical officer.
- 2. **Determine the team composition:** Determine the model of care which needs to be set up depending on the level of health facility (PHC/CHC/DH) and patient load. Identify which cadre of health staff need to be trained on new skills in order to establish streamlined patient flow. The members of the team must be motivated enough to carry out the newly designated tasks.
- 3. **Design workflows to reflect the new model of care:** Based on the composition of the new team and newly designated roles and responsibilities, determine the new workflow pattern or patient flow. Plan the workflow so that the members of the team are comfortable in doing the allocated tasks and the process is saving time while preserving quality.
- E.g.: When a patient's BP is under control, the staff nurse dispenses the same drugs to the patient and sends the patient directly to the pharmacist, instead of the patient going to the Medical officer.
- 4. Increase communication among the team members and with patients: Organise weekly meetings with the team to see their progress and modify the flow based on feedback. The team leader, typically a medical officer should keep the communication open with the team members. Make patients aware of the new roles of the health staff using wall posters/signs.

Examples:

- a. BP will be measured by a staff nurse after issuing OP slip
- b. Hypertension and diabetes medicines will be dispensed by a pharmacist
- 5. **Use a gradual approach to implement the model:** Give time for the team members to get adapted to the new workflow and their new roles. This might take weeks or months.

E.g.: A supervisor at the facility might take time to get used to entering patient details in the treatment cards or entering data online.

6. **Optimize the workflow:** After receiving feedback and observing the new workflow, optimize it so that the patient needs to visit fewer counters. This saves time and increases efficiency.

E.g.: A patient with controlled blood pressure meets only a staff nurse and a pharmacist and, in some cases, just a staff nurse (if the nurse can dispense drugs)

4.1.4 Responsibilities which can be shifted to non-physicians

Certain functions or skills can be shifted from physicians to other health staff such as staff nurses, supervisors, pharmacists, etc. They are:

- History taking
- Blood pressure measurement
- Continuing medication to those patients with controlled BP
- Providing lifestyle management advice
- Advice on adherence to medication

Table 1: Example team member and roles matrix for hypertension management

Task	Doctor	Nurse/ Community Health officer	Pharmacist	Counsellor	Community HW
Patient history		✓			✓
Diagnosis	✓				
Evaluation for secondary causes, other risk factors & organ damage	√				
Identify barriers to adherence		✓	✓	✓	✓
BP measurement		✓		✓	✓
Lifestyle counselling	✓	✓		✓	✓
Refill medications		✓	✓		✓
Titrate medications	✓				
Patient follow-up		✓		✓	✓
Refer to higher centre		✓			✓
Data entry		✓	✓	✓	✓

4.2 Opportunistic screening and patient flow

As discussed in chapter 2, all adults aged ≥ 18 years should be screened for hypertension at health care facilities. To ensure that every patient's BP is measured, the following measures can be undertaken:

a. Structural

- Putting up of notice boards stating that "All adults should check their blood pressure" and providing directions to the place of measurement.
- Setting-up an NCD pre-check area before the examination by the doctor and establishing proper patient flow.

b. Manpower-related

- Dedicated/ designated NCD staff nurses and counsellors for blood pressure measurement and recordings.
- Engaging available staffs in the clinic PHC ANM, health supervisor, educator, pharmacist, dressers, nursing students, etc.

c. Logistic

- Ensuring availability of professional digital BP monitors.
- Regular refresher training of staff in BP measurement.
- Documentation of BP measurement for all adults in OPD registers.

d. Administrative


- Gradual scale-up in facilities: start in few facilities; once established, use the lessons learnt in other facilities.
- District/State official should issue guidelines/orders on opportunistic screening.
- Discussing issue of opportunistic screening and registrations at the review meetings.

e. **Supportive supervision:** During supportive supervision, a supervisor can

- Identify a paramedical staff who can be trained and engaged for BP measurement
- Assess gaps in opportunistic screening (e.g. compare the OPD attendance and number screened)

Once a patient has been diagnosed with 'hypertension' and started on treatment by the medical officer, facility staff nurse (or another person designated for the job) should document details in treatment cards or the Simple app and facility hypertension register. A patient ID card/BP passport should be is issued to the patient.

Suggested Patient flow for opportunistic screening in clinic



4.3 Patient-centred services

The success of any program depends on how effective it is in reaching the patients and the community. That is why developing a patient-centric approach is crucial in ensuring the long-term sustainability of the program.

A patient-centred approach is "providing care that considers the patient's needs, values, preferences and ensures accessibility of quality services."



4.3.1 What are the ways to improve patient-centred services?

- Reduce and preferably eliminate the cost for medications and medical visits;
- Increasing patient convenience of visits and medication refills (e.g. refills for at least 30 days and when possible for 90 days);
- Use of once-daily treatment regimens to increase treatment adherence and make the patient feel comfortable taking the medicines;

- Improving access to blood pressure measurements and possibly medication refills at HWC and SC;
- Provide lifestyle advice and adherence counselling.

4.3.2 Strategies to establish patient-centred services

- Decentralized care: moving care closer to the patient's home (from district hospitals to PHCs; From PHCs to sub-centre/health and wellness centers);
- Home-based BP check-up and drug refills to bedridden patients and elderly patients;
- Awareness generation in the community about the importance of hypertension and its regular treatment - through ANMs and ASHAs in local meetings and gatherings;
- Form patient support groups for mutual motivation;
- Public education to increase awareness of the importance of blood pressure control.

4.4 Decentralisation to sub-centres/health and wellness centres (HWC)

Patient-centred services can only be made possible if the services under the program are decentralised to make them available at the sub-centre/health and wellness centre level.

When services like BP measurement and drug refills are available only at the level of PHC/CHC/DH, patients may find it difficult to visit the facility every month due to various reasons:


- Distance between the patient's home and facility
- Lack of adequate transport facilities
- Out-of-pocket expenditure on transport by the patient
- Inability to travel elderly/disabled/bedridden patients

Most patients come from rural areas with difficult access to PHC/CHC/DH and hence will find the services more acceptable if they are made available nearer to them

Decentralisation is "BP check-up and drug refills at the sub-centre level/HWC level"

Principle of comprehensive primary health care: Time to care < 30 mins


4.4.1 Strategies for decentralisation



Experience from Telangana: Decentralisation was initiated as a pilot in select facilities in IHCI districts of Telangana. The following strategies were adopted:

- Training of ANMs on IHCI components and BP measurement by CVHO and STS
- Orientation of ASHAs on components of IHCI
- Ensuring functional BP apparatus at all sub-centres
- Copies of original treatment cards given to ANMs to maintain at sub-centre
- Drugs supplied to sub-centres from the PHCs based on number of patients registered in those sub-centres
- Details of patients' visits entered in the copy of treatment card or in the register maintained by ANM during the follow-up visits
- ANM refills drugs for patients with controlled BP, while patients with uncontrolled BP are referred to PHC
- Data of follow up visits in the copies of cards transferred to the original cards at the PHC during monthly meetings
- Defaulters identified by ANM at the end of the month and information of those patients given to respective ASHAs for tracking and retrieval through home visits


4.4.2 Patient flow under decentralisation



4.4.3 Format for line list register at the sub-centre

						Mor	nth 1	Mor	nth 2
	Patien Patie		100/50	Address &	Adhar		Treatment		Treatment
Sl.No.		Patient	Age/Se	Phone	Numb		(Drug		(Drug
	t ld*	Name	X	Number	er		Name &		Name &
						Date/BP	Dose)	Date/BP	Dose)
		Ganta		H.no 1-28 Near high		09.07		08.08	
1.	23	Shyam	45/M	school	0098	134/84	Amlo 5mg	130/34	Amlo 5mg
*Only for regist	ered patier	nts							

The response to decentralization in Telangana is highly encouraging. For example, in Telangana, the follow-up and BP control rates were 77% vs.47% and 53% vs. 35% in decentralized and not-decentralized PHCs, respectively. This is because patients find it convenient to do a follow up at the subcentres as there is less travel and wait time. Further, the follow-up rates in decentralised villages were significantly higher than the district averages. (See figure below).



Decentralization of hypertension care to HWCs and subcentres is likely to enhance detection and control of hypertension and helps to achieve the National Action Plan goal of a 25% reduction in high blood pressure.

4.5 Health and Wellness Centre (HWC)

Transforming existing sub-centres and primary health centres into health and wellness centres will ensure universal access to an expanded range of comprehensive hypertension management services, including prevention of risk factors, promotion of healthy lifestyles, effective hypertension treatment, and rehabilitative care.

A team-based approach by mid-level healthcare provider (MLHP) and auxiliary nurse midwife (ANM) in HWCs can enable the delivery of high-quality care through a commensurate expansion in improved delivery of medicines and availability of diagnostics, use of standard treatment protocols and advanced technologies, including IT systems like Simple app.

4.5.1 Implementing IHCI in HWCs

- 1. **Manpower**:- MLHP is additional manpower in HWCs supporting already existing ANMs and ASHAs in sub-centres.
- 2. Capacity building: Training of staff on comprehensive hypertension management and control.
- 3. **Logistics and drugs**: All HCWs would be equipped with a professional digital sphygmomanometer, treatment cards, hypertension line list and follow up registers and adequate stock of all anti-hypertensive drugs as specified under the state hypertension treatment protocol.
- 4. **IEC**: Posters on the method of blood pressure measurement along with hypertension diagnosis and treatment protocols. Health education materials on lifestyle modifications.

- 5. **Recording and reporting**: Manually done through individual treatment card and hypertension register or through electronically-maintained data through the GOI CPHC NCD solution or the Simple app.
- 6. **Health promotion and counselling**: Counselling on lifestyle modifications and treatment adherence.

4.5.2 Services to be provided in HWCs under IHCI

- 1. **Opportunistic screening**: Early detection using professional Sphygmomanometer and linking with population-based screening. All suspected cases identified at HWCs would be confirmed by a medical officer at PHC or higher centre.
- 2. **Registration**: Confirmed cases would be registered at HWCs by issuing the treatment card or in the Simple app.
- 3. Standard treatment protocol: Equitable distribution of free and quality drugs as per the established state-specific standard treatment protocol. Treatment provided at HWCs to hypertensives whose blood pressure is under control. However, confirmation and initiation of treatment would be done only by the medical officer at PHC or higher centres.
- Referral services: for patients with uncontrolled BP or complications. In addition, suspected cases
 whose diagnosis need to be confirmed or treatment initiated will be referred to a PHC or higher
 centres.
- 5. **Follow up**: Tracking and follow up of each patient every month through individual treatment card ensuring the continuum of care. ASHA incentives would be tagged with home visits and follow up of treatment compliance.
- 6. **Linkage with mobile medical units (MMUs):**ANM/MLHP attending the MMUs would ensure the linkages of services
- 7. **Recording and reporting** HWCs will maintain individual treatment cards and hypertension register for tracking of treatment compliance and retrieval of defaulters. Monthly registration and quarterly and annual reports are sent to PHC.
- 8. **Health promotion and community mobilisation** Provision of regular advice on adopting a healthy lifestyle and avoiding modifiable risk factors along with training on yoga and meditation.

4.5.3 Roles of various field staff under the program

Staff Cadre	Roles
	Compile village level line list of hypertensives
	Mobilise patients for registration
	Maintain a copy of treatment cards or the follow-up register
	Measure BP of patients and give drug refills during follow up visits
	Enter details of follow up visits in treatment cards or follow up register
ANM	Give appointment for next follow up visit
	Refer to medical officer if BP is not under control or if any complications are present

Receive and maintain antihypertensive drugs from PHC pharmacist
Send monthly report of follow-ups and missed cases to PHC staff nurse
Share list of defaulters with ASHAs for home visits
Organise awareness activities related to NCDs during village level meetings
Coordinate with local public representatives in awareness activities
Screening for hypertension in the community and referral of suspected cases to PHC
Registration of confirmed cases under IHCI and issue treatment card and patient ID card
Monthly drug refills to patients with BP under control
Refer patients with uncontrolled BP or complications to Medical officer
Tracking of follow up visits with defaulter identification and retrieval
Follow up of patients receiving drugs at Mobile medical units
Maintain treatment cards and send regular reports such as Quarterly and Annual reports
Health education to patients on lifestyle modifications
Maintain a line list of hypertensives of their village
Mobilise patients for registration
Collect a list of defaulters from ANM
Make home visits to defaulters and counsel to come for follow up
Counselling patients on treatment adherence
Patient education about complications and danger signs

4.6 Lost to follow up – prevention, identification, and retrieval

For the success of IHCI, it is crucial for the program to ensure that people with hypertension registered with IHCI are regularly followed up at the health facilities for monitoring of blood pressure and refilling of medication.

For programmatic reporting, IHCI defines **'lost to follow up'** as those individuals who did not return to care for 12 months. **"Missed visit"** is defined as those individuals who did not return to care at least once in a quarter following 3-6 months of registration. In this section, we describe the strategies for prevention, identification, and retrieval of patients.

Based on the experiences of IHCI phase 1, the following factors that can affect lost to follow up have been identified:

1. Health system factors

- Drug stock-outs: patients lose trust with the system
- Non- or irregular availability of service providers
- Unfriendly staff
- Longer distance to health facilities or higher cost of travel
- Lack of patient education on importance of adherence and follow up
- Drug side effects

2. Patient factors

- Lack of awareness asymptomatic condition; lack of perceived importance of regular treatment
- Elderly patients and bedridden patients
- Preference for private sector/informal providers

In addition, the following factors hinder retrieval of patients back into the system:

- Large registrations in higher-level health facilities, such as district hospitals, where
 - o The clinic is not linked to community-level staff to retrieve patients
 - Registered patients may be from far-off places
- Poor documentation of patient contact details
- Lack of telephone facilities in clinics and nurses' concerns relating to the usage of personal phones for making patient calls.

4.6.1 Prevention of Loss to follow up

The focus should be on good quality implementation of IHCI strategies to prevent or reduce patient loss to follow up.

1. Availability of drugs and service providers

- i. Patients lose trust in the clinic/system if drugs and providers are frequently unavailable during their visit.
- ii. Ensuring uninterrupted medication through improved drug logistic systems would reduce the issue of shortage of drugs.
- iii. If there is a deficiency in human resources, a stop-gap arrangement should be made to ensure no interruption in services. For example, if there is no medical doctor at PHC, a medical doctor from neighboring PHC or CHC may be deputed to visit the PHC on a fixed day of the week. (This is being practiced in Punjab and Madhya Pradesh)
- iv. Patient BP monitoring and continuation of medications can be carried out by other trained staff in the clinic- staff nurse, health supervisor, ANM or pharmacist.
- 2. **Decentralization** Patients are more likely to come regularly for follow up if the clinics are closer to their home. This can be ensured at two levels.

- Patients detected with hypertension at higher facilities (district hospitals & CHCs) Register and initiate the treatment. Thereafter, facilitated 'transferring out' to a PHC
 closest to their place of stay. This has been piloted in Telangana with reasonable success.
- ii. Patients registered at PHCs, should be encouraged to follow up for medications and BP monitoring services at a sub-centre/HWC near their residence.

In parallel, ensure

- Availability of medications at the HWC/SC
- Systems for sharing of patient information between HWC/SC and PHC/CHC where the patient is registered

In Telangana, this is been tried in a few PHCs where sub-centres were provided with IHCI medications from the PHC and a copy of the treatment card. In these PHCs, programmatic data showed that the follow up was higher than the district average.

3. Patient counselling and education

- a. Counsel/educate patient during registration about the importance of regular treatment and follow up visits
- b. Staff who can counsel at various levels
 - i. Staff nurse
 - ii. Counsellor
 - iii. Pharmacist
 - iv. MLHP/ANM
- c. Patients must be educated on
 - i. Importance of regular treatment and BP monitoring
 - ii. Risk of stroke, heart attack, kidney failure if BP not controlled
 - iii. Availability of services
 - iv. Patients must come at least 3-4 days before the medicines are going to be finished

4. Documentation of patients' details

- Documentation of patient contact details in the treatment card is essential to retrieve the patient who missed visits. The details which must be documented are:
 - i. Full name
 - ii. Full address with landmark (PHC area, sub-centre, and village)
 - iii. Patient's phone number
 - iv. Phone number of relatives or neighbors if the patient does not have his/her own phone
- 5. **Documentation of every visit:** It is important to ensure all visits of a patient are documented and the blood pressure recorded. Lack of documentation will lead to an incorrect marking of 'missed visit'.
 - A good patient flow within a health facility will improve the documentation.

- The entry of patient's BP in OPD register cab be an effective way to ensure patients aren't missed
- Local measures may be undertaken. For example (Stamping of outpatient card). In higher health facilities such as district hospitals, the recording, and reporting are maintained at the NCD clinic. However, registered patients may visit other doctors in the facility to receive treatment for hypertension. These patients will be noted as missed follow up as they did not visit the NCD clinic, though they had followed up at the same facility (false negative reporting). To address this issue, District Hospital Ratlam has started using an NCD clinic stamp on outpatient cards. The pharmacist of the clinic has been instructed that the medication for hypertension is provided only to those patients whose cards have the NCD clinic stamp. If the stamp is missing, patients are requested to visit the NCD clinic where their visit is noted.

मरवार बल्लम माई पटेल शि:शुल्क औषि वितरण केन्द्र, रतालाम जिला चिकित्सालय, रतलाम (म.प्र.) व्याई भण्डार पर्जी पेजीयन क्र. 1257 900288) 6 विनोक नाम रोगी Aman chand 7-54/M 7. Amnodipine smg - 3

Practice of NCD clinic stamp at DH Ratlam, Madhya Pradesh

6. Patient-centred care

- i. Simple prescriptions: patients should get medication for a minimum of 30 days. If BP is under control and adequate drugs are available, medication may be provided for 90 days. If available, preferably provide fixed-dose combination medication.
- **ii.** Less wait time: patients are unlikely to visit clinics regularly if the wait time is long and if they must go to multiple counters. Minimal documentation and single window clearance may encourage patients to make a quick visit to the clinic.
- **7.** Friendly staff that make patients comfortable ensures that patients will want to come regularly for visits.

Patient reminders

- i. Some facilities in Telangana telephonically contact patients before the due date to remind them of their impending visit. However, this may not be feasible in busy clinics.
- **ii.** Short Message System (SMS): An automated reminder message (text message or WhatsApp message) before the due date may be tested for its effectiveness in improving follow up.

4.6.2 Identifying 'missed visits'

A. Paper-based reporting

- **1.** Two stack system (see chapter 5 for more details)
 - Commonly followed system for quick identification patients who missed a visit by the end of the month
 - Requires two shelves
 - On the first day of each month, all cards should be in the shelf 1.
 - As patients come for treatment during the month, the card is taken from shelf 1, updated and placed at corresponding numbers in shelf II.
 - On the last day of the month, review leftover cards on shelf 1. These are patients who did not visit the health facility during the month.
 - Once in three months, a list of patients who did not come for follow up should be prepared, ideally sub-centre wise and shared with the respective ANM/ASHA for follow up.

Example of two stack system of storage

Pre-printed patient registered numbers

Some PHCs in Kerala has a large number of registered patients (up to 2000) and also have only
one or two days of NCD clinic in a week. This has resulted in very busy clinics wherein
maintaining two stack system is difficult. Some clinics in Thrissur have designed a system of pre-



printed patient registration numbers



- At the beginning of the month, all IHCI registered patient ID numbers are printed on a sheet of paper. When a patient visits the facility his/her registration number is struck off.
- At the end of the month, all the numbers that are not struck out are the defaulters

			Defaul	ter Ident	ification:	HT/HD						
Name o	f Instituti	on:		Name of the Nodal Person of institution:								
Month	_			Total no: of defaulters identified in the month:								
0001	0041	0081	0121	0161	0201	0241	0281	0321	0361			
0002	0042	0082	0122	0162	0202	0242	0282	0322	0362			
0003	0043	0083	0123	0163	0203	0243	0283	0323	0363			
0004	0044	0084	0124	0164	0204	0244	0284	0324	0364			
0005	0045	0085	0125	0165	0205	0245	0285	0325	0365			
0006	0046	0086	0126	0166	0166 0206 0246 0286 03							
0007	0047	0087	0127	0167	0207	0247	0287	0327	0367			
0008	0048	0088	0128	0168	0208	0248	0288	0328	0368			
0009	0049	0089	0129	0169	0209	0249	0289	0329	0369			
0010	0050	0090	0130	0170	0210	0250	0290	0330	0370			
0011	0051	0091	0131	0171	0211	0251	0291	0331	0371			
0012	0052	0092	0132	0172 0212 0252 0292 0332 0								
0013	0053	0093	0133	0173	0213	0253	0293	0333	0373			
0014	0054	0094	0134	0174	0214	0254	0294	0334	0374			
0015	0055	0095	0135	0175	0215	0255	0295	0335	0375			

2. Line list of missed visits

- At the end of every month, based on various systems mentioned above, staff nurse identifies patients who missed their visits.
- List of patients who did not visit in the last three months are made and the patients contacted and reminded for follow up.
- Once every 3 months, coinciding with the quarterly report, a list of patients with missed visits who did not return to care for the last 3 months is made sub-centre-wise and shared with ANMs and ASHAs for further tracking and retrieval.

3. Follow up register

Many facilities (specifically those with high registration) maintain separate follow up register.
 Patients' contact details are entered registration number-wise and month-wise columns are provided for marking follow up over the subsequent 12 months. In the monthly column, the date of the visit is noted when the patient visits.

Advantages:

a. All contact and follow-up details of the patient are in one place

- b. Helps identify patients who miss visits
- c. Facilitates preparation of facility monthly report
- d. Allows identification of not just those who defaulted in the previous month but also patients who have defaulted for a longer duration
- e. Provides pattern of defaulters at a glance

B. Digital reporting

1. Overdue list from Simple App

The Simple app automatically generates the overdue list of patients who have missed visits after 30 days of the previous visit. This is accessed at the 'overdue' tab of the app. The list is also organised in order of priority (patients with BP≥160/100 and longer duration of 'no follow up') along with phone numbers for the ease of health facility nurse. The Simple app in mobile phones also has an overdue list from where staff can directly make calls to patients. The calling number is masked to ensure the privacy of the health staff phone number.

The overdue list may also be downloaded by the supervisors from the Simple app dashboard. The list can be downloaded at the end of every quarter.

Example of an overdue list from the SIMPLE app


		-	_								
Patient nam									Patient ac	Patient village or color	Patient phor
	Female	70		18-May-18			18-May-18			Mojpur	
	Female	52		24-Sep-18			24-Sep-18			Old bagria	
	Female	55	197	6-Mar-19			6-Mar-19			Near water tanki Bhaini	
Karamjit Kau		60		11-Mar-19			11-Mar-19			Near peer baba vill new	
Balwant Sing		59	146	3-Apr-19		CHC Bha	3-Apr-19	High		S/o shingar singh nanov	
Manjit Kaur	Female	70	134	15-Apr-19	160/90	CHC Bha	15-Apr-19	High		W/o kartar singh nanow	9915568046
Manjit Kaur	Female	52	134	15-Apr-19	140/100	CHC Bha	15-Apr-19	High		W/o Rashpal singh Shis	9815335108
Nishan Singh	Male	45	104	14-May-19	176/90	CHC Bha	14-May-19	High		Virsa singh Rajpura	9878791525
Baldev Kaur	Female	70	103	15-May-19	160/90	CHC Bha	15-May-19	High		Nanowal kalan	9915982503
Nancy	Female	60	97	20-Apr-18	160/90	CHC Bha	21-May-19	High		Old bagria	7347668977
Balbir Kaur	Female	60		10-Jun-19	160/90	CHC Bha	10-Jun-19	High		W/o dalbir singh alma	9872118989
Gurmeet Kau	Female	47	51	6-May-19	160/100	CHC Bha	27-Jul-19	High		Gandhi camp batala	7814162843
Kirandeep (2	Female	50	51	27-Jul-19	160/100	CHC Bha	27-Jul-19	High		Gandhi camp batala	8528446270
Sharanjit Kau	Female	80	38	19-Jul-19	160/90	CHC Bha	19-Jul-19	High		W/o harbans singh old b	9815727902
Harbans Kau	Female	60	419	4-Jul-18	148/90	CHC Bha	4-Jul-18			Near palace, b.m khan	
Amarjit Kaur	Female	53	375	16-Aug-18	140/90	CHC Bha	16-Aug-18			P.o. b.m. khan, jhanda	9876229855
Gurmeet Kau	Female	32	360	1-Sep-18	140/85	CHC Bha	1-Sep-18		Out side fr	Bhaini	9878083685
Kewal Singh	Male	65	347	14-Sep-18	150/90	CHC Bha	14-Sep-18			Jhanda	
Surjit Kaur	Female	57	321	9-Oct-18	150/90	CHC Bha	9-Oct-18			B.m. khan	
Jasbir Kaur	Female	34	185	20-Dec-18	140/90	CHC Bha	20-Dec-18			Lakhanpur	9914078413
Bachno Devi	Female	60	166	13-Mar-19	146/90	CHC Bha	13-Mar-19			W/o jagdish lal Vill Dtarp	8427048516
Swarn Singh	Male	60	146	20-Aug-18	140/90	CHC Bha	8-Mar-19			Mullanwal	9915946946
Sudesh Kum	Female	42	146	7-Aug-18	142/88	CHC Bha	2-Mar-19			Bhaini mian khan	8283006784
Rattan Kaur	Female	62	125	18-May-18	140/88	CHC Bha	24-Apr-19		Primary so	Kotli harchanda	9878587706
Harbhajan Si	Male	0	123	17-Aug-18	140/86	CHC Bha	26-Apr-19			P.o. alma	9876278363
Sunita	Female	42	119	30-Apr-19	150/90	CHC Bha	30-Apr-19			Bhadhroa ptk	9914456344
Lakhwinder F	Female	67	116	4-Dec-18	140/80	CHC Bha	2-May-19			Alma	8284875846
Malook Chan	Male	68	111	13-Nov-18	140/90	CHC Bha	7-May-19			Old bagria	9501780532
Dhalwinder S	Male	46	108	10-May-19	140/90	CHC Bha	10-May-19			Nirmal singh ALma	9876718341
Surinder Kau	Female	55	104	14-May-19	150/90	CHC Bha	14-May-19			Fulrha	9915302134
Jasveer Kaur	Female	50	98	20-May-19	150/90	CHC Bha	20-May-19			Jaspal singh BM khan	9779342679
Sarabjit Kaur	Female	60	95	7-Mar-19	140/86	CHC Bha	23-May-19			Vill ferochechi b m khan	9592321956
Gurmeet Kau	Female	70	95	23-May-19	140/90	CHC Bha	23-May-19			Vill raju bela	9876664376

4.6.3 Retrieval of patients who missed follow up visits

A. Retrieval strategies

1. Telephonic contact:

- Practiced in most facilities. Patient should be contacted over the phone if he/she did not return for the visit. The first attempt to connect with patients is telephonic contact irrespective of paper or digital record system. The call is usually done by health facility nurse. A list of patients who missed visit in the previous 3 months can be prepared for making calls.
- The phone calls that are made through the Simple app allows masking of the caller's phone number. The outcome of the call made to patient should be documented.



2. Home visits by ANM/ASHAs:

- Under the NPCDCS program there is a provision for incentives to ASHAs for ensuring follow up
 of patients with hypertension and diabetes. This provision should be leveraged for the retrieval
 of patients.
- At PHC level
 - Staff nurses prepare sub-centre-wise list of patients who missed visits and hand it over to the ANMs during the monthly meetings.
 - The ANMs return the list with their comments (after home contacts by ASHA workers)whether the patient agreed to return, could not be contacted, had taken medicine from private providers, or other reasons.
 - o This system is currently used in many facilities in Telangana
- At the level of district hospital or CHC
 - It is challenging to retrieve the patients due to the lack of community health workers at the higher-level facilities.

- The list of patients who missed visits can be prepared according to the PHC area (based on the name of the village). This strategy is being tried in many facilities in Telangana. The list is shared with respective PHC NCD nurse through WhatsApp
- PHC NCD nurse attempts retrieval through ANMs
- 3. **Short Message System (SMS):** The Simple app automatically sends reminder text messages requesting patients to return if they have missed their visit by 3 days.
- **4. Patient support groups:** can be tried in remote areas such as tribal areas and closely-knit communities
 - Local support groups can be formed by ASHAs, consisting of local influencers like elected representatives, teachers, local volunteers, village elders, etc.
 - The group can be educated about the patients with hypertension in their community and the importance of their regular follow up.
 - The group can speak to these patients with the objective of "pushing" them for follow up visits.

5. Phone calls by supervisors

- During supportive supervision visits, supervisors such as medical officers/district program
 officers/CVHO/STS can identify missed visits especially of patients with BP ≥ 160/100 mm of Hg
 and call them for retrieval.
- In the process, the staff nurse is also trained and motivated.
- For non responsive cases, concerned ANMs/ASHAs are to be contacted.

6. District/block level monthly reviews

- Regular monthly reviews at the district/block level, along with NPCDCS should be carried out.
- This will help in generating problem-specific discussions and identification of solutions that may require administrative support.

B. Effectiveness of retrieval strategies

As of now, the effectiveness of each of the retrieval strategy is unknown.

- Operational research in the sentinel sites under IHCl is being conducted and the results of this research are expected to provide significant insights. Initial data suggests that nearly half of the patients who were contacted returned to the health facility.
- Analysis of data from the simple app may provide important insights on:
 - The pattern of loss to follow up
 - Effectiveness of SMS and phone calls in the retrieval of patients
- CVHOs and supervisors should also make efforts to document effectiveness in a few health facilities in their districts.

Chapter 5: Information systems - monitoring indicators and reporting tools

Expected competency on completion of session: Ability to correctly maintain primary/secondary health care-level recording and reporting tools

Audience: Medical officers; facility staff nurses; district and state supervisors In this session:

- Understand the core Indicators for monitoring using facility reports: Quarterly & Annual
- Information system
 - Paper-based Patient BP passport with QR code; hypertension treatment card & facility hypertension register
 - Digital systems Simple App
- How to do facility reports Quarterly and Annual

An information system that will enable cohort-based monitoring is one of the core strategies of IHCI. This chapter will provide an overview of monitoring indicators and reporting tools for the paper-based system and an android based Simple app.

5.1 Core indicators

There are two health facility-level indicators calculated from the 'facility quarterly reports' and 'facility annual report'. (These reports are discussed in later part of the chapter)

5.1.1 Quarterly indicator – 3 to 6 monthly hypertension control rates

Percent of patients starting treatment during a quarter (cohort) who achieve BP control (<140/90) 3 - 6 months after the start of treatment

Number of patients with controlled BP (<140/90) during the last clinical visit who started hypertension treatment 3 – 6 months earlier (A2)


-----X 100

Total number of patients who started hypertension treatment 3 – 6 months earlier (A1)

- Tracer indicator for the quality of the program
- It is a measure of the effectiveness of treatment among patients
- Identify health facilities with lower performance and support them early with the required interventions
- Indicator can be measured for each treating health facility once every quarter


Understanding the patient cohorts for the quarterly report

- Cohort is defined by the quarter of registration
- BP control of each cohort is assessed 3- 6 months after the start of medication




3 - 6 months' cohort for quarterly indicator


BP control of cohort registered in January to March




BP control of cohort registered in April to June



BP control of cohort registered in July to September





5.1.2 Annual Indicator

Percentage of patients with hypertension who have controlled BP in a defined geographical area (reported annually):

Number of patients with controlled BP (<140/90) during quarter 1 of the next year (if the patient made more than one visit in the quarter, use most recent reading) (B2)

-----X 100

Estimated number of people with hypertension in the catchment population/geographical area (district/state/province level) (B1)

- The numerator will include all patients with blood pressure under control during the recent visit between January 1 to March 31 irrespective of year of registration. It will also include patients who got registered in previous years.
- Indicator of impact: coverage and quality of the programme
- Estimates coverage of patients with controlled hypertension in an area
- The aim is to increase the number of people with controlled BP to increase the impact of the programme

- Measured for a district or a State
- The denominator is derived from the estimated prevalence for a District/State
- Measured once in a year in April month each year

For Annual indicator - hypertension control coverage rate for one year

Date of reporting – 15th April of every year

All patients
registered
from start of
programme
by 31 Dec
2020

Ready reckoner to determine the quarter for which the quarterly report is to be prepared		
Month in which quarterly report prepared	Quarter for assessing if BP is under control (Yes/No) (A2)	Quarter in which patients registered for HTN Treatment (A1)
July, 2019	April – June, 2019	January – March, 2019
October, 2019	July – September, 2019	April – June, 2019
January, 2020	October – December, 2019	July – September, 2019
April, 2020	January – March , 2020	October – December, 2019
July, 2020	April – June , 2020	January – March, 2020
October, 2020	July – September , 2020	April – June, 2020
January, 2021	October- December , 2020	July – September, 2020
April, 2021	January – March , 2021	October- December, 2020
July, 2021	April – June , 2021	January – March, 2021
October, 2021	July – September , 2021	April – June, 2021
January, 2022	October – December , 2021	July – September, 2021
April, 2022	January – March, 2022	October- December, 2021
July, 2022	April – June , 2022	January – March, 2022
October, 2022	July – September , 2022	April – June , 2022
January, 2023	October – December , 2022	July – September , 2022



Exercise 1

Please complete the following table:

Date of reporting	On the given date of reporting, you will consider the denominator as the number of patients registered in Quarter/Year	On the given date of reporting, you will consider the BP measurement of patients in Column 2 in Quarter/year
Quarterly report		
15 April 2019		
15 April 2020		
15 July 2019		
15 January 2020		
15 October 2019		
Annual report		
15 April 2019		
15 April 2020		


Interpretation of core monitoring indicators




Exercise 2:

Examine figure 1 and 2 and answer the following questions:

- 1. Which indicator does the figure depict?
- 2. How do you interpret this graph?
- 3. What is the difference in the control rate between the two states?
- 4. What is the difference in the uncontrolled rate between two states and possible reasons?
- 5. What is the difference in the proportion of patients who missed visits between two states and possible reasons?







Exercise 3: Calculate the annual indicator with the information given below:

As per the Annual Health Survey, the prevalence of hypertension in district X of ABC state is 26.5%. The projected population for 2019, of adults above 18 years of age is 1,78,9695.

The number of patients with BP less than 140/90 in January 2019 is 655. Calculate estimated hypertension for the given population and annual hypertension control rate.

5.1.3 Hypertension Registration Rate

> Hypertension registration rate:

Total number of patients with hypertension registered at district/state under IHCI
------ X 100
Estimated number of people with hypertension in district/state

This is an important process indicator of the IHCI program. This indicator is used to evaluate the coverage of the program.

5.2 Paper-based reporting tools

5.2.1 Patient BP Passport

When a patient is registered at the health facility for treatment of hypertension, the patient is issued a 'BP passport' which is retained by the patient and will be brought back by each patient during the follow-up visits. It has information on patient identification with patient treatment number and QR code' which is pre-printed on the passport and allotted to the patient by the health facility.

In facilities with the Simple app reporting system

The patient treatment number and QR code will be used to register and retrieve the patient details in the Simple app.



In facilities with paper-based reporting system

In addition to patient treatment number and QR code, the patient ID number generated in a sequential manner starting from 00001 for each health facility. The same patient treatment number will be written in facility register as well as on the BP passport for easy storage and retrieval of treatment card as shown below.



On the day of the visit, the health care worker who attends the patient gives the date of the next visit. This is written on Page 1 of the BP passport. The BP value and drugs prescribed on the day of follow up is written on Page 2. The patient is advised to bring the BP passport every time he/she visits the health facility for follow up.



Purpose of the BP passport:

- Helps to retrieve the patient details in the Simple app or treatment card using the patient treatment number, ID number and QR code displayed in the BP passport.
- It also has a snapshot of the medications the patient is on serves as a treatment record for the
 patient.

5.2.3 Hypertension treatment card

A new 'hypertension treatment card' is made for each individual patient registered for the treatment of hypertension. These patients can be:

- o newly diagnosed with hypertension and starting treatment; or,
- o already on treatment at the facility or elsewhere for hypertension and wish to get/continue treatment at the health facility.

(Please note that one card is issued for one patient)

The treatment card of each patient captures information on:

- 1. Patient identification details
- 2. Prior medical history
- 3. Hypertension medication
- 4. Blood pressure values at registration and follow-up visits
- 5. Follow up of missed visit
- 6. Patient treatment outcomes: lost to follow up, transferred out, moved to a private practitioner, died
- 7. Additional information: laboratory investigations, previous medications, etc

The upper part of the front of the card is to be completed only during the first visit capturing information on patient identification details, and medical history. The lower side of the front of the card and reverse of the card is used for tracking medication and blood pressure values at registration and follow-up visits. In case the patient misses a follow-up visit for 3 months continuously, an attempt should be made by assigned staff to contact the patient either through phone or home visit. The date of contact and responses to retrieval efforts such as no response to the phone call, unable to locate the address, agreed to return or other reasons are captured at the lower side of the card.

If the patient is transferred to other health facilities (private or government) or lost to follow up (did not come for follow up for 12 months continuously) or died (confirmed by a relative) is captured on the second page of the card. Additional notes may be recorded on the reverse relating to patient's laboratory investigations and previous medication history, medication side effects, missed medication history etc.

atient name					Registrat	ion date		Patient II	O numb	er
					DD	I MM	YY	00001,000	002, 0000	l l
Age				_	Health	facility				
Gender	Male	Female (Transgende	ər		District				
Full address						JISHICL				
(s/o, d/o, w/o House Number, Name of Hamlet/Village/Colony/Nagar/ Town/Nearest landmark)				(-	Already o	on medica	tion for hyper	tension?	O Yes	O No
Nearest subcenter					Already o	on medica	tion for diabet	tes?	O Yes	○ No
Phone number					Past histo	ory of hea	rt attack?		O Yes	○ No
Other phone no.					Past histo	ory of stro	ke?		O Yes	O No
Other ID number					Past histo	ory of kidr	ney disease?		Yes	○ No
Blood sugar Freatment dose Ple	ase write dose									
Blood pressure	1	1	1	1		1	- 1	- 1		- 1
Treatment dose Ple	ase write dose	•								
Amlodipine										
Telmisartan										
Chlorthalidone										
Hydrochlorothiazide										
*										
Enalapril										
Enalapril Losartan										
Enalapril Losartan Aspirin										
Enalapril Losartan Aspirin Statin										
Enalapril Losartan Aspirin Statin Metformin	icit places	CONTACT PAGE	lu to roture t	0.0370						
Enalapril Losartan Aspirin Statin Wetformin		contact prompt	ly to return t		oted	Date conf	tact attempted	Date	e contact (attempted
Enalapril Losartan Aspirin Statin Metformin If a patient misses a v	Date cor		Date conta		nted	225	tact attempted		e contact a	
Hydrochlorothiazide Enalapril Losartan Aspirin Statin Metformin If a patient misses a v Date contact attempted No response House not found	Date cor	stact attempted	Date conta	act attemp		O No re		0		nse

atient name				Registr	ation date		Patient ID num	ber
				DD	I MM	YY	00001, 00002, 000	003
Treatment date								
Blood pressure	- 1	1		1	1		1	1
Blood sugar								
Treatment dose Ple Amlodipine	ase write dos	e	1	Ĭ		ī	Ĭ	i
Telmisartan								
Chlorthalidone								
Hydrochlorothiazide								
Enalapril								
Losartan								
Aspirin								
Statin								
Metformin								
f a patient misses a vi	Date con No r Hou	tact attempted esponse se not found sed to return	Date conta	nct attempted sponse e not found d to return	○ No re	act attempted sponse e not found ed to return	Date contac No resp House Agreed	oonse not found
Outcome of follow-u Transferred to anot Moved to a private Lost to follow up (N	her public he practitioner.	Write name of p		e:				

On initial registration and each follow-up visit, non-physician staff enters the date of visit, blood pressure, and treatment dose. During a follow-up visit, if the patient's BP is under control (i.e. systolic <140 and diastolic <90), then non-physician staff dispenses the next month's supply of medication and enters the information in the treatment card. However, if BP is not under control, then the patient is referred/sent to the doctor for up-titration of medication as per protocol and patient's clinical assessment.

If a medicine prescribed by the doctor is not listed in the treatment card, the name of that medication should be added in the blank rows provided for the same.

Purpose of the hypertension treatment card:

- 1. At individual patient level: This helps to track patient's treatment and blood pressure with an objective to keep it below 140/90 mmHg. The card provides information that is needed for individual patient management: the date of the previous visit, due date of follow up, BP control status, regularity of patient visits, and longitudinal data of patient's medications and BP.
- 2. At the program level: It will be used to assess the overall impact of the program. The information will be used to
 - a. Update facility hypertension register
 - b. Prepare quarterly and annual facility reports
 - c. Facilitate supervision
 - d. Facilitate digitalization
 - e. Support operations research

Learner Activity

Exercise 4: How to complete the hypertension treatment card.

Review the patient details and complete the blank treatment card given on the next page.

Please refer to this completed treatment card for future exercises.

Case study 1

Patient name – Rohan Sharma

Age/Sex -34/M

Health Facility - SA Nagar PHC

On 1.1.19, he visits the PHC for the first time to get his blood pressure checked, BP - 146/96 mmHg. The medical officer advises the patient on salt reduction in diet and to review after one month.

On 6.2.19 -the patient returns, the BP was found to be 150/96 mmHg. The medical officer decides to start treatment for this patient. The treatment card was issued.

Address - No 121, Nethaji colony, Thambaram west, Kancheepuram district 600044

Neighbbour's phone number – 981856XXXX. The nearest subcentre to the PHC is Kundrathur.

Rohan's history: Smoker from the age of 17 until 3 years back and an occasional alcoholic. There was no other significant history in the past and in the family.

On examination: Height – 167 cm and weight – 60 kg

Treatment – T. Amlodipine 5 mg per day. The patient collects the prescribed drugs from the pharmacy for 30 days. The patient was asked to come back for a review after one month.

The staff nurse entered the details of the treatment card into the facility hypertension register and assigned patient ID number – 00001.

Following this, the patient's visits are as follows.

4.3.19 - BP - 150/85 mmHg. The doctor adds T. Telmisartan 40 mg per day.

5.4.19 - BP - 130/80 mmHg. Advised to continue the same drugs.

5.5.19 - BP - 124/80 mmHg. Advised to continue the same drugs.

4.6.19 - BP - 120/80 mmHg. Advised to continue the same drugs.

5.7.19 – BP - 125/76 mmHg. Advised to continue the same drugs.

3.8.19 – BP - 130/80 mmHg. Advised to continue the same drugs.

Patient name				Regis	stration date		Patient ID num	nber
				DI	D MM	YY	00001, 00002, 00	003
Age				He	alth facility			
Gender	◯ Male	Female (Transgend		District			
Full address					DISTRICT			
(s/o, d/o, w/o								
House Number, Name of Hamlet/Village/Colony/Nagar/ Town/Nearest landmark)				Alrea	dy on medicat	ion for hyper	tension? () Ye	s No
lown/ivearest landmark)				Alrea	dy on medicat	ion for diabet	tes? Ye	s No
Nearest subcenter				Poot	hiotony of hoo	t attack?	O v-	- ON-
Phone number				rast	history of hear	i allauk?	○ Ye	s () No
Other phone no.				Past	history of strok	ce?	O Ye	s No
Other ID number				Past	history of kidn	ev disease?	○ Ye	s No
Treatment dose Ple Amlodipine Telmisartan	ease write dos	e						
Chlorthalidone								
Hydrochlorothiazide								
Enalapril								
Losartan								
Aspirin								
Statin								
Metformin								
		contest prompt	tly to return	to care				
If a patient misses a v	isit, please	contact promp						
	_	ntact attempted	Date con	tact attempted	Date conta	act attempted	Date contact	ct attempted
Date contact attempted No response	Date co	ntact attempted	O No r	esponse	O No re	sponse	○ No res	ponse
If a patient misses a v Date contact attempted No response House not found	Date co	ntact attempted	O No r		O No re		○ No res	
Date contact attempted No response	Date co	ntact attempted	O No r	esponse	O No re	sponse	O No res	ponse

atient name				Registra	ation date		Patient ID nun	nber
				I DD	i MM	YY	00001, 00002, 00	003
							00001, 00002, 00	
Treatment date								
Blood pressure	1	1	1	1	1	1	1	- 1
Blood sugar								
Treatment dose Plea	ase write dos	se						
Amlodipine								
Telmisartan								
Chlorthalidone								
Hydrochlorothiazide								
Enalapril								
Losartan								
Aspirin								
Statin								
Metformin								
f a patient misses a vis	Date cor	contact prompt	Date conta	act attempted		act attempted		ct attempted
House not found	_	se not found		sponse e not found		sponse e not found	○ No res	not found
Agreed to return	_	ed to return	_	ed to return		ed to return		d to return
0	0		0		0		0	
Outcome of follow-up	<u> </u>							
Transferred to anoth		ealth facility Writ	te facility nam	ne:				
Moved to a private p								
Lost to follow up (No			oon and an english and the control of the control o					
Died. Write date:								
Additional notes (Lat	os, previou	is medications	etc.)					

Exercise 5: Case study 2



Review the patient details and the completed treatment card. Spot mistakes on the card.

Name – Radha Srinivasan, Age/Sex – 56/F

Health Facility – SA Nagar PHC

Patients history - a known case of hypertension for the past 6 months and is on treatment as given by another health facility. On reviewing her prescription reports, she is under T. Amlodipine 5 mg daily. However, her BP was not under control.

BP - 131/99 mm Hg.

The medical officer decides to modify her management as per protocol.

Date of registration: 8.1.19

• Patient ID treatment number: 00002

• Address: No 6, CLC works lane, Thambaram, Kancheepuram district: Pin code: 600044.

• Phone number: Not available

Alternate number: 98976***** (spouse number)

Nearest subcentre - Kundrathur

Relevant history - she chews tobacco, is not an alcoholic and her elder brother had died due to heart attack a vear back.

On examination, height – 157 cm and weight – 76 kg. The medical officer prescribes the following medicines. T. Amlodipine 5 mg daily along with T. Telmisartan 40 mg OD. The patient is advised to review after one month. The lab results are as follows as on 4.2.19

Total cholesterol: 167

Random blood sugar: 140 mg/dl

Urine albumin: Nil

Serum creatinine: 0.7 mg

4.2.19, BP - 129/81 mmHg, advised continuing the same

2.3.19 – BP- 117/73 mmHg, advised continuing the same

2.4.19 - BP - 120/72 mmHg, advised continuing the same

12.5.19 – BP - 124/76 mmHg, advised continuing the same

The patient did not return for treatment in June. On the 1stJuly, the nurse called the patient and the patient said she was feeling fine and so there was no need to continue treatment.

Patient name	NAME OF THE OWNER, OWNER, OWNER, OWNER,	STATE OF THE PARTY.		Registrat	ion (date	Patien	t ID numi	oer.	SPEC	NEW YORK
Radh	a Sriviv	reusan		08	01	19	0	0	0	0	2
	PER SERVICE				iM.	YY	the state of the s	002,00003		-	SIMISE
Age	56			Hea		0000000000	AA	Jagar	PH	C	
Gender		Female O Tr	The second second		D	District		Complement			STORE
Fall Address (s/o, d/o, w/o House no, name of	Thanbas	LC Wolks	Lane,	A ready o	n me	edication f	or hyper	tension?	O yes		O No
hamlet/ village/ colony/ Nagar/ town,	Karchip		- 1	Past histo	ry of	heart att	ack?		0	Yes	O No
nearest landmark)	Pincode.	600044	r	Past history of stroke?					O yes		O'No
Nearest subcenter				Past history of kidney disease?					0	res	ONO
Phone num Other phone	NA			Has diabe	tes?				0	Yes	O No
num-	-Vancas - Contraction	×××××									
Other ID num	AIN		100								
mportant When	At registration				-		al		٧.		
Treatment date	At registration	4/2/19	2/3/19	2/4/10	-		9		₩.		
reatment date	At registration	4/2/19			-		9		⋄.		
Treatment date DD/MM/YY Blood pressure	At registration	129/81	2/3/19	2/4/10	-		9		٧.		
Treatment date DD/MM/YY Blood pressure	At registration 6 1 19 131 99 Please write dos	129/81	2/3/19	2/4/10	-		9		¥.		
Treatment date DD/MM/YY Blood pressure Treatment dose	At registration 6/1/19 131/99 Please write dos	129/81	2/3/19	2/4/10		N			*		
reatment date D/MM/Y Blood pressure reatment dose miodipine	At registration 6 1 19 131 99 Please write dos	4/2/19 129/81 5 Mg	2/3/19 117/73 5 Mg	2/4/19 N 5 mg		12/5/1 N 5mg			¥-		
Treatment date Slood pressure Treatment dose Amilodipine	At registration 6 1 19 131 99 Please write dos	4/2/19 129/81 5 Mg	2/3/19 117/73 5 Mg	2/4/19 N 5 mg		12/5/1 N 5mg			*		
Freatment date DD/MM/YY Blood pressure Freatment dose Amilodipine Felmisartan Chlorthalidone	At registration 6 1 19 131 99 Please write dos	4/2/19 129/81 5 Mg	2/3/19 117/73 5 Mg	2/4/19 N 5 mg		12/5/1 N 5mg			*		
reatment date ob/MM/YY Blood pressure reatment dose omlodipine felmisartan thlorthalidone tydrochlorothiazide	At registration 6 1 19 131 99 Please write dos	4/2/19 129/81 5 Mg	2/3/19 117/73 5 Mg	2/4/19 N 5 mg		12/5/1 N 5mg			*		
reatment date D/MM/YY Blood pressure reatment dose miodipine elmisartan chlorthalidone rydrochlorothiazide malapril osartan	At registration 6 1 19 131 99 Please write dos	4/2/19 129/81 5 Mg	2/3/19 117/73 5 Mg	2/4/19 N 5 mg		12/5/1 N 5mg			*		
Freatment date ob/MM/YY Blood pressure Freatment dose Amilodipine elmisartan Chlorthalidone lydrochlorothiazide malapril osartan Atenolol	At registration 6 1 19 131 99 Please write dos	4/2/19 129/81 5 Mg	2/3/19 117/73 5 Mg	2/4/19 N 5 mg		12/5/1 N 5mg			*		
Treatment date DD/MM/YY Blood pressure Treatment dose Amiodipine Telmisartan Chlorthalidone	At registration 6 1 19 131 99 Please write dos	4/2/19 129/81 5 Mg	2/3/19 117/73 5 Mg	2/4/19 N 5 mg		12/5/1 N 5mg					

If a patient misses a visit, please contact promptly to return to care

| Date contact attempted |
|------------------------|------------------------|------------------------|------------------------|------------------------|
| O No response |
| O House not found |
| O Agreed to return |
| 0 | 0 | 0 | 0 | 0 |

PRINCES AND ADDRESS OF THE PARTY OF THE PART				Regi	stration	date		Patien	ID nur	nber	SHALL SHALL	il in
Radha				80	01	1	9	0	0	0	0	2
	S District Name			DI		M	w	10000	1,00002/	00003	Direction of the last	Est.
		P THE RESERVE OF THE	MANUFACTURE STATE	ilegile.			AUTOMORE N			NATIONAL PROPERTY.	West and the	esio:
Treatment date	•						in a					
Blood pressure								1900	-			
Treatment dose	Please write	dose		1			W.S.				1	
Telmisartan		1 100										
Chlorthalidone							V	-				
Hydrochlorothiazide	4/6									si pr		
Enalapril		-										
Losartan			1111	10	us li i		da Calife	1	HODE	555		
Atenolol				\top								
Aspirin										- N		
Statin				-								
200011	- 4			+								
	*			+		-						
If a patient misses a	d Dat	e contact promptly to	Date co		ttempted		Date contac O No respo	A 10 3 3 3 1 1 1 1	d		ntact atte	
	01	House not found	O Hou	ise not	found		O House n	ot found		O Hou	se not fo	und
O No response	0.1	Agreed to return	O Agri	eed to	return		O Agreed t	o return		O Agre	ed to re	turn
O No response O House not found O Agreed to return	0		0									
O No response O House not found O Agreed to return			0			_		_				
Date contact attempte O No response O House not found O Agreed to return O	0		0	N'								
O No response O House not found O Agreed to return O Outcome of follow-	O										7.	
O No response O House not found O Agreed to return O Outcome of follow	O up nother publi	ic health facility. Write	e facility na			*					7.	
O No response O House not found O Agreed to return O Outcome of follow O Transferred to a O Moved to a priv	o up nother publi	ic health facility. Writ ner. Write name of pr	e facility na								7. 6.	
O No response O House not found O Agreed to return O Outcome of follow	up inother publi ate practition p (No follow	ic health facility. Writ ner. Write name of pr	e facility na								7.	

Storage of treatment cards and retrieval of missed visit/lost to follow up in facilities with the paper-based reporting system


Cards should be stored systematically to facilitate retrieval during the follow-up visit. They will be needed for recording treatment and progress during follow-up visits and updating facility hypertension registers. There should be appropriate and safe storage space and tools available such as two columns of shelves as depicted in the schematic picture below. Arrange cards sequentially, by patient ID number to:

- Help to retrieve cards easily during the patient visit
- Identify which patients have missed follow up visits in the previous month so that they can be called and reminded for follow-up for the collection of drugs.
- Identify which patients have been lost to follow up i.e. those patients who have not received care in the health centre for four continuous quarters (1 year). This applies only to patients who were registered in the first quarter of the calendar year or previous years as given in the example below. For the patients who got registered in subsequent quarters, the loss to follow up will be taken into count in the subsequent annual report. For example, for a patient who got registered in Jan 2019, if he didn't come for follow up any time until March 2020, he will be considered as lost to follow up in the annual report of April 2020. For a patient who got registered in April 2019, and did not come for follow up until March 2020, he cannot be considered as lost to follow up in the annual report of April 2020.

Management of hypertension treatment cards:

- On the first day of each month, all cards should be in shelf/rack I.
- As patients come for treatment during the month, record BP and medicines prescribed and move cards to corresponding numbers in shelf/rack II.
- On the last day of the month, review leftover cards on shelf I. These are patients who did not visit the health facility during the month. If the patient has not visited continuously for a total of three months, move the card to the box labelled <u>"missed visit"</u>. For such patients, make an attempt to call each one and counsel to remind them to come for treatment as soon as possible. If the patient doesn't return, visit or have a community worker (ASHA, ANM) visit if possible, to motivate patients to return. If not visited for 12 months, move the card to the box labelled "lost to follow up".
- If patient reports seeking care at another public or private facility, move the card to "transferred" (confirming with the other facility if possible); note the name of the facility.
- If a patient has died, as confirmed by the patient's relative, the card should be moved into a box labelled <u>"died"</u>.
- At the end of each month, move the rest of the cards back to shelf I and repeat the process for every month.
- At the end of each year, call every patient in the **lost to follow up box** and try to retrieve them to treatment.

How to store treatment cards in the health facility:



Note: In smaller facilities, like sub-centres, with fewer patients, hypertension cards can be kept in a tray instead of cabinets, which are more suitable for larger facilities with a larger number of cards.

5.2.3 Facility hypertension register

Each facility maintains a 'facility hypertension register' which has line listing of all patients on blood pressure treatment in that health facility. Each health facility designates a staff member who will be responsible for maintaining this register. This register is maintained at the health facility level by the data assistant/dedicated NCD staff nurse/health worker designated for this task. It is:

- updated with new patients registered
 - o at the time of issuing the treatment card or entering in the Simple app
- updated for BP control status and other outcomes of registered patients in districts not using the Simple app
 - o every quarter, and
 - at the end of the year

This register helps to:

- Determine the percentage of patients at the facility whose BP was under control after 3 to 6 months of registration.
 - Indicates the quality of services provided by the health facility
- Determine annual blood pressure control rates i.e. the percentage of patients whose BP was under control during the January-March quarter every year.
 - Indicates coverage of hypertension services in the given community
- Aids in the preparation of the quarterly and annual facility reports.

Facility hypertension register - Non-Simple app

Date of registration	Patient ID number	Name s/o, d/o, w/o	Age	Gender	Phone number	Full address (House no, Name of hamlet/ village town, nearest landma	
		Entere	d i	m	mediate	ely after	
			I .	l		ent card	

- 1. BP Control Y (Yes) Systolic blood pressure <140 and Diastolic blood pressure <90 during most recent visit of quarter
- 2. BP Control N (No) Systolic blood pressure ≥140 OR Diastolic blood pressure ≥ 90 during most recent visit of quarter
- 3. MV: Patient missed visit for recent 3 continuous months or blood pressure was not measured or not documented
- 4. LFU: No visit in the previous 12 months and treatment status not known
- 5. TO: Transfer to another govt facility/patient opted to take treatment in another govt facility (mention name of facility if known)
- 6. Pvt: Shifted to Pvt facility Contacted and taking treatment in the private sector (mention name of doctor if known)
- 7. Died: Mention date of death if known

Nearest subcer		Quarterly HTN (3-6 months after	outcom registratio	ne é		HTN 0	outcome 0		Annual HTN outcome Q1 2021					
Health & wellr center	iess	BP cont Y/N/ N		BP cont Y/N			r outcomes / TO/ Pvt/		BP	control Y/N			tcomes / Pvt/	: MV/ Died
											_			
				+								1		
												Γ		
												Γ		
	П			En	te	re	d la	ter	•			Γ		
	Г											Γ		
												Γ		
Quart	erly HTN	I Outcome		Annual HTN Outcome	Total regist		Control	Uncon	trol	MV	LFU	то	Pvt	Died
Total Registered	Contro	ol Uncontrol	MV	Q1 2020										
				Q1 2021										

At the end of quarter and year, enter the summary information given as perforated sheet in the register on the total number of patients registered, on how many of them achieved BP control at 3 to 6 months after treatment initiation and during annual follow up.

IHCI Quarterly Report

Name of district:

Name of Health facility:

	1.		*
Name of State:			
Date of reporting: da	ay, month/Year		
Summary report for	Quarter:	Year	
		Quarterly Outcom	e
Total Registered	BP Controlled	BP Uncontrolled	Missed Visit

IHCI Annual Report

Name of Health facility:	Name of district:
Name of State:	
Date of reporting: day, month/Year	
Annual Summary Report for the year	

Total		Annual Outcome								
Registered	BP	ВР	Missed	Lost to	Transferred	Shifted to	Died			
	Controlled	Uncontrolled	Visit	Follow Up	to other Govt	Private				

How to fill out the facility hypertension register

In the non-Simple app districts:

- Information of patients with hypertension, for whom treatment card has been issued, should be recorded sequentially in the facility hypertension register with the patient ID number.
- At the time of issuing the treatment card, information of patients newly registered should be entered in the register. The left six columns of the register are entered using the information on the first page of the hypertension treatment cards. The information on the nearest sub-centre has to be **additionally** entered in the register.
- Right columns of the register are for recording BP control status of patients at 3 to 6 months after
 the start of treatment (for quarterly facility report) and during Q1 (January-March) every year (for
 annual facility report). In case of other outcomes, such as missed visit, lost to follow up (LFU),
 taking treatment from the private sector, transfer to other government hospital, and death, the
 entry should be made in the register in the given respective column.

Reporting BP control status of registered patients in the facility hypertension register

The treatment outcome (in terms of BP control status) of each patient registered for antihypertensive treatment is assessed 3 to 6 months after the start of treatment. For example, if a patient is registered for treatment in Q1, his BP control status will be determined in Q2. The same will be reported in the first month of Q3.

For each patient, a 3 -6 monthly treatment outcome will be assessed and entered only once in the facility hypertension register. Steps are as follows:

- 1. Step 1 Ascertain the quarter of registration: In the first week of every quarter, determine a quarter of registration of patients whose 3 to 6 monthly treatment outcomes will be reported in the current quarter. For example: As seen in the table, if the report is being prepared in the first week of July 2019, patients registered during January-March 2019 will get reported in the facility hypertension register for their BP control status.
- 2. <u>Step 2 Establish the cohort through patient identification numbers:</u> From the facility hypertension register, identify patient identification numbers of patients registered for treatment during the quarter ascertained in step 1. For example, patients with IDs from 0201 0274 were registered during quarter 1 of 2019 (Jan-Mar 2019).
- 3. <u>Step 3 Retrieve treatment cards</u> of patients with ID numbers determined in step 2 (as in the example, ID numbers 0201-0274).
- 4. <u>Step 4 Ascertain the quarter</u> in which the BP status of these patients will be assessed. For example, in this case, the quarter for assessing BP status is April to June 2019.

- 5. <u>Step 5</u> Now, go through the follow-up sheet of each patient card, and review the BP recorded during the *last visit* of the patient during the quarter assessed in step 4. For example, from April to June in our case. Please note that:
 - If the patient visited in April, May and June, use the BP reading of June.
 - If the patient visited in April and May, use the BP reading of May.
 - If the patient visited in April, use the BP reading of April
 - If no entry is made in the quarter, mark it as missed visit
- 6. <u>Step 6 Report BP control status of the patient in 'facility hypertension register'</u> in quarterly/annual report column using BP record of the patient as seen from his/her 'treatment card' during step 5.
 - Write 'Yes' if BP <140 and <90
 - Write 'No' if BP ≥140 and/or ≥90
 - Other outcomes include:
 - Missed visit (MV): Patient did not have any visit during the quarter (3 months continuously) of BP assessment or BP was not measured or BP recording was not documented
 - Lost to follow up (LFU): No visit in the previous 12 months and treatment status not known
 - Transfer to private sector (Pvt): Contacted and taking treatment in the private sector (mention name of doctor if known)
 - Transfer to other governmentfacility (TO):Transferred to another government facility/patient opted to take treatment in another government facility (mention name of the facility if known)
 - Death: Mention date of death if known

Facility hypertension register in simple app districts

Date of registration	Name s/o, d/o, w/o	Age	Gender	Phone number	Full address (House no, Name of hamlet/ village/colony/ Nagar/ town nearest landmark)	١,
-						
╫				_ •	C :	
+					r soon after	
	registe	riı	ng	the p	atient	
╀						

^{1.} TO: Transfer to another govt facility- Transferred to another govt facility/patient opted to take treatment in another govt facility (mention name of the facility if known)

2. Pvt: Shifted to Pvt facility - Contacted and taking treatment in the private sector (mention name of doctor if known)

3. Died- Mention date of death if known

Nearest subce	enter/ Health &	Entered in Simple app	<u>Q1</u> :	2020	Q1 2021	
	ss center	(enter ✓ if yes)		omes:	Outcomes	
			TO/ Po	rt/ Died	TO/ Pvt/ Di	ied
		Ento	red lat	or		
		LIILG	i Eu iai	.CI		
Total	Anr	nual HTN Outcome Q	1 2020	Annu	al HTN Outcome Q1 202	1
Total						
Registered	Transfer to other	Shifted to Pvt	Died	Transfer to other Govt	Shifted to Pvt	Died
	Govt					+

In Simple app districts:

Since the BP status (control/uncontrol) of the patients can be obtained from the Simple app dashboard, information on outcome status is captured along with entry on whether entered in the Simple app and basic demographic details of patients as discussed earlier.



Exercise 6: Complete facility hypertension register

The facility hypertension register form and 6 treatment cards - (a, b, c, d, e & f) are given below.

Calculate the following based on the information given in the cards.

- 1. Quarterly BP status report to be prepared in the month of October 2019
- 2. Annual report for the year April 2020

Hypertension Treatment Card

One card for every patient given or prescribed medicines to treat hypertension, regardless of regimen

Patient name		Regist	ration	date	Patient	ID numl	er		558/416
Vasud	lovan M	2	1	19	0	0	D	0	1
garreton (Almheirean		DO	MM	YY	00001,000	02,00003	WIELE.	1170	A STATE OF
Age	32		Health	facility	SAN	Jagar	PHC		
Gender	O'Male O Female O Transgender		t	District	Karch	ipur	m		
Full Address (s/o, d/o, w/o House no, name of	SIO Manadevan. 62-E, Shree Apte.	Alread	ly on m	edication	n for hypert	ension?	O y	es	O No
hamlet/ village/ colony/ Nagar/ town,	II nd Main Road, Raja Annamalai puran.	Past h	istory o	f heart a	ttack?		OY	es	ONo
nearest landmark)	Kanchipuran - 600 028	Past h	istory o	f stroke?			O ye	s	O No
Nearest subcenter	Kurdrathur	Past h	istory o	f kidney	disease?		O ye	5	O No
Phone num	XXXXXX3128	Hacdi	abetes?				O v	00	ONO
Other phone num		nas ui	abetesi						0 110
Other ID num									

Important When BP is ≥140 or ≥90, escalate treatment as per IHCI protocol

Treatment date	At registration	4/2/19	2/3/19	4/4/19	15/5/19	5/6/19	2/7/19	2/8/19
Blood pressure	200/100	160/90	150/90	150/90	140/90	140/90	130/90	130/100
Treatment dose	Please write dos	e						
Amlodipine	5 mg	10 mg	10 mg	10 mg	10 mg	10 mg	10 mg	10mg
Telmisartan			40 mg	40 mg	80 Mg	80 Mg	80 mg	80 Mg
Chlorthalidone					0	0	0	12.5 mg
Hydrochlorothiazide					-			0
Enalapril	940		p.ff.					OR SHE
Losartan								
Atenolol								
Aspirin				-33				
Statin								
3.2								

If a patient misses a visit, please contact promptly to return to care

| Date contact attempted |
|------------------------|------------------------|------------------------|------------------------|------------------------|
| O No response |
| O House not found |
| O Agreed to return |
| 0 | 0 | 0 | 0 | 0 |

Copy name, registration date, and patient ID number from front of the card

atient name		O THE PER		Registratio	n date		Patien	t ID nu	mber	in the	
Vasud	evan M	701		2 \	19	YY	0	0	0	0	1
				00	Nim	AT .	000	01,00002	,0005		
reatment date D/MM/YY	4/10/19	51nl19	3/12/19	1/1/20	2 2	20	3/3/	20			
lood pressure	120/95	120/80	120/85	120/90	120	190	130	190			
reatment dose	Please write o	dose 10 mg	10 mg	10 mg	100	19	101	mg	A least		
elmisartan	80 NA	80 Mg	80Mg	80mg	801	ug	80	Mg		H	
hlorthalidone	12.5 mg	12.5 mg	12.5 mg	12.5m	12.5	Mg	12.5	MA			ý.
ydrochlorothiazide	0	0	4		0	V		0			
nalapril						191					
osartan			10000				No.	15 B			
tenolol											
spirin	9/4/1	trees.	1000	19	HUE	10			11/2		
tatin	114	100				T		200			
		ALC: N			-						
	House not found O House not found		Date cont O No res O House	e contact attempted No response House not found O Agreed to return O				Date contact attempts O No response O House not found O Agreed to return O			
Outcome of follow	another public	health facility. Wr		2:							
O Moved to a pr O Lost to follow	un (No felless	a fac 12 manths?									

b Hypertension Treatment Card

One card for every patient given or prescribed medicines to treat hypertension, regardless of regimen

W/O GOOD 3313, 9th LIC C Kanchipu Kundro 044	t Street olony. scam-60 other	2004.		n facility District medication of heart a of stroke? of kidney	SA Nag Kanchipu Kanchipu tor hypertensio	av PHC	O NO O NO O NO O NO O NO
O Male O W/O Good 33/3, 9 t LIC C Kanchipu Kundro	pal Street otony. Mam-60 othur 2464	2004.	Already on Past history Past history Past history	n facility District medication of heart a of stroke? of kidney	SA Nag Kanchipu for hypertensio ttack?	OYPHC NYOUN O YES O YES O YES	O No O No O No
O Male O W/O Good 33/3, 9 t LIC C Kanchipu Kundro	pal Street otony. Mam-60 othur 2464	2004.	Already on Past history Past history Past history	District medication of heart a of stroke? of kidney	Kanchipo for hypertensio ttack?	n? O yes O yes O yes O yes	O No O No O No
W/O GOOD 3313, 9th LIC C Kanchipu Kundro 044	pal Street otony. Mam-60 othur 2464	2004.	Past history Past history Past history	nedication of heart a of stroke? of kidney	n for hypertensio	O Yes O Yes O Yes O Yes O Yes	O No O No O No
3313, 9t LIC C Karchipu Kurdro 044	t Street olony. scam-60 other	2004.	Past history Past history Past history	of heart a of stroke? of kidney	ttack?	O yes O yes O yes	O No O No O No
LIC C Karchipu Kurdro 044	otony. 11am-60 2thuy 24643	2004.	Past history Past history	of stroke? of kidney		O yes	O No O No
044	2464 3		Past history	of kidney		O Yes	ONo
044	2464 3	2259	Past history	of kidney			
044	2464 3	2259			USCUSE!		
1 100		2259	Has diabete	s?		O yes	O No
o is ≥140 or	SOO ercolote				E CALLERY		
is ≥140 or	>00 accelete						
HIIII			614/19		916/19	-	10/8/11
Hilia	8/2/19	7/3/19		-		-	10/8/10
30/100	120/90	120 90	120/80	-	150/80	-	130 90
ease write dos	e				10.1	List Hotel	100
5 mg	5 mg	5 mg	5 mg		5 Mg	14.85	5 Mg
			0		0	MR. THE R.	0
	THE PERSON						5
16-					Name and Park		
							la.
							15
isit, please co	ntact promptly	to return to ca	are				process to
O No re	sponse	O No respons	se	O No res	oonse	O No response	
	sit, please co	t registration H1119 812/19 Bol100 120/90 Base write dose S Mg S Mg	tregistration H1119 812/19 713/19 Sol100 120/90 120/90 sase write dose 5 Mg 5 Mg 5 Mg Sit, please contact promptly to return to ca Date contact attempted O No response O House not found O House not O House not	tregistration H1119 812/19 713/19 614/19 Sol100 120/90 120/90 120/80 asse write dose 5 Mg 5 Mg 5 Mg 5 Mg Sit, please contact promptly to return to care Date contact attempted O No response O House not found Date contact attempted O No response O House not found	H1119 812/19 713/19 614/19 — Sol100 120/90 120/90 120/80 — Passe write dose S Mg S Mg S Mg S Mg Sit, please contact promptly to return to care Date contact attempted O No response O No response O House not found O House not found O House	t registration H1119 812/19 713/19 614/19 — 916/19 Sol100 120/90 120/90 20/80 — 120/80 sase write dose 5 Mg 5 Mg 5 Mg 5 Mg 5 Mg Sit, please contact promptly to return to care Date contact attempted O No response O House not found O House not found Date contact attempted O No response O House not found Date contact attempted O No response O House not found	tregistration H1119 8/2/19 713119 6/4/19 — 9/6/19 — sol100 120/90 120/90 — 120/80 — asse write dose 5 Mg 5 Mg 5 Mg 5 Mg 5 Mg Sit, please contact promptly to return to care Date contact attempted O No response O No response O House not found O House not found O House not found O House not found Date contact attempted O No response O House not found O House not found O House not found Date contact attempted O No response O House not found O House not fo

Patient name	44.35.35			Registra	tion d	ate	Patient ID no	umber	
Dharini	G	876		7	1	19	0 0	0 0	1
No. of the last		11 15 11 11 11	COLUMN TWO	DD	MA	u yy	00001,0000	2,00003	-
Treatment date	-	10/10/19			_	-	-	-	65
Blood pressure		130/90	120/90	130	35	-	-	-	
reatment dose	Please write d	ose							
Amlodipine			5 mg	15 M	2		1 37		
elmisartan		31.0	3,10		0				
Chlorthalidone									
tydrochlorothiazide					-				
nalapril									
					-	CLASS SERV		-	
osartan				-					
Atenolol									
Aspirin							MIST A		1
Statin								MET L	
						- 1			
If a patient misses :	a visit, please c	ontact promptly	to return to ca	re					
								5/1/20	
Date contact attempte		contact attempted		7 THE PROPERTY OF THE PARTY OF			t attempted	Date contact attempt	
D No response D House not found		response ouse not found	O No res O House	not foun	d	O No resp O House n		O No response O House not f	
O Agreed to return	O Ag	reed to return	O Agree	d to retur	n	O Agreed	to return	O Agreed to re	eturn
	0		0			U		O .	
(1/2)									
Outcome of follow-	-up								
O Transferred to a				e:					
O Moved to a priv			practitioner:						
O Lost to follow u		for 12 months)							
O Died. Write date	e:								

Patient name				Registrati	on date	Patient ID n	umber	Seal P
Kanag	a Mari	appan	77.7	12	1 19	0 0	0 6	3
Age	44	SHOW HE WAS	distant.	DD M		00001,00002,00 SANac		September 1
Gender	VB/10/10/10/20	- 0-				Karchip	0	
Full Address (s/o, d/o, w/o	W/D May			Already or		or hypertension		O No
House no, name of hamlet/ village/	Winco	Main P	cad,	Past histor	v of heart att	ark2	O yes	O No
colony/ Nagar/ town, nearest landmark)	Karchipu	10M - 604	408		y of stroke?	deki -	O yes	ONO
Nearest subcenter	Kundrad	thur			y of kidney di	isease?	O Yes	O No
Phone num Other phone	AXXX	x x y 40	184	Has diabet	tes?		O yes	O No
num Other ID num								
	Please write dose	5 MA		15 mg	5 mg	1 Smg		
Amlodipine	5 Mg	5 Mg		5 mg	5 mg	5 mg		
Telmisartan	0.3%							
Chlorthalidone								
Hydrochlorothiazide) A C		10		200			
Enalapril			en .				Principal Princi	
osartan								
					,			
Atenolol								
Atenolol Aspirin				100				
Aspirin								e service
Aspirin				2		_		
				2				

Patient name	Basin Mill	THE SHEAR ST		Regis	tration	n date		Patient	ID nu	ımber	
Karage	a Mar	iappan		12	1	19		10	0	0	0 3
				00		мм	YY	0000	1,00007	2,00003	
Treatment date	Dan ve		_	-		1)//2	20	2/2	20	1/3/20	120/8
Blood pressure	-	-	-	-		120/8	0	120	85	120/80	120/8
Treatment dose i	Please write o	dose		1 -		150	9	5.	^9	5 mg	15mg
Telmisartan										V	1
Chlorthalidone											
Hydrochlorothiazide		- BE N									-
Enalapril										1	
Losartan			1	0 2179	9707			100		No. III re	du mary
Atenolol											
Aspirin		Flat -							-		of the feet day
Statin				_							
	711	L CONTROL									
If a patient misses a	_	contact promptly t	1/1	care	empted	Date	contact:	attempted		Date conta	ct attempted
O-No response O House not found O Agreed to return O	0 N	o response ouse not found greed to return	O No re O Hous	esponse se not fo ed to re	und	O No O Ho	respon			O No resp O House O Agreed O	oonse not found
Outcome of follow-u	р		E+								
O Transferred to an	other public	health facility. Writ	e facility nan	ne:							
O Moved to a priva	te practitione	er. Write name of p	ractitioner:								
O Lost to follow up	(No follow u	p for 12 months)									
O Died. Write date:											

್ಲಿ Hypertension Treatment Card

One card for every patient given or prescribed medicines to treat hypertension, regardless of regimen

Patient name	IRES TO			Regist	ration	date	Patient	ID nu	mber	STEPLEM
Mutho	waran '	K	-11	1	4	19	0	0	0	0 4
				00	MM	YY	00001,000	02,0000		- WEUM
Age	37			,	Health	facility	SA	Nag	gar PHC	
Gender	O Male C	Female O Tri	nsgender			District	Karch	ripu	ryam	
Full Address (s/o, d/o, w/o House no, name of	100	thiravel Blooms F	lak	Alread	y on n	nedication	for hyperte	ension	1? O Ves	O No
hamlet/ village/ colony/ Nagar/ town,		woun, 2nd		Past his	story	of heart at	ttack?		O yes	O No
nearest landmark)		100 - 604		Past his	story	of stroke?			O yes	O No
Nearest	Anago	puther		Past his	story	of kidney	disease?		O yes	O No
Phone num Other phone num	××××	XXX G7	98	Has dia	betes	?			O yes	O No
Other ID num										
	1/4/19	15/19	7/6/19	1171		2/8/19			4/10/19	111111
	At registration	12 2		10.00	٠,		1 0		1 / /	1
D/MM/YY	334.74.4					7777	-		-	111111
lood pressure	120/85	120/80	125 75	120/	08	110/8	0 120	175	120/80	120/75
reatment dose	Please write do	se								
mlodipine	5 Mg	5 mg	5 Mg	5 mg	1	5 M	1 51	19	5 Mg	5 Mg
elmisartan							0	A		0
hlorthalidone										
ydrochlorothiazide	15			1	711					
nalapril	un D	to no on		I I I	910					
osartan							-			
tenolol										
spirin										
tatin			150	1						
							on hour	1		
If a patient misses :	ı visit, please co	ontact promptly	to return to ca	re	,				1	1
Date contact attempte O No response O House not found O Agreed to return	O No r O Hou	ntact attempted esponse se not found eed to return	Date contact at O No respons O House not I O Agreed to r	e found		Date conta O No resp O House o O Agreed	not found	(Date contact atte O No response O House not fo O Agreed to re	und

Patient name	ient name					date		Patient ID number					
MW	harasan	K		1 4		19		0	0	0 0		4	
				DD	М	M Y	r	0000	1,00002,0	00003			
Treatment date	4/12/19	V-75.	_	1/3	3/20	1141	20						
Blood pressure	120/80	-	-	121	08/0	150/8	0	-					
Treatment dose	Please write do	ose		5	ng	5 Mg)	100					
Telmisartan				-				197			-		
Chlorthalidone Hydrochlorothiazide							-			_			
Enalapril							_				+		
Losartan			550					1.96	10 04	1070		75	
Atenolol							Н				1		
Aspirin		rate has				1		To all		Eurle			
Statin								100					
0.00000													
If a patient misses	a visit, please co	ontact promptly to	o return to	care									
Date contact attempt O No response O House not found O Agreed to return O	House not found O House not found O Agreed to return O Agreed to return		O No r	ontact attempted Date contact attempted O No response O House of House of Contact of Con			respo use no	not found O Hou			contact attempt response use not found reed to return		
Outcome of follow			£										
		ealth facility. Write . Write name of pr		rie:									
O Lost to follow													
O Died. Write da	te:												

0

Hypertension Treatment Card

One card for every patient given or prescribed medicines to treat hypertension, regardless of regimen

Patient name				Registration date			Patient	Patient ID number				
Jennifer Veronica James				10	4	19	0	0	0	0 5		
Age	42			Health facility SA Naga				Park and				
Gender		District Karchipi										
Full Address	O Male O Female O Transgender W/O James			Already on medication for hypertension?								
louse no, name of A MAY		sha, Flot 3B,		Allead	ay on n	Oles	ONG					
hamlet/ village/ colony/ Nagar/ town,	Netafi Colony 4th Street, Karchipuram - 604407. Anagaputhur			Past history of heart attack?					O yes	O No		
nearest landmark)				Past history of stroke?					O yes	O No		
Nearest subcenter				Past history of kidney disease?					O yes	O No		
Phone num				Has diabetes?					O yes	ONO		
Other phone num	0492	0492 240932										
Other ID num								OHIE		SHIPPER N		
						-	-			10/11/19		
	At registration											
reatment date D/MM/YY	10/4/19	7/5/19	+	-		-	-		10/10/19	10/11/10		
lood pressure	130 85	130/80	-	-		-	-		120/90	120/99		
reatment dose	Please write dos	e										
mlodipine	5 mg	5 Mg							5 Mg	5Mg		
elmisartan												
hlorthalidone												
ydrochlorothiazide												
nalapril	100											
osartan												
tenolol												
spirin										- 1.0		
tatin												
									Transfer Plant			
			-		-					-		
If a patient misses :	e visit place co	stact promptly	to return to	care								
ii a patient misses :	a visit, piease coi	nace promptly	co recarn to	care .		910	9/2019					
O No response O No response O House not found O House not found		Date contact attempted O No response O House not found O Agreed to return			Date contact attempted O No response O House not found O Agreed to return			Date contact attempted O No response O House not found O Agreed to return				

Patient name			R	legistration	date	Patient	Patient ID number				
Jenrifer Veronica James				0 4	19	0	0	0 0			
				DD N	AM YY	00001	,00002,00	0003	M I		
Freatment date	_	1/1/20	2/2/20	+	3/4/20						
Blood pressure	-	120/90	120/80	-	120/85	11 10	m				
Freatment dose	Please write o	iose					Phil.				
Amlodipine		5 mg	5 mg		5 mg	-	2010				
Telmisartan		0	7		0						
Chlorthalidone					1 3 7		1				
fydrochlorothiazide					7						
nalapril											
osartan				0.00	THE RESERVE		100	19 m	No. of Control		
ktenolol											
spirin	1.50				- 12	11-1	31.1	1,,,	4-		
tatin											
2000											
If a patient misses a	visit, please	contact promptly	to return to car	e		4	pule				
	-			ct attempted	Party 1991	ict attempted		Data santus			
Date contact attempted Date contact attempted O No response O No response		O No resp	onse	O No res		O No response					
O House not found O House not found O Agreed to return		O House r O Agreed		O House O Agreed		O House not found O Agreed to return					
)	200	0			0	0					

One card for every patient given or prescribed medicines to Hypertension Treatment Card treat hypertension, regardless of regimen Patient name Registration date Patient ID number Maarisany 20 0 6 0 DD Age Health facility SA Nagar Karchipuyam Gender District O'Male O Female O Transgender Full Address SloMuniappa O Yes O No Already on medication for hypertension? (s/o, d/o, w/o 13. 1st Cross Street. House no, name of hamlet/village/ hrundale Colony. O Yes O No Past history of heart attack? colony/ Nagar/town, Karchipwan - 609007 nearest landmark) O yes ONO Past history of stroke? Nearest agaputher Past history of kidney disease? O Yes O No subcenter XXX 589 Phone num O No O yes Has diabetes? Other phone num Other ID num Important When BP is ≥140 or ≥90, escalate treatment as per IHCI protocol At registration Treatment date 2014/19 25/7/19/26/8/19/27/9/19/25/10/19 DD/MM/YY 110/80 120/85 Blood pressure 120/85 20/85 110/85 120 85 120/80 Treatment dose Please write dose Amlodipine 5 Mg 5 Mg MA 5 mg 5 Mg 5 Mg 5 mg Telmisartan Chlorthalidone Hydrochlorothiazide Enalapril Losartan Atendial Aspirin Statin If a patient misses a visit, please contact promptly to return to care Date contact attempted O No response O House not found O Agreed to return 0 0

Patient name	1	ner Elvery	1	Registration	date	Patient ID nu	mber
Mao	ymair	W		20 4	19	0 0	0 0 6
	9		MARCH SHIP	70,720	M YY	00001,00002	
						II. I Constitution	
Treatment date	26/12/19	15/1/20	16/2/20	16/3/20			
Blood pressure	120/85	120/80	120/80	120/80	1944		
reatment dose	Please write de	ose					
mlodipine	5mg	5 Mg	5 mg	5 mg		A LANGE TO SERVICE THE	6.6
elmisartan	0	V	0	0		1	
hlorthalidone							
lydrochlorothiazide							
nalapril							
osartan			U	THE NEWS			
tenolol							
spirin		data a ret	Page 18	-			teel were
tatin							
			I E	33.12			
f a patient misses	a visit, please c	ontact promptly	to return to car	re			
p	A STATE OF THE STA						
Date contact attempt		contact attempted		ect attempted	Date contac		Date contact attempted O No response
) No response) House not found	0 но	response ouse not found		not found	O No respo O House n	ot found	O House not found
O Agreed to return	O Ag	reed to return	O Agreed O	to return	O Agreed t	o return	O Agreed to return O
	17.00						8
Outcome of follow	v-up						
O Transferred to	another public h	nealth facility. Wr	ite facility name	:			
O Moved to a pri							
O Lost to follow	up (No follow up	for 12 months)					
O Died. Write da	te:						

For exercsie 6 – Facility Hypertension Register

Date of registration	Patient ID number	Name s/o, d/o, w/o	Age	Gender	Phone number	Full address (House no, Name of hamlet/ village/colony/ Nagar/ town, nearest landmark)

^{1.} BP Control - Y (Yes) - Systolic blood pressure <140 and Diastolic blood pressure <90 during most recent visit of quarter

^{2.} BP Control - N (No) - Systolic blood pressure ≥140 OR Diastolic blood pressure ≥ 90 during most recent visit of quarter

^{3.} MV: Patient missed visit for recent 3 continuous months or blood pressure was not measured or not documented

^{4.} LFU: No visit in the previous 12 months and treatment status not known

^{5.} TO: Transfer to another govt facility/patient opted to take treatment in another govt facility (mention name of facility if known)

^{6.} Pvt: Shifted to Pvt facility - Contacted and taking treatment in the private sector (mention name of doctor if known)

^{7.} Died: Mention date of death if known

Nearest subcer	nter/	Quarterly HTN (3-6 months after	<u>outcom</u> registratio	n)		HTN 0	utcome 0			Ann	ual HTI Q1 2		ome .	
Health & wellr center	ness	BP cont Y/N/ M		BP cont Y/N			r outcomes / TO/ Pvt/		В	Control Y/N		her out		
											_			
	-										+			
														-
Quart	erly HTN	Outcome		Annual HTN Outcome	Total regist	tered	Control	Uncon	itrol	MV	LFU	то	Pvt	Died
Total Registered	Contro	Uncontrol	MV	Q1 2020										
				Q1 2021										
						1	 09							

5.3 Digital systems

The use of mobile phones and wireless technologies has grown exponentially across the globe in recent times. Digital technologies in the management of hypertension can ensure:

Efficient and high-quality care

- Efficient communication and use of information across health care providers
- Provision of timely and secure access to longitudinal clinical data that can help prevent
 NCDs and improve the delivery of care


Simple app


Simple is an android app that helps health care workers manage the recording of blood pressure measurements and medications. A web-based Simple dashboard gives health system managers the feedback they need to improve BP control across their facilities.

The Simple app system consists of the following recording and reporting tools that are maintained and utilized at health facilities implementing the India Hypertension Control Initiative:

- Simple android app for data entry
- BP passport with QR code for patient identification
- · Simple web-based dashboard for monitoring

Simple android app for data entry: Healthcare workers enter BP values and BP medications at each patient's visit. Finding patients takes only 3-4 seconds with a scannable patient ID system.









BP passport for patient identification: The BP passport is a patient ID card in which blood pressure and medicines can be recorded during every visit. The BP passport card also has a QR code which will help to quickly look up a patient in the Simple app in subsequent visits. Every patient registered will get a BP passport. When a patient forgets or loses their BP Passport, a new one can be issued easily.

Simple web-based dashboard for monitoring:

Facility administrators, district, and State officials can monitor the performance of facilities in near real time through a secure web-based dashboard. They can track registration rates, follow-up and BP control rates of all registered patients with hypertension across all facilities in the district or state. They can also track the



number of calls made through the app by healthcare workers to patients who are at default risk or lost to follow up.



Advantages of the Simple app

• **Fits in workflows:** Simple is fast and fits into most workflows, so healthcare workers spend more time with patients and less time doing data entry.

- Easy to learn: Healthcare workers can learn Simple in the field in less than an hour.
- Works on any Android device: Simple works on any modern Android phone or tablet, version 5 or above.
- **Offline performance:** Simple works in offline mode as well. Data is synced whenever the user's internet is active.
- Interoperable with other systems: HL7 FIHR compatible messaging and APIs make the Simple app interoperable with many health systems.
- **Secure:** Patient data is encrypted on the device and is aligned with top industry-standard security.
- Free and truly open source: Simple's codebase is freely available and open source.

Pilot in India

Simple was deployed in Oct 2018 in Punjab and thereafter in Maharashtra under the India Hypertension Control Initiative. Simple has had strong uptake in public health facilities in these two states. Healthcare workers appreciate that Simple is easy to learn, simple to use, and takes up very little data. In a recent survey, nurses and doctors gave Simple a 4.5/5-star rating.

More details on the Simple app can be found at https://www.simple.org/

Other digital systems

The public health system in India has several digital recording and reporting systems for NCDs - either in use or currently under development. Broadly these systems are used at two levels.

- Community-level for creating family records and population-based screening
- Health facility level for clinical data records

The Ministry of Health and Family Health Welfare has partnered with DELL and TATA Trust to create Comprehensive Primary Health Care – IT solutions. Further, many states have their own digital systems for clinical data records. Irrespective of the software used for NCD clinical records, if the longitudinal records of patient blood pressure are available, IHCI dashboards can be generated for monitoring.

5.4 Facility reports

The medical officer will be responsible for timely submitting quarterly and annual reports. Reports will be prepared by the data entry operator/designated health staff. Based on these reports the core indicators are calculated.

The facility report comprises of the following variables:

S. No	Serial number of health facilities, district wise
District	District name
Block	Name of block to which the health facility belongs to wherever
	applicable
Facility type	Either PHC/CHC/GH
Health Facility name	Full name of health facility
Q1_R	Number of patients registered in quarter 1
Q1_C_n	Number of patients under control in quarter 1
Q1_UC_n	Number of patients not under control in quarter 1
Q1_MV_n	Number of patients missed visit in quarter 1
Q2_R	Number of patients registered in quarter 2
Q2_C_n	Number of patients under control in quarter 2
Q2_UC_n	Number of patients not under control in quarter 2
Q2_MV_n	Number of patients missed visit in quarter 2
Q3_R	Number of patients registered in quarter 3
Q3_C_n	Number of patients under control in quarter 3
Q3_UC_n	Number of patients not under control in quarter 3
Q3_MV_n	Number of patients missed visit in quarter 3
Q4_R	Number of patients registered in quarter 4
Q4_C_n	Number of patients under control in quarter 4
Q4_UC_n	Number of patients not under control in quarter 4
Q4_MV_n	Number of patients missed visit in quarter 4
ANN_R	Number of patients registered in health facility
ANN_C_n	Number of patients under control in first quarter of subsequent year
ANN_UC_n	Number of patients not under control in first quarter of subsequent
	year
ANN_MV_n	Number of patients missed visit in first quarter of subsequent year
ANN_LFU_n	Number of lost to follow up for 12 months continuously
ANN_PVT_n	Number of patients taking treatment in private sector
ANN_TO_n	Number of patients transferred to other gvt. facility for treatment
ANN_DTH_n	Number of deaths
•	·

Registered: Total hypertensive patients registered in the health facility under IHCI **BP Controlled:** Systolic blood pressure <140 and diastolic blood pressure <90 during last visit of quarter

BP Uncontrolled: Systolic blood pressure ≥140 or Diastolic blood pressure ≥90

Missed visit (MV): If the patient did not visit for follow up for 3 months consecutively or blood pressure not measured or blood pressure not documented

Loss to follow up (LFU): If the patient did not visit for 12 months continuously and treatment status not known

Transfer to Private (TFRPVT): Taking treatment in the private sector

Transfer to the government (TO): Transferred to other government facilities for treatment or patient opted to take treatment from the government facility

Death (DTH): Death of registered patient

Sample facility report – Quarter

S.No	Health Facility name	Q1_R	Q1_C_ n	Q1_UC_ n	Q1_M V_n	Q2_ R	Q2_C_ n	Q2_UC_ n	Q2_M V_n	Q3_ R	Q3_C_ n	Q3_UC_ n	Q3_M V_n	Q4_ R	Q4_C_ n	Q4_UC_ n	Q4_M V_n
		Repoi	rt for qu	arter 1 (A	A)					Repo	ort for q	uarter 3 ((A)				
						Repo	ort for qu	uarter 2 (A)					Repo	ort for qu	uarter 4 (A)

Sample facility report – Annual

S.No	Health Facility name	ANN_R	ANN_C_n	ANN_UC_n	ANN_MV_n	ANN_LFU_n	ANN_PVT_n	ANN_T0_n	ANN_DTH_n
				Report t	for annual (B))			

Section A of facility report is submitted by 15th of first month of every quarter as 'facility quarterly report'. On 15th April every year, Section B is also submitted as 'facility annual report'.

5.4.1 Facility quarterly report

Data to fill 'facility quarterly report' is compiled from the 'facility hypertension register'. Data reported in this form helps to calculate a 3 to 6-month BP control rate in patients getting treatment at this facility.

How to compile facility quarterly report:

The facility quarterly report is prepared and submitted preferably in the first week or the latest by the 15th of the first month of every quarter. Let us understand how to complete this report by using an example:

- To enter a form with a reporting date of 15 July 2019:
- o Reporting quarter to assess BP status would be Quarter 2 of 2019, i.e. 1 April to 30 June
- o Registration quarter would be Quarter 1 of 2019, i.e. 1 January to 31 March

Determine A1: Count all patients who were registered between these two dates and fill A1.

Determine A2: Out of A1, count how many patient's BP control statuses have been documented as 'Yes' in the column titled as 'Quarterly HTN status'. As discussed earlier this column corresponds to patients with BP reading <140/90 in Reporting Quarter (1 April to 30 June) in their treatment cards. Fill the count in A2.

5.4.2 Facility annual report

Section B of the facility report constitutes the facility annual report

- Submitted on 15th April every year
- **Determining B2** (number of patients at the facility who have their BP in control during the first quarter of the year):
 - o By summing up 'Yes' in the column 'Annual HTN outcome' of the corresponding year.
 - This can be done by writing the total of each page in page summary at the bottom of each page, and
 - Then sum up the page total for all patients registered before 1st Jan of the current year
- Determining B1 (estimated number of patients with hypertension in the area):
 - This will be calculated for the district level and above
 - This will be based on the recent most survey result

Purpose of facility report


- Assessing success rate in bringing hypertension under control among registered patients: at 3
 to 6 months after treatment initiation and annually during Q1
- Sharing the results of reports with health workers can help them understand how their efforts have improved the control rate.
- Helps the supervisor understand areas that need additional support

5.5 Monitoring cycle



COLLECT DATA

- 1. Define and standardise indicators
- 2. Standardize data collection tools
- 3. Define collection processes
- 4. Define reporting frequency and data flow pathways



TAKE ACTION

- 10. Provide feedback to staff that collected the data
- 11. Make programme changes if needed
- 12. Use information for planning

INTERPRET INDICATORS

9. What do the indicators say about the program?

ANALYSE DATA

- 5. Check data quality
- 6. Compile and aggregate data
- 7. Calculate indicators
- 8. Visualize indicators (e.g. chart, tables)



Answer key for Monitoring Indicators and Reporting tools

Exercise 1: Determining the Quarter: Complete the following table

Date of Reporting	On the given date of reporting, you will consider the denominator as the number of patients registered in Quarter	On the given date of reporting, you will consider the BP measurement of patients in Column 2 in Quarter
15 April 2019	October- December, 2018	January – March , 2019
15 April 2020	October- December, 2019	January – March , 2020
15 July 2019	January– March, 2019	April– June, 2019
15 January 2020	July – September, 2019	October- December, 2019
15 October 2019	April – June, 2019	July – September , 2019
Annual report	Denominator	Numerator
15 April 2019	Estimated number of people with hypertension in the catchment population/geographical area (district/state/province level)	January – March 2019
15 April 2020	Estimated number of people with hypertension in the catchment population/geographical area (district/state/province level)	January – March 2020

Note: For annual report:


- The numerator will include all patients with blood pressure under control during the recent visit between January 1 to March 31 irrespective of year of registration. It will also include patients who got registered in previous years.
- The denominator is derived from the estimated prevalence for a District/State


Interpretation of Core indicators of Monitoring

Exercise 2: Examine figure 1 and 2 and answer the following questions

- 6. Which indicator does the figure depict?
 - **Annual Indicator**
- 7. How do you interpret this graph?
- 8. What is the difference in control rate between two states?
- 9. What is the difference in uncontrolled rate between two states and possible reasons?
- 10. What is the difference in proportion of patients who missed visits between two states and possible reasons?

Note: Have an overall discussion of how the graph is presented. Compare the control rate, uncontrolled rate, missed visits between states X and Y and discuss possible reasons for the difference.





Exercise 3: Calculate annual indicator with the information given below:

As per the Annual Health Survey, the prevalence of hypertension in district X of ABC state is 26.5%.

The projected population for 2019, of adults above 18 years of age is 1,78,9695. The number of

patients with BP less than 140/90 in January 2019 is 655. Calculate estimated hypertension for the

given population and annual hypertension control rate.

Total >18 years' population: 1,78,9695

Total expected HTN cases: 4,74,269

Annual HTN control rate: 655 / 4,74,269 *100 = 0.1

120

Exercise 4: How to complete hypertension treatment card

Patient name	To the same of the			Regis	tration	date	Patien	t ID numbe	r	- Den	
ROHAN	SHARMA	Number of the Control		6	2	19	0	0	0	0	1
Age				DD	MM Health f	YY facility		002,00003	0		
	34					District	SA	YAUAR .			
Full Address	OMale O						LANG	ICEPURA		0	4
(s/o, d/o, w/o House no, name of hamlet/ village/	THAMBARA									res W	
colony/ Nagar/ town, nearest landmark)	KANCHEET	PUKAH DI.	STEILT	Past history of heart attack?						res O	
	600044				nistory of					res O	
Nearest subcenter Phone num	KUNDERT		history of		ey disease?			Yes D			
Other phone num	981856×	×××	Has d	labetesr					163		
Other ID num Important When Bl	D is >140 or >0	n escalate tro	atment a	os por II	HCI prot	ocol			10.00		
important when be	At registration								1		1
Treatment date DD/MM/YY	6/2/19	4.3.19	5.4.	19	5.5.1	19	4.6.19	5.7.19		3 · 8 · 19	
Blood pressure	150/96	150/85	130/	80	124/8	80	120/80	125/76	/	30/80	
Amlodipine Telmisartan Chlorthalidone	5mg	40mg	40m		40rr		5mg	40mg		40mg	
Hydrochlorothiazide											
Enalapril											
Losartan		C Alexandra			mangar.						
	7	Company Company	N Manage				Village and				
Atenolol							Agreement of				
Aspirin	19 9				•						
Statin											
The sections								-			
If a patient misses	a visit, please	contact prom	ptly to re	eturn to	care						
Date contact attempted O No response	Date cont	act attempted sponse	Date con		mpted		Date contact at O No respons	е	ON	contact atter	
O House not found		not found	O House				O House not f O Agreed to r			ouse not for greed to ret	
O Agreed to return	O Agree O	d to return	O Agree	to reti	um		O Agreed to 1	Cearri	0		

Exercise 5: Spot mistakes on card

Hyperter	nsion Tr	eatme	nt Card	One o			en or prescribe ension, regard	
Patient name	ENGINEERING IN			Registratio	on date	Patient ID	number	Selation 6
Radi	na Sriniv	asan		08 0	1 19	0	0 0	0 2
51 000	150		DECEMBER 1	DD MA	h facility	00001,00002	20x PH	C
Gender	-	. 0.	MINISTRA	Mary Mary	District		RILT NO	
Full Address	O Male O	Female OTO		Already on	medication for	CONTRACTOR AND ADDRESS OF THE PARTY AND ADDRES	CONTRACTOR OF THE PERSON NAMED IN	Yes (GNo
(s/o. d/e, w/e House no, name of	Thambax			P	ast His	10R4 I	1 WRUHL	
hamiet/willage/ colony/Nagar/town,	Kanchip			NAME OF THE OWNER.	of heart atta	ick?		res Ono
Nearest (andmark)	NOT N	600044		Past history		1918	0	Marin of the Contract
subcenter	NA	078)		Past history	of kidney dis	easer	A SHAPP OF THE PARTY OF	BE 20 20 20
Other phone num		×××××		Has diabete	157		0	ves Onc
Other ID num	NN				WOOD THE		34400	
Important When	DD is >140 as	>00		s nor IUCI na	etecal		. V.	
important when	BF 15 2140 UI		· REUSTA			WD.		
Landing Mary	Atregistration	The second second					-	
Treatment date DD/MM/YY	(6/1/19)	14/2/19	2/3/19	2/4/19	12/5/10	1	har	
Blood pressure	131/99	129/81	117/73	(N)	(N)	Van	-	
Treatment dose	Please write dos	c				CBPV	ALUES A	107 ENT
Amlodipine	5 mg	5 mg	5 mg	5 mg	5mg		1 9	
Telmisartan	40 Mg	40 Mg	40 Mg	40 Mg	Homa			
Chlorthalidone					-	-		
Hydrochlorothlazide	and the		-		DC THE S		201	
Enalapril	in a	PAR SIL					E.	0
Losartan	16.540	أعماعها			3162			
Atenolol							al terr	
Aspirin								
Statin			4 3				and the latest and the same	
			L.C.	. 7.5	hero(33	Alexander of	No. of the	karlin and
			THE		E 18	1	A place to the	100
If a patient misses a	visit, please cor	ntact promptly	to return to ca	re				
			act Not					
O No response	d Date con O No re	tact attempted sponse	O No respons		O No respon		O No respon	
O House not found	O House	not found d to return	O House not f	ound	O House not O Agreed to	found	O House not O Agreed to	
O Agreed to return								

SPOT MISTAKES ON CARD Copy name, registration date, and patient ID number from front of the card Registration date Patient ID number Patient name 2 0 Radha 80 0 0 Treatment date **Blood** pressure Treatment dose Please write dose Amlodipine Telmisartan Chlorthalldone Hydrochlorothiazide Enalapril Losartan Atenolol Aspirin Statin If a patient misses a visit, please contact promptly to return to care Date contact attempted O No response O No response O No response O No response O House not found O Agreed to return Outcome of follow-up O Transferred to another public health facility. Write facility name: O Moved to a private practitioner. Write name of practitioner: O Lost to follow up (No follow up for 12 months) O Died. Write date: Additional notes (Labs, previous medications, etc.) LAB VALUES NOT ENTERED

Exercise 6: Complete facility hypertension register

oate of	Patient	Name		per per		Full address	Nearest subcenter/	Quarterly HTN	outcome	Annua	HTN outcome Q1 2020	Annu	al HTN outcome Q1 2021	
egistration	number	s/o, d/o, w/o	Age	Gend	Phone number	(House no, Name of hamlet/ village/colony/, Nagar/ town, nearest landmark)	Health & wellness center	(3-6 months after r BP contr Y/N/ M	lo	BP control Y/N	Other outcomes: MV/ LFU/ TO/ PVt/ Died	BP control Y/N	Other outcomes: MY	7
2.1.19	0000/	SYASUDEVAN	32	~	×××××× 3/2	B I HAIN BOAD, RAPREMAN, KANCHERERAN-60002	KUNDERTHUR			~				
7.1.19	00002	MAHADEVAN DHARINI-G W/O GOPAL	35				KUNDRATHUR				MV			
		KANALA MARIADAN	44	F	×××××× 41.36	33/3, 9# STEELT, LICCOLOM, LANCHEFURAN - GODOL, 166, 370 MAIN ROAD, WIMO NALDE, KANCHEETURAN-604408	KUNDRAINUR			Y				
1.4.19	00004	K-MUTHARASAS	1 00		XXXXXX	14-6, BLOOMS FLATS, VARADATURAN, 2 nd STREET, KANCHERDRAN-604226	AMAGAPUTHUR	У		Y				
0.4.19		JEHNIEGR VEREN	+	F		DAMIRALA FLAT 38. NETAJI	AHAGAPUTHUR	MV		Y				
20.4.19	00006	M.HARISAMY S/O MUNIMPPA		м	2407327 ******	COLONY, 4th STEET, KANCHET COMOT 13, 1nt CROSS STREET, ARUNDAU	ANAWADUTHUR	Y		×				
		Syottomining			589	COLONY, BANCHEEFURAH -609507								
			-											
						<90 during most recent visit of quarter	Quarter	HTN Outcome			Total Control	Uncontrol M	V LFU TO PVt	Died
3. MV: Patier	nt missed vi	systolic blood pressure of for recent 3 continuo evious 12 months and t	us mon	ths or	blood pressure was	e 90 during most recent visit of quarter not measured or not documented	Total	ontrol Uncont	rol MV	Outcome Q1 2020	registered Collision	, ,		
. TO: Trans	fer to anoth	er govt facility/patient	opted to	take	treatment in anothe	r govt facility (mention name of facility if known) r (mention name of doctor if known)	2	2	,	Q1 2021	9			+

Chapter 6: Supportive supervision

Expected competency on completion of session: Ability to conduct supervisory visits and provide constructive feedback to sub-centre/PHC/CHC/District Hospital staff.

Audience: Supervisors of the block, district, state, and national level

In this session you will learn about:

- Supervision visits schedule preparation
- Supportive supervision checklist
- Interpersonal communication

Good supervision is the process of helping staff improve their own performance continuously.

6.1 Purpose of supervision

Effective management of hypertension requires the cooperation of several health care providers in peripheral health facilities. As a supervisor, you will be responsible for ensuring that screening, diagnosis, treatment, and monitoring of patients with hypertension are undertaken as per guidelines. Supervisory visits to health units give you the opportunity to assess the performance and provide technical advice and guidance so that the staff can provide better services.

- Good supervision is the process of helping staff improve their performance.
- Supervision is an opportunity to improve staff knowledge and skills.
- Supervisory visits are an opportunity to jointly address the problem and explore solutions. The supervisory visit gives you the opportunity to see and better understand the problems which staffs face, especially at peripheral health facilities.
- During these visits, you can
 - Observe and reinforce good practices.
 - o Identify and correct inadequate performance before it becomes a major problem.
- Supervisory visits also give staff the opportunity to talk with you.
- Regular supervisory visits place an emphasis on helping the staff identify and solve problems, instead of finding fault. This will create a good working relationship between you and the staff of the district.

6.2 Approaches to supervision

Traditionally, public health programs have used an authoritarian inspection or control approach to supervision. This approach is based on the thinking that health staff are unmotivated and need strong control to perform correctly. It has been shown that a supportive approach, where supervisors and health staff work together to solve problems and improve performance, delivers improved results.

Supportive supervision explores if workers are aware of the program priorities and problems and recognize the fact that workers already know how well-placed they are to achieve those priorities. Supportive supervision helps local workers understand their programmatic data, interpret it in their local context and identify programmatic gaps. The hallmark is to listen and to acknowledge all positive points. Supportive supervision leads to a dialogue that jointly explores problems, sets priorities and formulates solutions.

Supportive supervision explores if workers are aware of the program priorities and problems and recognize the fact that workers already know how well-placed they are to achieve those priorities. Supportive supervision helps local workers understand their programmatic data, interpret it in their local context and identify programmatic gaps. The hallmark is to listen and to acknowledge all positive points. Supportive supervision leads to a dialogue that jointly explores problems, sets priorities and formulates solutions.

Supportive supervision is about helping to make things work, rather than checking to see what is wrong.

"They should smile when they see you walking over the hill to visit"

- Effective supervisors are welcomed by the staff they supervise
- Frank feedback doesn't mean hostile feedback
- Joint problem-solving shows that the supervisor and the staff person are on the same team

6.3 Steps of supervision

Step 1: Planning regular supervisory visits • Where: using data to decide prior

- Where: using data to decide priority supervision sites
- When: schedule supervision visits using a work plan
- What: decide what to focus on during supervision

Step 2: Conducting supportive supervision visits

- Observation
- Use of data
- Problem solving
- On the job training
- Recording observations and feedback

Step 3: Follow-up

- Follow up on agreed actions by supervisors and supervised staff
- Regular data analysis
- Feedback to all stakeholders

6.3.1 Step 1: Planning supervisory visits

Where to conduct the visits:

- In general, each health facility should be visited at least once in a quarter.
- o If there are more health facilities, then prioritize your visits based on the following criteria:
 - Low / Decreasing blood pressure control rate
 - Low / Decreasing registrations
 - Follow-up of key issues identified during the last visit
 - Did not visit even once in the last quarter
 - Delayed / Incomplete / Inaccurate reporting in the last quarter
 - New staff who may need training

When to schedule supervisory visits:

o Plan your 3-month calendar using approximately 70 working days per quarter.

- Ensure other planned works such as block, district, state or national level review meetings, training of new staff, preparation of reports or other planned work are included.
- The schedule should be feasible and practical, considering the distance, transportation difficulties, or constraints due to weather and travel conditions.
- Try not to rush your visit. Plan to spend enough time at each health facility so that you can
 do a good job of supervising.
- The health staff under supervision should be informed of the schedule.
- Consider other planned activities of health staff being supervised, such as weekly/monthly meetings and special activities (e.g., outreach clinics, market days, etc).

What to focus on:

 Prepare a summary of the review of previous supervision reports, or data analysis, to identify what to focus on during supportive supervision visits. An example is provided below:

Name of facility	3-6-month control rate	Last quarter supervision visit	Additional remarks	Focus of the planned visit
A	25%	Patient treatment had not been escalated according to the protocol	New staff had been recruited	Training on the treatment protocol
В	80%	There was an inconsistency between reported data and facility hypertension register data	Patient records and registers were not updated	Verify data. Provide on- the-job training
С	-	Missing report of some patients	Hypertension treatment cards out- of-stock	Provide support to print the treatment cards
D	30%	Stock out of core drugs had been reported	Sufficient drugs had not been indented	Training on drug inventory projections and indenting

Remember: Always keep the concerned officials informed about the visit well in advance. Involve the health facility in charge during the visit. Share a summary of findings and recommendations at the end of your visit. Written feedback will help you in the follow-up of key issues for subsequent visits. A summary of your key observations should be shared with all concerned officials at the institution/block/ district level on a regular basis.



Exercise 1. Supportive supervision planning

There are 150 SCs, 40 PHCs and 10 CHCs in a district. Plan your visits for the first quarter of 2020 (January to March) and mark your visits on the calendar. All facilities had a BP control rate of <50% in the last quarter. In addition, PHC Khera had drug stock-outs while PHC Sundal has only one doctor

who has been on sick leave for the last 3 months. Note that you are busy during the first week of the quarter to prepare various reports. There is a district-level review meeting on the last Monday of every month and a state-level review every other month.

January 2018

		-		Notes:

February 2018

				Notes:

March 2018

			Notes:

6.3.2 Step 2: Conducting supportive supervision visits

A **simple supervision checklist** facilitates systematic data collection on input, process, output and outcome indicators at the health facility. It enables a comparison of indicators among facilities of same level, thereby, allowing supervisors to identify good and replicable practices. The checklist can help to identify key problems and discuss possible solutions to address these problems.

Most importantly, supervisors should fix problems and address urgent issues during the visit. For example, if a supervisor finds a treatment card of the patient whose last recorded BP is 180/110 and hadn't turned up for treatment this month, then the supervisor should immediately call the patient.

Please refer to a supportive supervision (SS) checklist and a checklist for facilities using Simple App. SS is organized with the following sections:

- 1. Screening and BP measurement
- 2. Treatment outcome
- 3. Patient recording and reporting system
- 4. Identification and tracking of missed patient
- 5. Pharmacy
- 6. Laboratory facilities
- 7. Telephone calls by STS

Supervisory visits improve performance

- Supervision contributes to the clinical and monitoring quality
- The most efficient system will vary in different types of facility
- A role of the supervisor is to transfer successful experiences
- As a result, staff should be able to self evaluate their achievements
- A major and very common problem for supervisors is lack of time:
 - To travel to multiple facilities and arrive at opportune hours
 - To cover multiple patient paths and clinical areas in large facilities
 - To balance observation/advice and direct clinical involvement

India Hypertension Control Initiative (IHCI) Supportive Supervision Checklist

Simple App / non-Simple App facility

District i	name:	Name of supervisor:		
Facility t	ype & name: DH/ AH/ SDH/ RH / CHC / PHC/ UPHC /SC			
Name of	f medical officer in charge:	Designation:		
Last mo	CVHO/STS/Both/			
Number	Others			
Last mo	nth registration: reported actual	Date:		
Is the H	TN treatment protocol displayed on the wall or desk? □ Yes □ No			
Is the BF	P measurement checklist displayed? □ Yes □ No			
1	Screening and BP measurement			
1.1	Number of staff nurse:	NCD nurse posted under NPCDCS		
1.2	Number of Medical officers:			
1.3	Number of functional BP instrument/s in the facility (Digital/Aneroid/Mercury/LED)	D,A,M,		
1.4	Who does BP measurement in the facility? (Multiple choices)	NCD SN / SN /ANM/ Others (specify)		
1.5	How many days in a week, opportunistic screening is done at the facility? (No. of days)			
1.6	In previous 3 working days			
	a) No of adults whose BP was measured			
	b) Total no of adult outpatients			
		NA		
1.7	Observe BP measurement for at least one patient. If there is no patient, get your own BP checked a. If staff is tying the cuff properly	Y N Y N		
	b. Patient's sitting position is correct			

	Ĩ	c. BP app	paratus position is correct				Υ	N		
1.8	Are	e all adults with BP ≥140/90 referred to the medical officer for management?					Y	N	NA	
2	Tre	atment out	come							
			s registered two months be ved till 25 cards are review		case of fewer than	n 25 registrations in that or	ie mor	th,	then	previous
2.1	Num	ber of cards								
Assess th	ne tre	eatment out	come for each card. (Use a	•	•	one treatment outcome per	card)			
a. Number with BP controlled (<140 and <90) at last visit			b. Number with BP uncontrolled (>140 or >90) and treatment intensified at last visit	uncontr <u>></u> 90) and	oer with BP olled (≥140 or d treatment not ed at last visit	d. Number for whom BP / treatment not documented at last visit	e. Number who visit the facility f previous two mo (missed visit)		for	
3		Patient reco	ording and reporting syste	m						
3.1		Was the fac	ility hypertension register	up to dat	e till last week			Υ	N	
3.2		b) Number	of blank patient BP passpo of blank treatment cards a on-simple app both (a) and	vailable a	t facility (For sim	ple app only (a) to be				
3.3		•	place to store treatment of two-stack system in place		nging treatment c	ards?				NA NA
3.4		Are the card	ds arranged by serial numb	er to faci	litate easy retriev	/al?	Υ	N	NA	
4		Identification	on and tracking of the mis	sed visit						
4.1		Identificatio	on mechanism for missed p	atient	Two stack system / Follow up register / Simple App / Others / None					
4.2		Tracking mechanism for missed patients Phone call / IVRS / SMS / ASHA through / None						it/C)thers	i
4.3		No. of patie	nts who missed visit in the	previous	quarter based o	n available list/ list ı	not ava	ilab	ole	
4.4		a. Overdue								
		b. if, yes date DD/MM/YYYY								
4.5		Among pati	ents who missed visit, how	many w	ere contacted eit	her through phone call or h	iome v	isits	;?	
E		Dharmacy								

5.1	Number of days for which HTN medicir by the facility	ispense	30, 15, 7, other () days									
5.2	Is drug stock register maintained and u regularly	pdate	ed	١	Y N							
5.3	Drug name				Is stock sufficient for one quarter for registered patients? (Write Y/N/NA)							
1	Amlodipine											
li	Telmisartan											
lii	Losartan											
lv	Enalapril											
V	Chlorthalidone											
Vi	Hydrochlorothiazide											
Vii	Others (specify)											
Viii	Others (specify)											
6	Laboratory facilities											
6.1	Is there a functional laboratory at the f	acility	' ?	Υ	N							
6.2	If yes to 6.1, please encircle the type of to HTN patients	tests	offered									
	1. S. Creatinine 2. S. Electroly	rtes	3. L	Irine	proteir	ո 4	. Any o	ther _				
7	Telephone calls (To be done by STS)											
7.1	No of phone calls made on the day of vloss to follow up patients, high risk pati			.0 cal	lls to be	made	to pat	ients v	vho ha	ve miss	ed visits,	
	a. Missed visit / loss to follow up patier	nts										
	b. High risk patients											
	c. Others											
7.2	Missed visit/ loss to follow up patients											
		1	2	3	4	5	6	7	8	9	10	
	IHCI registration no.											
I	Current status											

a. If on treatment					
b. If not on treatment					

- (i. Current status: **a.** Agree to visit **b.** Not willing to return **c.** Discontinued/ not willing to take treatment at all **d.** unable to contact/no response / wrong number **e.** Had visited the facility in the past 60 days (2 months) **f.** Death)
- (ii. If agreed to visit/not willing to return, treatment status of the patient: **a.** On treatment, **b.** Not on treatment)
 - **a.** If on treatment, reason: **a.** Taking Treatment from other Government Hospital **b.** Taking Treatment from Private Hospital/Clinic **c.** Others (Specify)
 - **b.** If not on treatment, reason: **a.** Too long a wait in health facility **b.** Drugs were not available **c.** Drugs are given for a few days only **d.** Side effects of the drugs given from the facility **e.** Given drugs do not work **f.** Distance from home **g.** No proper conveyance to reach **h.** No one to help to reach health facility **i.** Too sick to make the trip **j.** Bedridden **k.** The financial burden of transportation cost

Checklist for assessment of Simple App

1.1	Who is using the simple app?	
	a. NCD Staff Nurse	Y N
	b. NCD counsellor	Y N
	c. Doctor d. Pharmacist	
	d. Pharmacist e. Others (Specify)	Y N
	c. Stricts (open, y	Y N
		Y N
1.2	Are you filling the details directly in the app?	Y N
1.3	Do you face any challenges in patient retrieval?	Never / Sometimes
1.4	If any challenges faced, specify:	
1.5	Are all patients registered?	Y N
1.6	If no, reasons	Unable to sync/ Technical
		errors in the app/
		Unsupported device/ High OP load/ Incorrect patient
		flow
1.7	Are all follow up nationts undated in simple and consurrently?	YN
1.7	Are all follow-up patients updated in simple app concurrently?	Y IN
1.8	Is the simple app user satisfied with the application?	1/2/3/4/5
	(Likert scale: Not satisfied at all 1 – 5 Very satisfied)	
1.9	Do you face any challenges in getting timely support for issues	Y N Help not
	experienced while using the simple app?	required
1.10	If yes, whom do you contact?	
1.11	Are you using the overdue list function?	Y N
1.12	How frequently do you call patients?	
1.13	Does the call masking work?	Never /Sometimes
	Soco are can maxing work:	/Always
1.14	Are you being charged for the calls?	Never /Sometimes
	,	/Always
1.15	Are the patients receiving SMS?	All / Few / No
1.16	Are you using the 'progress' tab for reviewing status of program in	Y N
	your health facility?	110
	your redier ruency:	

1.17	Are you using the 'progress' tab for preparing reports?	Y N
1.18	Do you discuss the facility performance with supervisor?	Y N
1.19	How many patients are registered in Simple app?	
1.20	How many patients are registered in facility hypertension registers?	/ Registered not maintained
	(Difference should be automatically calculated)	

Refer *Annex A* for instructions on using the supervision checklist.

Use the checklist to conduct supervision visits by

Observation:

- How staff does their work
- Observe the availability and usage of IHCI related logistics in the health facility such as BP monitor, protocol poster, BP passports, treatment cards, and facility hypertension register
- Watch how the patient moves inside the health facility and how services are organized including BP measurement, counselling, and treatment
- Listen to how they interact with patients

• Interview:

- Speak with various cadres of health staff to understand their roles and assess their knowledge
- Ask if there is any shortage in IHCI related logistics
- o Phone call to patients to understand the quality of service being provided

• Examination:

- Check records and validate data
- Verify blood pressure entries on the treatment card
- Assess treatment outcome using the patient treatment cards
- Check prescriptions on the treatment card to see if treatment is given as per protocol
- Validate entries on the patient card with the facility hypertension register versus reports
- Check drug stock status

Always conduct supervision together with the health facility staff. The purpose of supervision is to help solve problems together.

Exercise 2: Collecting information for the supervision checklist



Please review the supervision checklist provided to you by the facilitator. For each section of the supportive supervision checklist, discuss how best to collect information.

Effective Communication Tips

Feedback should aim to help the recipients improve their effectiveness and should focus on developing skills and strengthening areas that need improvement, rather than criticizing or judging the recipient for inadequacy.

- The provider should suggest some possible alternatives to what the recipient has been doing.
- Feedback should help the recipient set reasonable goals for changing and improving performance or behaviour.

Be supportive

- Start on a positive note. Emphasize what really went well, and praise what the individual or group is doing right.
- See if the recipient is aware of the issues or concerns that the feedback addresses before stating them directly. If it comes from the recipient himself, he is much less likely to be defensive, and apt to be more constructive and creative in discussing alternatives.
- Don't look for expressions of guilt or responsibility, but rather for changes that will improve the effectiveness of an individual's or organization's efforts.
- Especially if you're dealing with the opposition, or with the targets of advocacy, assume— or, better yet, identify and describe—common ground and your common interest in making things better.
- Focus on the **specific issue**, and don't point fingers.
- Identify the issue or problem as clearly and specifically as possible. Once you've done that, stick to exploring it. The question is not "Who's to blame?" but "How do we make this work as well as possible?"

Be honest

- Providing formative feedback, being supportive, and not blaming doesn't mean 'not being honest'. On the contrary, formative feedback requires honesty, the dishonesty renders it useless.
- Deal directly with the real problem or issue. Identify it clearly. If you know, explain how it became a problem, and help the recipient work out strategies for fixing it now and preventing its recurrence in the future.
- If the issue is a personal one, identify it clearly and help the recipient understand how to address it.

Feedback should be frank, constructive, and practical

- Understand what the actual problems facing staff are staff are best positioned to identify these problems
- Be systematic, including meticulous review of records use and disseminate practical checklists and job aids
- Help solve problems on the spot whenever possible (e.g., help update records and establish a mechanism to do so in the future, solve logistic problems when possible such as provision of forms or protocol copies when needed)
- Model good behavior (e.g., speak with patients and health workers privately and respectfully; call patients whose BP is dangerously high and who didn't return for care before leaving the visit)
- Give realistic, not theoretical, solutions
- Don't give false praise. Catch people doing the right things and reinforce these.

Ask questions in a friendly manner and you are likely to obtain more useful information. Always praise good performance.

6.3.2 Step 3: Follow-up activities

Soon after the supervisory visit, share the feedback report with all concerned. The feedback report is prepared based on the observations/ findings of visit.

Prefill the data in the feedback form based on the available reports: The report includes data on previous monthly registrations and quarterly BP control rate which a supervisor needs to fill before visiting facility.

Complete the form after completion of visit: The feedback also includes input and process indicators and data on adequacy of protocol drugs.

- It is always a good practice to arrive at prioritized recommendations with timelines with the staff being supervised and add in the feedback report.
- Use the opportunity of supervision to provide on-the-job training and identify training needs and mention in the feedback form.

Discuss the findings and handover the form: Discuss your findings with health unit supervisor and appropriate staff. Work with the staff to find possible solutions and mention it in comments section

After the visit, a copy of the report stays at the health facility and keep a copy for your files and sharing it with district officials. Giving and receiving feedback is a sincere attempt to help the recipient improve his/her performance, behaviour, understanding, relationships, or interpersonal skills. This is corrective feedback, and all of us need it from time to time.

Supportive supervision does not end with the conducted visit. Follow-up should be done after the visit to act on issues as agreed with health facility staff, particularly to solve any urgent issues related to equipment or drug supply.

Establish a system for continuous feedback and improvement

- No program is perfect
- The best programs have information systems that indicate when and where they are getting off track
- The best supervisors establish, strengthen, and disseminate these information systems so health workers themselves can track and improve their own performance
- Demonstrate the value of accurate, timely data in improving performance

IHCI Supportive Supervision – Feedback to Health facilities

Name of Block:Name of Institution:Date of visit:Program started on:Name of Supervisor:Designation:

	Trend Co	verage %	
Month & Year		Total Registere	t l
# Regd.		Estd. Target Populatio	n

Quarterly Report Analysis								
Quarter/treatment card analysis	Total Regd.	Control %	Uncont- rol %	Missed visits	Remarks			
Treatment card analysis								

Input		Process	Drug stock for 3 months				
Dedicated Staff	Y/N	Opportunistic Screening (None / Few / Majority)		Amlodipine	A	ı	s
Functional digital BP monitor	Y/N	BP measured by health staff before consulting MO	Y/N	Telmisartan / Losartan	A	ı	S
BP Measurement Checklist	Y/N	BP Measurement Technique C-correct, I-Incorrect		Chlorthalidone / Hydrochlorothiazide	A	ı	S
Treatment Protocol	Y/N	Defaulter Identification System	Y/N	Enalapril	A	ı	S
BP Passport / ID cards (100 nos.)	Y/N	Defaulter Retrieval System	Y/N		A	ı	S
Treatment cards (100 nos.)	Y/N/NA	Timely Report Submission	Y/N		A	ı	S
Storage facility for Treatment cards	Y/N/NA	Patient Education & Counselling	Y/N	Other	A	ı	S
Facility Hypertension Register	Y/N	Other		Other	А	ı	S

Y- Yes N- No NA-Not Applicable

^{*}A – Adequate; I – Inadequate; S – Stock out

Suggestions / Comments	
Follow up of previous supervisory visits:	1
	ı
	ı
	ı
Current supervisory visits:	ı
	ı
	ı
	ı

Signature of Supervisor

Signature of Medical Officer

Supervision is not a one-time activity. Periodic follow up is required to ensure the recommendations are implemented.

- Continue to analyse data to review if there is improvement in performance.
- Communicate regularly with staff to see if recommendations are being followed.
- If needed, conduct a follow-up visit to the facility before the next supervisory visit to support health staff, reinforcing key messages, and ensuring that urgent problems identified during the supervisory visit are solved.

Key Messages

- Supervision should be data/evidence based.
- Start feedback with positive points.
- Discuss issues with the health staffs and reach a common understanding of problem and their solution.
- Leave the health facility with a plan of action on 3-5 key issues with timelines.



Exercise 3: Discussion: What are the possible data you can use to perform evidence-based supervision?



Exercise 4: Role play on problem solving and feedback

Pick one problem from the summary report in exercise 3, keeping in mind principles of good communication, provide feedback to the PHC staff.

References:

- 1. RNTCP M5-10, MOH, India
- 2. Supportive Supervision, Module 4, WHO/IVB/08.04

Annex A: How to Use the IHCI Supportive Supervision Checklist

- Use the checklist for every supervisory visit by CVHO, CVH-STS, officials and others who supervise the IHCI at health facilities
- Before going to the facility: review observations & recommendations of the previous supervisory visit to the facility, monthly IHCI report and quarterly BP control report of facility
- Carry printed treatment protocols and BP measurement checklist so that same can be given to health facilities, if not displayed
- The checklist should capture data and observation pertaining to NCD clinic of facility; if NCD clinic is not established at facility then data and observation pertaining to the whole facility should be captured
- Provide continuous on-job training to health care providers

Checklist to be filled through: (1) Observation of processes; (2) Talking with patients; (3) Reviewing records and reports (4) Discussion with health staff at facility

1. Screening and BP measurement

- Ask about number of staff nurse posted to do exclusive work related to NCD under NPCDCS or staff nurse designated to do NCD work in addition to other duties
- Ask about number of medical officers posted
- o Ask about number of functional BP monitors of different types
- Observe/ask who all do measure BP
- Ask for number of days in a week, opportunistic screening is done; verify the data of previous 3 days related to opportunistic screening; If data is not available for 3 days write "NA"
- Observe process of BP measurement for at least one patient for minimum basic standard; If there is no patient at all, get your own BP checked
- Observe if all adults with BP ≥ 140/90 mm hg are referred to Medical Officer

2. Treatment outcome

 Review treatment cards of all patients registered in a month, two calendar months before the visit. The outcome of these patients will be assessed in the previous two months of visit. (e.g., for supervisory visit done from 1st to 30th November 2019, patients registered in August 2019 is to be reviewed and their outcome is to be assessed in September and October 2019)

Visit during	Review cards of patients registered in	Assess outcomes in
January 2020	October 2019	November and December 2019
February 2020	November 2019	December 2019 and January 2020

March 2020	December 2019	January and February 2020
April 2020	January 2020	February and March 2020
May 2020	February 2020	March and April 2020
June 2020	March 2020	April and May 2020
July 2020	April 2020	May and June 2020
August 2020	May 2020	June and July 2020
September 2020	June 2020	July and August 2020
October 2020	July 2020	August and September 2020
November 2020	August 2020	September and October 2020
December 2020	September 2020	October and November 2020

- If total registered patients in that month are less than 25, then patients registered in the previous month in the sequence are to be reviewed till 25 cards are verified
- If any patients (whose cards you identify) have missed a visit and last recorded blood pressure was greater than 180 systolic or greater than 110 diastolic, make efforts to call patient along with health staff and return patient to care as rapidly as possible
- Patients with BP under control, whether they are on protocol drugs or on any other drug, they are in 2.1a. However, if a patient's BP is not under control, it is important to note, who is being treated per-protocol (count in 2.1b) and who is not treated as per protocol (count in 2.1c) in the last visit
- o If patients' BP and/or treatment is not documented in treatment card, then count them in 2.2d
- Patients who did not visit the clinic for two assessment months count them in 2.2e as a missed visit patient (and NOT to be counted in any other sections)
- o Reviewed patients are to be categorized in only one of the five outcomes

3. Patient recording and reporting system

- Cross-check with NPCDCS and pharmacy register to determine if every patient dispensed medicine for HTN is registered in the program
- Check for number of Blank BP passport, treatment card at facility and ensure adequate availability

4. Identification and tracking of missed visit patient

- o Observe/ Ask for type of identification mechanism for missed visit patients
- Observe/ Ask for tracking mechanism for missed visit patients
- o Ask for no. of patients who missed visit in previous quarter
- Ask if, overdue list is being shared with ASHAs/ ANMs. If response is Yes, ask for date on which last overdue list was shared
- Ask for number of missed visit patients who were contacted either through phone call or home visit

5. Pharmacy

- o Observe for number of days hypertension medicine is dispensed by facility
- Visit pharmacy, review records and stocks, discuss with the pharmacist
- o Examine stock register for stock and expiry of all HTN protocol drugs
- Check if drug stock is enough for next quarter. Guide pharmacist for timely indenting accordingly

6. Laboratory facilities

 Confirm from laboratory and treatment card that patients are being tested as per state treatment protocol. Write NA, if state protocol doesn't require it.

7. Telephone calls (Must be done by STS during supervisory visit)

- Identify patients for phone call with either of this indicator: (1) who have missed visit
 in previous quarter/ loss to follow up for more than 12 months (2) who have systolic
 BP more than 180 mmhg or diastolic BP more than 110 mmhg (3) for any other
 indication like verification of record, overwriting in treatment cards, with borderline
 BP control, etc.
- Phone call to patients of missed visit/ loss to follow up must be done till responses are received from at least 10 patients
- Record IHC registration number, current status and willingness to return of each patient.

How to categorize the treatment outcomes in the supervisory checklist?

